

Cancer in South Australia 2022

With projections to 2025



**Government
of South Australia**

Preventive Health SA

Published April 2026
© Preventive Health SA

ISSN 0819 – 3835

Suggested citation: Cancer in South Australia 2022 – with projections to 2025. Adelaide: South Australian Cancer Registry, Epidemiology and Research Division, Preventive Health SA, Government of South Australia, 2026.

Acknowledgements

The South Australian Cancer Registry (SACR), operating within the Epidemiology and Research Division of Preventive Health SA, relies on the cooperation of a large number of agencies and clinicians to provide it with the vital information required to succeed.

The SACR would like to thank the health information managers, clinicians, hospitals, radiotherapy centres and pathology laboratories for their continued support of the registry. The valued support of the Registrar of Births, Deaths and Marriages is also appreciated. The interactions between the registry and its stakeholders are very positive and greatly appreciated.

The ongoing expertise and contributions of staff members of the SA Cancer Registry, Information Systems team, and the Data Analytics and Health Translation team within Preventive Health SA is greatly appreciated.

Contents

Acknowledgements	3
Contents	4
List of Tables	5
List of Figures	5
Executive Summary	6
Introduction	8
Annual Report	8
The Collection	8
Data Sources	9
Quality Assurance	10
The Report	10
Most Common Cancers in 2022	11
Incidence	11
Mortality	17
Trends in Cancer Incidence and Mortality	23
Incidence	23
Mortality	24
Projections	25
Most Common Cancers	26
Appendix 1 – Methods and Terminology	31
Appendix 2 – List of Site-Specific Tables	33
Appendix 3 – Quality Measures	63

List of Tables

Table 1 - South Australian persons: incidence, age-standardised rates, lifetime risk, leading cancer types, 2022.....	13
Table 2 - South Australian males: incidence, age-standardised rates, lifetime risk, leading cancer types, 2022	14
Table 3 - South Australian females: incidence, age-standardised rates, lifetime risk, leading cancer types, 2022	15
Table 4 - South Australian persons: mortality, age-standardised rates, lifetime risk, leading cancer types, 2022	19
Table 5 - South Australian males: mortality, age-standardised rates, lifetime risk, leading cancer types, 2022	20
Table 6 - South Australian females: mortality, age-standardised rates, lifetime risk, leading cancer types, 2022	21
Table 7 - Male cancer incidence, mortality rates (2022) and projections (2022-2025), South Australia.....	25
Table 8 - Female cancer incidence, mortality rates (2022) and projections (2022-2025), South Australia	25

List of Figures

Figure 1 - Most common cancers in South Australia 2022 – Males	11
Figure 2 - Most common cancers in South Australia 2022 – Females	12
Figure 3 - Most common cancers in South Australia 2022, by age group	16
Figure 4 - Most common cancer deaths in South Australia 2022 – Males	17
Figure 5 - Most common cancer deaths in South Australia 2022 – Females	18
Figure 6 - Most common cancer deaths in South Australia 2022, by age group	22
Figure 7 - Trends in cancer incidence - numbers and rates, South Australia, 1977-2022.....	23
Figure 8 - Trends in cancer mortality - numbers and rates, South Australia, 1977-2022	24
Figure 9 – Female breast cancer incidence and mortality, South Australia, 1977-2022 with projections to 2025	26
Figure 10 - Prostate cancer incidence and mortality, South Australia, 1977-2022 with projections to 2025	27
Figure 11 - Lung cancer incidence and mortality, South Australia, 1977-2022 with projections to 2025.....	28
Figure 12 - Colorectal cancer incidence and mortality, South Australia, 1977-2022 with projections to 2025	29
Figure 13 - Melanoma incidence and mortality, South Australia, 1977-2022 with projections to 2025.....	30

Executive Summary

In 2022, there were 11,391 new cases of cancer diagnosed in South Australia (age standardised rate 497.7 per 100,000 population), while there were 3,901 cancer deaths (159.3 per 100,000 population).

Between 2018 and 2022 male cancer incidence rates decreased by 1.3% per annum, while in female incidence rates decreased by 1.4% per annum. Mortality rates in males decreased by 3.4% per annum between 2018 and 2022 and female mortality rates decreased by 1.3%.

Cancer is a disease predominantly affecting the older population. In South Australia in 2022 people aged over 65 accounted for 65.3% of all cancer cases and 81.8% of all cancer deaths. The lifetime risk of being diagnosed with cancer in South Australia (calculated to age 75) was 1 in 3 for males and 1 in 4 for females. The lifetime risk of mortality from cancer in South Australia was 1 in 12 for males and 1 in 15 for females.

In 2022 the most common cancers for males were prostate cancer, which accounted for 34.1% of all male cancers, colorectal cancer (9.0%) and lung cancer (9.0%). The most common cancers for females in 2022 were breast cancer, which accounted for 30.9% of all female cancers, colorectal cancer (10.7%) and lung cancer (9.1%).

Lung cancer remained the leading cause of cancer death among South Australian males (18.5%), followed by prostate cancer (12.2%) and colorectal cancer (9.6%). Lung cancer (18.9%), breast cancer (12.6%) and colorectal cancer (10.9%) were the leading causes of cancer deaths among females in South Australia during 2022.

Lung cancer incidence rates in males have decreased by 3.6% per annum between 2018 and 2022, and rates are projected to plateau between 2022 and 2025. Lung cancer mortality rates in males have decreased by 4.6% per annum over the same period and are projected to plateau between 2022 and 2025. Lung cancer incidence rates in females have decreased by 0.9% per annum between 2018 and 2022, and rates are projected to plateau between 2022 and 2025. Lung cancer mortality rates for females have decreased by 0.4% per annum between 2018 and 2022 and are projected to continue to decrease between 2022 and 2025.

Prostate cancer incidence rates in South Australia have increased by 3.6% per annum between 2018 and 2022, and mortality rates have decreased by 4.0% per annum over the same period. Prostate cancer incidence rates are projected to continue to increase, while mortality rates are projected to plateau between 2022 and 2025.

Melanoma incidence rates in males decreased by 4.4% per annum between 2018 and 2022, while mortality rates have decreased by 5.7% per annum over the same period. Melanoma incidence rates in females have increased by 0.6% per annum between 2018 and 2022, while mortality rates have increased by 3.2% per annum.

Female breast cancer incidence rates decreased by 0.6% per annum between 2018 and 2022, while mortality rates decreased by 3.0% over the same period. Female breast cancer incidence rates are projected to plateau between 2022 and 2025, while mortality rates are projected to continue to decrease.

Colorectal cancer incidence rates in males have decreased by 3.7% per annum between 2018 and 2022, and mortality rates have decreased by 3.9% per annum over the same period. Colorectal cancer incidence rates in females have decreased by 3.7% per annum between 2018 and 2022, and mortality rates have decreased by 2.6% per annum over the same period. Colorectal cancer incidence and mortality rates for males and females are projected to decrease between 2022 and 2025.

In Australia, The National Strategy for the Elimination of Cervical Cancer in Australia was released in 2023 and aims to eliminate cervical cancer as a public health problem in Australia by 2035. This is defined as less than four new cases of cervical cancer per 100,000 population. In South Australia in 2022, rate of cancer of the cervix was 6.5 cases per 100,000 population.

Introduction

Annual Report

The South Australian Cancer Registry (SACR) has been collecting data on cancer incidence and mortality since 1977. Information on new cancers and cancer related deaths are notified under the *Health Care Act 2008*. Pathology laboratories and health care institutions are required to notify the SACR of any cancer diagnosed at their facility. The Cancer in South Australia 2022 report presents the cancer data for 2022, describes the trends in cancer in South Australia over the years 2018-2022, and projects incidence and mortality rates from 2022 to 2025.

The collection is a rich source of data that has many uses to support the control of cancer. Data are used to describe trends in cancer incidence and death in South Australia. They inform cancer service planning, health policy and also help evaluate cancer prevention, screening and treatment services, as well as identifying issues for population-specific groups. The SACR enables surveillance of trends in cancer incidence, mortality and survival within South Australia by cancer type and by age, sex, geographic area of residence and diagnostic period. It also allows comparison nationally and internationally using agreed standards, by providing South Australian cancer data to the Australian Institute of Health and Welfare's Australian Cancer Database, and to the International Agency for Research on Cancer.

Continuous monitoring permits a prompt response to public concerns about clusters of cancers or regional elevations. This has been an area of increased activity for SACR staff in recent years.

South Australia also has a separate clinical cancer registry, which collects more detailed information including stage, grade, initial course of treatment, and a range of prognostic factors for specific tumour sites. The clinical registry allows clinicians to add information on stage of progression of disease at diagnosis, other prognostic indicators, initial round of treatment, and initial response to care. The clinical cancer registry is used by clinicians to monitor changing patterns of care and effects of these changes on survival rates and other case outcomes. These data are used to support clinical epidemiological studies where more detailed information is required.

The Collection

The SACR collects information on all invasive cancers. Non-melanoma skin cancers are only collected for squamous cell carcinoma of the lip and for skin of genitalia and perineum and for basal cell carcinoma of the skin of genitalia and perineum.

The SACR collects a minimum data set for each cancer case, including such elements as place of residence, sex, date of birth, date of diagnosis, cancer site and morphology, means of diagnosis, whether there were multiple primary sites of cancer, Aboriginal status, country of birth, and date, place and cause of death, where applicable.

The primary site and morphology of South Australian cancer incidence are coded using the third edition of the International Classification of Diseases for Oncology (ICD-O-3.1). For most ICD-O-3 sites reported here, topography codes were used, except for a small number of sites including haematological malignancies when a combination of morphology and topography codes was used. For ease of reference a list of all sites and their ICD-O-3 codes have been summarised in Appendix 2. In reports prior to 2008, the primary sites of cancers diagnosed in South Australia were coded using the International Classification of Diseases, Ninth Edition (ICD-9-CM Australian version). The morphologies were coded according to the Systematised Nomenclature of Medicine and Modifications (SNOMED). In published reports from 2011 – 2014 cause of death was coded in ICD-10-AM, 7th Edition. From the 2015 report onwards, deaths were coded and tabulated using ICD-O-3.

The SACR has used the Surveillance, Epidemiology and End Results Program (SEER) Multiple Primary Rules for all cases diagnosed from 2011 onwards (the rules can be found at: <http://seer.cancer.gov/tools/mphrules/>). These rules are based on site and histology and guide registration of multiple primaries per individual in a standardised way. These rules have the effect of increasing the number of cases registered, as cancers that would previously not be recorded, for example a second case of breast cancer in an individual, could now be recorded according to the SEER Multiple Primary rules.

In order to ensure ongoing comparability of the cancer data over time, the information presented for 2022 has been reduced to a single primary according to the specifications of the International Association of Cancer Registries (see at: http://www.iacr.com.fr/images/doc/MPrules_july2004.pdf). This will also have the effect of making the SACR cancer report comparable with other jurisdictions in Australia that use the same process to reduce cancer registrations to a single primary.

Data Sources

Primary sources of information include pathology laboratories, hospitals, radiotherapy departments and the Registrar of Births, Deaths and Marriages (BDM). Notifications are mandated by the Health Care (Reporting of Cancer) Variation Regulations 2022 under the *Health Care Act 2008*. For cancers diagnosed in 2022 it is estimated that the SACR received 95% of all notifications electronically.

Quality Assurance

The SACR has a number of processes that enhance the quality of the data collected. Notification from multiple sources for a given case of cancer increases the likelihood that the case will be recorded. An attempt is made with all notified cases to trace pathology if it is missing as the definitive source to record the detail of the cancer. The SACR undertakes an annual internal de-duplication procedure to ensure there are no duplicate individuals on the database. In addition, a number of quality assurance checks are run over the cancer data to ensure that the high-quality data within the registry is maintained. It is estimated that the SACR is near 100% ascertainment.

In September 2024 the new South Australian Cancer Registry Database (SACReD) application was operationalised and replaced the previously used Registry Plus software system. The modernised web-based application is customisable and improves coding efficiencies. There are a series of validation checks that report in real time possibly inconsistent information such as certain sex/cancer combinations, morphology/topography combinations, age/cancer combinations so that they may be corrected before the case reaches the database. Additionally, prior to reporting the data, a series of internal checks are undertaken looking for possible errors and these are reviewed and corrected if necessary.

The SACR supports standardised coding through development and implementation of coding manuals and regular internal coding meetings to discuss any difficulties on classifying a notified cancer.

The Report

The SACR collection is continually updated with the most recent available information. Accordingly, numbers in this report for earlier years may vary slightly from those in previous publications, with some South Australian cases eventually found to have been diagnosed elsewhere or diagnosed in earlier years. Death certificate information can reveal information about a person's cancer history and often leads to investigation which can also affect case numbers.

Included in this report are the most common cancers in terms of incidence, mortality, age and sex differences, and distribution by age. Trends are also examined in cancer incidence and mortality for each major cancer site, with projections to 2025.

Appendix 1 outlines the methods used in the report. Appendix 2 outlines the topography/morphology codes that were used to create the report categories and Appendix 3 presents quality measures for the SACR. This includes the proportion of Death Certificate Only cases among other measures.

Most Common Cancers in 2022


There are many types of cancer, varying by site of origin (primary site) and by tumour type (histology). This section describes the patterns of the most common invasive cancers by primary site in South Australia for 2022, examining incidence (new cases) and mortality (deaths), by both sex and age groups.

Incidence

In 2022, there were 11,391 new diagnoses of cancer in South Australia (Table 1). There were 6,384 cancers diagnosed in males (ASR 581.8 per 100,000) and 5,007 in females (ASR 426.5 per 100,000) resulting in an age-adjusted male-female ratio of 1.36 (Table 2 and Table 3). Cancers in males accounted for 56.0% of all cases, with 1 in 3 males and 1 in 4 females being diagnosed with invasive cancer in their lifetime (calculated to age 75, see Methods and Terminology).


Prostate cancer was the most commonly reported cancer in males, accounting for 34.1% of all cancers. Colorectal cancer (9.0%), lung cancer (9.0%), melanoma of skin (6.5%), and Non-Hodgkin Lymphoma (4.0%) were the next most common cancers among males. These five cancers accounted for 62.7% of all newly diagnosed cancers among males in 2022 (Table 2 and Figure 1).

Figure 1 - Most common cancers in South Australia 2022 – Males



Breast cancer remained the most commonly reported cancer in females, accounting for 30.9% of all cancers, followed by colorectal cancer (10.7%), lung cancer (9.1%), melanoma of skin (6.6%) and uterine cancers (4.5%). These five cancers accounted for 61.9% of all cancers diagnosed among females in 2022 (Table 3 and Figure 2).

In Australia, The National Strategy for the Elimination of Cervical Cancer in Australia was released in 2023 and aims to eliminate cervical cancer as a public health problem in Australia by 2035. This is defined as less than four new cases of cervical cancer per 100,000 population. In South Australia in 2022, rate of cancer of the cervix was 6.5 cases per 100,000 population.

Figure 2 - Most common cancers in South Australia 2022 – Females

Cancer was predominantly a disease of the elderly in South Australia with 65.3% of cancer diagnosed occurring in the 65 years and over age group (7,440 cases, Table A2.61).

In children under the age of 15 years, there were 52 cases in 2022, 26 males and 26 females (Table A2.61). The most common childhood cancers were leukaemia (23 cases) (Figure 3).

For people in the 15 to 44 year age group there were 649 cancers diagnosed in 2022, 263 males and 386 females (Table A2.61). The most common cancers in this age group were female breast cancer (115 cases), colorectal cancer (83 cases), testicular cancer (61 cases), melanoma of skin (60 cases), and thyroid cancer (38 cases) (Figure 3).

In the 45 to 64 year age group, there were 3,250 cancers diagnosed in 2022 – 1,716 males and 1,534 females (Table A2.61). The most common cancers in this age group were female breast cancer (640 cases), prostate cancer (591 cases), colorectal cancer (279 cases), lung cancer (230 cases), and melanoma of skin (211 cases) (Figure 3).

Below the age of 55, female cases for all cancers (1,011 cases) outnumber male cases (746 cases). This trend reverses from 55 years of age, when male cases predominate (58.5% of cases). This is due largely to female breast cancer cases in the 35 to 54 age group and prostate and lung cancer in the over 55 year male age group (Tables A2.19, A2.28 and A2.38).

In those aged 65 years and over, there were 7,440 cancers diagnosed in 2022 – 4,379 male cancers and 3,061 female cancers (Table A2.61). The most common cancers in this age group were prostate cancer (1,584 cases), female breast cancer (793 cases), lung cancer (789 cases), colorectal cancer (751 cancers), and melanoma of skin (479 cases) (Figure 3). Colorectal cancer is traditionally diagnosed in older patients although the South Australian data for 2022 show that incidence is beginning from age 15 to 19 years, increasing steadily to age 85 years and over (Table A2.12).

Table 1 - South Australian persons: incidence, age-standardised rates, lifetime risk, leading cancer types, 2022

Site Name	Incidence				% of All Cancer
	New Cases	ASR (A)	ASR (W)	Risk (1 in n)	
Prostate	2178	90.3	59.0	1 in 14	19.1
Female breast	1548	71.9	51.4	1 in 19	13.6
Colon and rectum	1113	48.6	31.9	1 in 33	9.8
Trachea, bronchus and lung	1029	42.8	26.7	1 in 37	9.0
Melanoma of skin	750	33.2	22.7	1 in 45	6.6
Non-Hodgkin lymphoma	445	19.4	13.1	1 in 70	3.9
Pancreas	348	14.4	8.9	1 in 112	3.1
Kidney	332	15.1	10.8	1 in 85	2.9
Other and unspecified sites	303	12.7	7.5	1 in 161	2.7
Bladder	289	11.9	6.9	1 in 159	2.5
Body of the uterus	227	10.2	7.1	1 in 122	2.0
All leukaemias	217	9.7	7.5	1 in 151	1.9
Stomach	206	8.7	5.7	1 in 178	1.8
Brain	173	8.0	6.2	1 in 173	1.5
Multiple myeloma/Plasma cell tumours	173	7.3	4.6	1 in 241	1.5
Liver and intrahepatic bile ducts	160	6.6	4.1	1 in 252	1.4
Thyroid gland	154	7.9	6.5	1 in 172	1.4
Oesophagus	144	6.0	3.8	1 in 246	1.3
Connective and other soft tissue	143	6.3	4.2	1 in 269	1.3
Ovary	97	4.4	3.2	1 in 296	0.9
Myelodysplastic syndromes	94	3.7	2.1	1 in 524	0.8
Tongue	91	4.1	2.9	1 in 297	0.8
Gallbladder and bile ducts	89	3.6	2.1	1 in 482	0.8
Testis	79	4.7	4.6	1 in 298	0.7
Heart, mediastinum and pleura	75	2.9	1.6	1 in 1049	0.7
Small intestine	70	3.1	2.1	1 in 453	0.6
Hodgkin lymphoma	61	3.4	3.2	1 in 443	0.5
Mouth	60	2.6	1.8	1 in 587	0.5
Cervix uteri	60	3.3	2.9	1 in 420	0.5
Other chronic myeloproliferative and haematological disorders	58	2.6	1.8	1 in 575	0.5
Skin of lip	56	2.5	1.7	1 in 561	0.5
Oropharynx	53	2.4	1.8	1 in 461	0.5
Lip	47	2.1	1.4	1 in 629	0.4
Anus, anal canal, anorectum	43	2.0	1.4	1 in 717	0.4
Larynx	40	1.7	1.1	1 in 917	0.4
Renal pelvis, other and unspecified urinary organs	40	1.7	1.0	1 in 1095	0.4
Vulva	38	1.6	0.9	1 in 1482	0.3
Other and unspecified female genitalia	35	1.5	1.1	1 in 931	0.3
Salivary gland	27	1.2	0.9	1 in 1207	0.2
Eye	27	1.3	1.0	1 in 1130	0.2
Retroperitoneum and peritoneum	24	1.1	0.8	1 in 1449	0.2
Bone, joints and articular cartilage	19	1.0	1.0	1 in 1217	0.2
Skin of anus (including perineum, perianal skin)	19	0.8	0.5	1 in 1680	0.2
Nose, nasal cavities, middle ear and accessory sinuses	17	0.8	0.6	1 in 1533	0.1
Polycythaemia vera	16	0.7	0.5	1 in 1494	0.1
Male breast	15	0.7	0.4	1 in 2132	0.1
Hypopharynx	14	0.7	0.5	1 in 1625	0.1
Vagina	13	0.6	0.4	1 in 2457	0.1
Other endocrine glands	13	0.7	0.7	1 in 1853	0.1
Penis	12	0.6	0.4	1 in 2403	0.1
Cranial nerves, spinal cord, meninges etc.	12	0.6	0.4	1 in 2103	0.1
Thymus	10	0.5	0.4	1 in 2468	0.1
Other lymphomas	9	0.3	0.2	1 in 9750	0.1
Immunoproliferative neoplasms	7	0.3	0.2	1 in 7358	0.1
Unspecified sites - lip, oral cavity and pharynx	6	0.2	0.2	1 in 4102	0.1
Nasopharynx	4	0.2	0.1	1 in 7231	0.0
Other male genital organs	3	0.1	0.1	1 in 20563	0.0
Mast cell tumours	3	0.1	0.1	1 in 11202	0.0
Malignancy of histiocytes and accessory lymphoid cells	2	0.1	0.1	1 in 20563	0.0
Placenta	1	0.1	0.1	1 in 24427	0.0
All cancers	11391	497.7	336.4	1 in 3	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82

Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)

Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation

Table 2 - South Australian males: incidence, age-standardised rates, lifetime risk, leading cancer types, 2022

Site Name	Incidence				
	New Cases	ASR (A)	ASR (W)	Risk (1 in n)	% of All Cancer
Prostate	2178	190.8	123.7	1 in 7	34.1
Colon and rectum	577	54.1	35.7	1 in 28	9.0
Trachea, bronchus and lung	575	51.4	31.1	1 in 32	9.0
Melanoma of skin	418	38.8	25.7	1 in 40	6.5
Non-Hodgkin lymphoma	253	23.4	15.5	1 in 60	4.0
Kidney	233	22.0	15.4	1 in 58	3.6
Bladder	218	19.7	11.4	1 in 97	3.4
Pancreas	182	16.2	10.1	1 in 91	2.9
Other and unspecified sites	150	13.8	8.2	1 in 138	2.3
Stomach	139	12.3	7.7	1 in 126	2.2
All leukaemias	127	12.0	9.2	1 in 121	2.0
Oesophagus	113	10.1	6.4	1 in 143	1.8
Liver and intrahepatic bile ducts	113	10.2	6.3	1 in 151	1.8
Brain	103	10.0	7.5	1 in 135	1.6
Multiple myeloma/Plasma cell tumours	98	8.9	5.7	1 in 187	1.5
Connective and other soft tissue	83	7.9	4.9	1 in 230	1.3
Testis	79	9.3	9.3	1 in 149	1.2
Tongue	63	6.0	4.2	1 in 199	1.0
Myelodysplastic syndromes	60	5.3	2.8	1 in 439	0.9
Heart, mediastinum and pleura	59	5.1	2.8	1 in 599	0.9
Thyroid gland	50	5.2	4.2	1 in 281	0.8
Oropharynx	45	4.2	3.0	1 in 255	0.7
Gallbladder and bile ducts	42	3.8	2.1	1 in 470	0.7
Mouth	34	3.1	2.1	1 in 454	0.5
Larynx	34	3.1	1.9	1 in 529	0.5
Hodgkin lymphoma	34	3.8	3.3	1 in 410	0.5
Lip	33	3.2	2.2	1 in 403	0.5
Small intestine	33	3.1	2.1	1 in 431	0.5
Skin of lip	33	3.2	2.2	1 in 398	0.5
Other chronic myeloproliferative and haematological disorders	28	2.6	1.7	1 in 640	0.4
Renal pelvis, other and unspecified urinary organs	23	2.1	1.3	1 in 720	0.4
Eye	17	1.7	1.2	1 in 1095	0.3
Salivary gland	15	1.4	0.9	1 in 1141	0.2
Male breast	15	1.4	0.9	1 in 1034	0.2
Hypopharynx	14	1.4	1.0	1 in 788	0.2
Anus, anal canal, anorectum	14	1.3	1.0	1 in 1152	0.2
Bone, joints and articular cartilage	14	1.5	1.5	1 in 786	0.2
Penis	12	1.2	0.8	1 in 1172	0.2
Nose, nasal cavities, middle ear and accessory sinuses	10	1.0	0.7	1 in 1329	0.2
Other endocrine glands	9	1.0	0.8	1 in 1400	0.1
Thymus	8	0.8	0.6	1 in 1541	0.1
Skin of anus (including perineum, perianal skin)	8	0.8	0.5	1 in 2054	0.1
Retroperitoneum and peritoneum	7	0.8	0.6	1 in 2235	0.1
Polycythaemia vera	7	0.6	0.5	1 in 1667	0.1
Unspecified sites - lip, oral cavity and pharynx	5	0.4	0.3	1 in 1967	0.1
Other lymphomas	5	0.4	0.2	1 in 8807	0.1
Cranial nerves, spinal cord, meninges etc.	4	0.5	0.4	1 in 2690	0.1
Other male genital organs	3	0.3	0.1	1 in 9853	0.0
Immunoproliferative neoplasms	3	0.2	0.1	1 in 9853	0.0
Nasopharynx	2	0.2	0.1	1 in 9853	0.0
Mast cell tumours	1	0.1	0.0	N/A	0.0
Malignancy of histiocytes and accessory lymphoid cells	1	0.1	0.0	N/A	0.0
All cancers	6384	581.8	382.1	1 in 3	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82

Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)

Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation.

Table 3 - South Australian females: incidence, age-standardised rates, lifetime risk, leading cancer types, 2022

Site Name	Incidence				% of All Cancer
	New Cases	ASR (A)	ASR (W)	Risk (1 in n)	
Female breast	1548	138.3	99.7	1 in 10	30.9
Colon and rectum	536	43.5	28.3	1 in 41	10.7
Trachea, bronchus and lung	454	35.9	23.0	1 in 43	9.1
Melanoma of skin	332	28.6	20.2	1 in 50	6.6
Body of the uterus	227	19.5	13.7	1 in 63	4.5
Non-Hodgkin lymphoma	192	16.0	10.8	1 in 85	3.8
Pancreas	166	12.8	7.9	1 in 142	3.3
Other and unspecified sites	153	11.7	6.8	1 in 189	3.1
Thyroid gland	104	10.5	8.9	1 in 124	2.1
Kidney	99	8.8	6.5	1 in 152	2.0
Ovary	97	8.5	6.2	1 in 152	1.9
All leukaemias	90	7.7	5.9	1 in 197	1.8
Multiple myeloma/Plasma cell tumours	75	5.8	3.5	1 in 332	1.5
Bladder	71	5.3	2.9	1 in 394	1.4
Brain	70	6.2	4.9	1 in 239	1.4
Stomach	67	5.7	3.9	1 in 286	1.3
Connective and other soft tissue	60	5.1	3.7	1 in 318	1.2
Cervix uteri	60	6.5	5.7	1 in 213	1.2
Liver and intrahepatic bile ducts	47	3.5	2.1	1 in 669	0.9
Gallbladder and bile ducts	47	3.4	2.0	1 in 495	0.9
Vulva	38	2.9	1.8	1 in 768	0.8
Small intestine	37	3.1	2.1	1 in 477	0.7
Other and unspecified female genitalia	35	2.9	2.0	1 in 480	0.7
Myelodysplastic syndromes	34	2.5	1.4	1 in 641	0.7
Oesophagus	31	2.5	1.5	1 in 742	0.6
Other chronic myeloproliferative and haematological disorders	30	2.7	1.9	1 in 524	0.6
Anus, anal canal, anorectum	29	2.5	1.7	1 in 529	0.6
Tongue	28	2.4	1.7	1 in 556	0.6
Hodgkin lymphoma	27	3.0	3.1	1 in 480	0.5
Mouth	26	2.1	1.4	1 in 808	0.5
Skin of lip	23	1.9	1.3	1 in 910	0.5
Retroperitoneum and peritoneum	17	1.4	0.9	1 in 1097	0.3
Renal pelvis, other and unspecified urinary organs	17	1.3	0.7	1 in 2128	0.3
Heart, mediastinum and pleura	16	1.1	0.6	1 in 3445	0.3
Lip	14	1.1	0.7	1 in 1339	0.3
Vagina	13	1.1	0.8	1 in 1260	0.3
Salivary gland	12	1.1	0.8	1 in 1263	0.2
Skin of anus (including perineum, perianal skin)	11	0.8	0.5	1 in 1453	0.2
Eye	10	1.0	0.9	1 in 1163	0.2
Polycythaemia vera	9	0.8	0.6	1 in 1360	0.2
Oropharynx	8	0.8	0.6	1 in 1871	0.2
Cranial nerves, spinal cord, meninges etc.	8	0.6	0.4	1 in 1784	0.2
Nose, nasal cavities, middle ear and accessory sinuses	7	0.6	0.5	1 in 1805	0.1
Larynx	6	0.5	0.3	1 in 2877	0.1
Bone, joints and articular cartilage	5	0.5	0.4	1 in 2671	0.1
Other endocrine glands	4	0.5	0.6	1 in 2648	0.1
Other lymphomas	4	0.3	0.2	1 in 10710	0.1
Immunoproliferative neoplasms	4	0.3	0.2	1 in 5895	0.1
Nasopharynx	2	0.2	0.2	1 in 5672	0.0
Thymus	2	0.2	0.2	1 in 5625	0.0
Mast cell tumours	2	0.2	0.2	1 in 5750	0.0
Unspecified sites - lip, oral cavity and pharynx	1	0.1	0.0	N/A	0.0
Placenta	1	0.1	0.1	1 in 12248	0.0
Malignancy of histiocytes and accessory lymphoid cells	1	0.1	0.1	1 in 10710	0.0
All cancers	5007	426.5	297.0	1 in 4	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82


Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)

Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation.


Figure 3 - Most common cancers in South Australia 2022, by age group

Ages 0 - 14 years (n=52)




- All leukaemias - 44%
- Connective and other soft tissue - 12%
- Brain - 12%
- Bone, joints and articular cartilage - 6%
- Kidney - 6%
- Other cancers - 21%

Ages 15 - 44 years (n=649)




- Female breast - 18%
- Colon and rectum - 13%
- Testis - 9%
- Melanoma of skin - 9%
- Thyroid gland - 6%
- Other cancers - 45%

Ages 45 - 64 years (n=3,250)



- Female breast - 20%
- Prostate - 18%
- Colon and rectum - 9%
- Trachea, bronchus and lung - 7%
- Melanoma of skin - 6%
- Other cancers - 40%

Ages 65 years + (n=7,440)




- Prostate - 21%
- Female breast - 11%
- Trachea, bronchus and lung - 11%
- Colon and rectum - 10%
- Melanoma of skin - 6%
- Other cancers - 41%

Mortality


In 2022, there were 3,901 cancer deaths in South Australia (Table 4). There were 2,148 cancer deaths in males (ASR 193.3 per 100,000, Table 5) and 1,753 in females (ASR 132.5 per 100,000, Table 6).

Lung cancer was the most commonly reported cancer cause of death in males, accounting for 18.5% of all male cancer deaths. Prostate cancer (12.2%), colorectal cancer (9.6%), pancreatic cancer (7.5%), and liver cancer (4.6%) were the next most common cancer causes of death among males (Figure 4).

Figure 4 - Most common cancer deaths in South Australia 2022 – Males



Lung cancer was also the most commonly reported cancer cause of death in females, accounting for 18.9% of all female cancer deaths. Female breast cancer (12.6%), colorectal cancer (10.9%), pancreatic cancer (8.8%), and cancer of unspecified site (6.3%) were the next most common cancer causes of death among females (Figure 5).

Figure 5 - Most common cancer deaths in South Australia 2022 – Females

Cancer deaths were very rare in the 0-14 age group (4 cases) (Table A2.61).

For people in the 15 to 44 year age group, there were 68 cancer deaths in 2022 – 30 male and 38 female deaths (Table A2.61). The most common cancer deaths in this age group were colorectal cancer (15 deaths), brain cancer (8 deaths), cervical cancer (6 deaths), liver cancer (5 deaths) and leukaemia (4 deaths) (Figure 6).

In the 45 to 64 year age group, there were 638 cancer deaths in 2022 – 340 male and 298 female deaths (Table A2.61). The most common cancer deaths in this age group were lung cancer (129 deaths), colorectal cancer (64 deaths), pancreatic cancer (59 deaths), female breast cancer (48 deaths), and brain cancer (41 deaths) (Figure 6).

In those aged 65 years and over, there were 3,191 deaths caused by cancer in 2022 – 1,778 male and 1,413 female deaths (Table A2.61). The most common cancers in this age group were lung cancer (598 deaths), colorectal cancer (319 deaths), pancreatic cancer (254 deaths) prostate cancer (248 deaths), and cancers of unspecified site (172 deaths) (Figure 6).

Deaths from cancer generally increase with age for both sexes, with the majority of cancer deaths occurring from the age of 65 (81.8%). The likelihood of dying from cancer was similar for males and females up to and including the age of 54 years. However, after the age of 55 years the rate of male deaths was higher and increased more steeply than in females (Table A2.61).

Table 4 - South Australian persons: mortality, age-standardised rates, lifetime risk, leading cancer types, 2022

Site Name	Mortality				
	Deaths	ASR (A)	ASR (W)	Risk (1 in n)	% of All Cancer
Trachea, bronchus and lung	729	29.5	17.3	1 in 60	18.7
Colon and rectum	398	16.5	9.1	1 in 141	10.2
Pancreas	315	12.8	7.6	1 in 141	8.1
Prostate	261	10.1	4.9	1 in 292	6.7
Female breast	221	9.2	5.4	1 in 207	5.7
Other and unspecified sites	201	8.1	4.1	1 in 414	5.2
Liver and intrahepatic bile ducts	143	6.0	3.7	1 in 283	3.7
Bladder	128	5.0	2.5	1 in 679	3.3
Stomach	124	5.0	2.8	1 in 393	3.2
Non-Hodgkin lymphoma	122	4.9	2.6	1 in 502	3.1
Brain	120	5.4	3.7	1 in 273	3.1
All leukaemias	117	4.8	2.8	1 in 435	3.0
Oesophagus	112	4.7	2.9	1 in 365	2.9
Kidney	91	3.8	2.4	1 in 490	2.3
Multiple myeloma/Plasma cell tumours	86	3.4	1.8	1 in 663	2.2
Gallbladder and bile ducts	79	3.2	1.7	1 in 808	2.0
Heart, mediastinum and pleura	64	2.5	1.3	1 in 1315	1.6
Ovary	62	2.6	1.6	1 in 558	1.6
Melanoma of skin	60	2.4	1.3	1 in 964	1.5
Body of the uterus	55	2.2	1.3	1 in 682	1.4
Myelodysplastic syndromes	53	2.1	1.0	1 in 1101	1.4
Connective and other soft tissue	35	1.4	0.7	1 in 1640	0.9
Small intestine	25	1.0	0.5	1 in 2228	0.6
Retroperitoneum and peritoneum	24	1.0	0.6	1 in 1436	0.6
Tongue	22	0.9	0.6	1 in 1208	0.6
Renal pelvis, other and unspecified urinary organs	21	0.8	0.4	1 in 4102	0.5
Cervix uteri	20	1.1	0.9	1 in 1263	0.5
Thyroid gland	19	0.8	0.5	1 in 2103	0.5
Oropharynx	18	0.8	0.5	1 in 1307	0.5
Other chronic myeloproliferative and haematological disorders	18	0.7	0.3	1 in 22749	0.5
Other and unspecified female genitalia	17	0.7	0.4	1 in 3088	0.4
Larynx	16	0.6	0.3	1 in 3021	0.4
Anus, anal canal, anorectum	15	0.7	0.5	1 in 2432	0.4
Mouth	12	0.5	0.3	1 in 3549	0.3
Vulva	11	0.5	0.2	1 in 5321	0.3
Eye	10	0.4	0.2	1 in 18542	0.3
Salivary gland	8	0.3	0.2	1 in 7324	0.2
Nose, nasal cavities, middle ear and accessory sinuses	8	0.3	0.2	1 in 6885	0.2
Hypopharynx	6	0.3	0.2	1 in 5285	0.2
Bone, joints and articular cartilage	6	0.3	0.2	1 in 4205	0.2
Penis	6	0.3	0.2	1 in 7524	0.2
Other endocrine glands	5	0.3	0.2	1 in 5576	0.1
Other lymphomas	5	0.2	0.1	N/A	0.1
Nasopharynx	4	0.2	0.1	1 in 11375	0.1
Hodgkin lymphoma	4	0.2	0.1	1 in 7280	0.1
Immunoproliferative neoplasms	4	0.2	0.1	1 in 20563	0.1
Polycythaemia vera	4	0.2	0.1	1 in 6885	0.1
Thymus	3	0.1	0.1	1 in 6825	0.1
Skin of anus (including perineum, perianal skin)	3	0.1	0.1	N/A	0.1
Vagina	3	0.1	0.1	1 in 10216	0.1
Lip	1	0.0	0.0	N/A	0.0
Unspecified sites - lip, oral cavity and pharynx	1	0.0	0.0	1 in 22913	0.0
Skin of lip	1	0.1	0.0	1 in 23423	0.0
Male breast	1	0.0	0.0	N/A	0.0
Testis	1	0.1	0.1	1 in 21731	0.0
Other male genital organs	1	0.0	0.0	N/A	0.0
Cranial nerves, spinal cord, meninges etc.	1	0.1	0.0	1 in 23423	0.0
Malignancy of histiocytes and accessory lymphoid cells	1	0.0	0.0	N/A	0.0
All cancers	3901	159.3	91.1	1 in 13	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82

Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)

Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation.

Table 5 - South Australian males: mortality, age-standardised rates, lifetime risk, leading cancer types, 2022

Site Name	Mortality				
	Deaths	ASR (A)	ASR (W)	Risk (1 in n)	% of All Cancer
Trachea, bronchus and lung	398	35.3	20.4	1 in 51	18.5
Prostate	261	23.3	11.1	1 in 140	12.2
Colon and rectum	207	19.2	10.6	1 in 121	9.6
Pancreas	161	14.2	8.3	1 in 119	7.5
Liver and intrahepatic bile ducts	98	8.9	5.3	1 in 185	4.6
Bladder	91	8.3	4.1	1 in 531	4.2
Other and unspecified sites	91	8.4	4.2	1 in 351	4.2
Oesophagus	86	7.8	4.8	1 in 213	4.0
Stomach	78	6.8	3.8	1 in 269	3.6
Non-Hodgkin lymphoma	73	6.5	3.4	1 in 521	3.4
All leukaemias	73	6.6	3.7	1 in 359	3.4
Brain	68	6.6	4.5	1 in 237	3.2
Kidney	64	5.8	3.6	1 in 337	3.0
Heart, mediastinum and pleura	53	4.7	2.4	1 in 780	2.5
Multiple myeloma/Plasma cell tumours	49	4.3	2.3	1 in 598	2.3
Melanoma of skin	39	3.4	1.8	1 in 733	1.8
Myelodysplastic syndromes	34	3.0	1.5	1 in 867	1.6
Gallbladder and bile ducts	32	2.9	1.4	1 in 886	1.5
Connective and other soft tissue	22	1.9	1.0	1 in 944	1.0
Tongue	16	1.4	0.9	1 in 704	0.7
Oropharynx	16	1.5	1.0	1 in 736	0.7
Small intestine	15	1.3	0.7	1 in 1361	0.7
Larynx	14	1.3	0.7	1 in 1741	0.7
Other chronic myeloproliferative and haematological disorders	12	1.1	0.5	1 in 11180	0.6
Thyroid gland	11	1.0	0.7	1 in 1299	0.5
Renal pelvis, other and unspecified urinary organs	9	0.8	0.4	1 in 4651	0.4
Mouth	8	0.7	0.4	1 in 2560	0.4
Salivary gland	6	0.6	0.3	1 in 5238	0.3
Hypopharynx	6	0.6	0.4	1 in 2560	0.3
Nose, nasal cavities, middle ear and accessory sinuses	6	0.5	0.3	1 in 3320	0.3
Penis	6	0.6	0.4	1 in 3658	0.3
Eye	6	0.5	0.2	1 in 8807	0.3
Retroperitoneum and peritoneum	5	0.4	0.2	1 in 4404	0.2
Bone, joints and articular cartilage	4	0.4	0.3	1 in 3521	0.2
Hodgkin lymphoma	4	0.4	0.3	1 in 3535	0.2
Immunoproliferative neoplasms	4	0.3	0.2	1 in 9853	0.2
Polycythaemia vera	4	0.4	0.2	1 in 3320	0.2
Anus, anal canal, anorectum	3	0.3	0.2	1 in 11598	0.1
Thymus	3	0.3	0.2	1 in 3285	0.1
Other lymphomas	3	0.3	0.1	N/A	0.1
Other endocrine glands	2	0.2	0.1	1 in 5576	0.1
Nasopharynx	1	0.1	0.1	1 in 11180	0.0
Unspecified sites - lip, oral cavity and pharynx	1	0.1	0.1	1 in 11124	0.0
Male breast	1	0.1	0.0	N/A	0.0
Testis	1	0.1	0.1	1 in 10801	0.0
Other male genital organs	1	0.1	0.0	N/A	0.0
Cranial nerves, spinal cord, meninges etc.	1	0.1	0.1	1 in 11598	0.0
Malignancy of histiocytes and accessory lymphoid cells	1	0.1	0.0	N/A	0.0
All cancers	2148	193.3	107.4	1 in 12	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82

Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)

Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation.

Table 6 - South Australian females: mortality, age-standardised rates, lifetime risk, leading cancer types, 2022

Site Name	Mortality				
	Deaths	ASR (A)	ASR (W)	Risk (1 in n)	% of All Cancer
Trachea, bronchus and lung	331	24.8	14.6	1 in 72	18.9
Female breast	221	17.0	10.1	1 in 107	12.6
Colon and rectum	191	14.3	7.9	1 in 167	10.9
Pancreas	154	11.6	6.9	1 in 167	8.8
Other and unspecified sites	110	7.8	3.9	1 in 495	6.3
Ovary	62	4.8	3.0	1 in 289	3.5
Body of the uterus	55	4.2	2.5	1 in 355	3.1
Brain	52	4.3	3.0	1 in 321	3.0
Non-Hodgkin lymphoma	49	3.6	2.0	1 in 486	2.8
Gallbladder and bile ducts	47	3.5	1.9	1 in 742	2.7
Stomach	46	3.5	2.0	1 in 678	2.6
Liver and intrahepatic bile ducts	45	3.5	2.2	1 in 555	2.6
All leukaemias	44	3.4	2.1	1 in 540	2.5
Bladder	37	2.5	1.3	1 in 929	2.1
Multiple myeloma/Plasma cell tumours	37	2.6	1.4	1 in 738	2.1
Kidney	27	2.0	1.2	1 in 865	1.5
Oesophagus	26	2.0	1.1	1 in 1094	1.5
Melanoma of skin	21	1.5	0.8	1 in 1351	1.2
Cervix uteri	20	2.2	1.9	1 in 640	1.1
Retroperitoneum and peritoneum	19	1.5	1.0	1 in 880	1.1
Myelodysplastic syndromes	19	1.3	0.7	1 in 1462	1.1
Other and unspecified female genitalia	17	1.4	0.8	1 in 1592	1.0
Connective and other soft tissue	13	0.9	0.4	1 in 5100	0.7
Anus, anal canal, anorectum	12	1.1	0.8	1 in 1390	0.7
Renal pelvis, other and unspecified urinary organs	12	0.9	0.4	1 in 3661	0.7
Heart, mediastinum and pleura	11	0.8	0.4	1 in 3570	0.6
Vulva	11	0.8	0.4	1 in 2739	0.6
Small intestine	10	0.7	0.3	1 in 5332	0.6
Thyroid gland	8	0.6	0.3	1 in 5100	0.5
Tongue	6	0.5	0.3	1 in 3540	0.3
Other chronic myeloproliferative and haematological disorders	6	0.4	0.2	N/A	0.3
Mouth	4	0.3	0.2	1 in 5562	0.2
Eye	4	0.3	0.1	N/A	0.2
Nasopharynx	3	0.2	0.1	1 in 11570	0.2
Skin of anus (including perineum, perianal skin)	3	0.2	0.1	N/A	0.2
Vagina	3	0.2	0.1	1 in 5287	0.2
Other endocrine glands	3	0.3	0.3	1 in 5395	0.2
Salivary gland	2	0.2	0.1	1 in 11570	0.1
Oropharynx	2	0.1	0.1	1 in 4868	0.1
Nose, nasal cavities, middle ear and accessory sinuses	2	0.1	0.1	N/A	0.1
Larynx	2	0.1	0.1	1 in 9735	0.1
Bone, joints and articular cartilage	2	0.2	0.2	1 in 5110	0.1
Other lymphomas	2	0.1	0.1	N/A	0.1
Lip	1	0.1	0.0	N/A	0.1
Skin of lip	1	0.1	0.1	1 in 11826	0.1
All cancers	1753	132.5	77.7	1 in 15	100.0

Notes: See Appendix 2 for ICD-O-3 coding ranges

Other coding groups of interest (eg Mesothelioma, Leukaemias, Melanomas etc) can be found in Tables A2.62-A2.82


Age-standardised rates are expressed per 100,000 and standardised to the Australian 2011 population ASR (A)

Age-standardised rates are expressed per 100,000 and standardised to the new World standard population 2011 ASR (W)

Lifetime risk is calculated to age 75. Where risk marked N/A not calculated due to unreliable calculation.


Figure 6 - Most common cancer deaths in South Australia 2022, by age group

Ages 15 - 44 years (n=68)




- Colon and rectum - 22%
- Brain - 12%
- Cervix uteri - 9%
- Liver and intrahepatic bile ducts - 7%
- All leukaemias - 6%
- Other and unspecified sites - 6%
- Other cancers - 38%

Ages 45 - 64 years (n=638)



- Trachea, bronchus and lung - 20%
- Colon and rectum - 10%
- Pancreas - 9%
- Female breast - 8%
- Brain - 6%
- Other cancers - 47%

Ages 65 years + (n=3,191)



- Trachea, bronchus and lung - 19%
- Colon and rectum - 10%
- Pancreas - 8%
- Prostate - 8%
- Other and unspecified sites - 5%
- Other cancers - 50%


Trends in Cancer Incidence and Mortality

Incidence

When accounting for a generally ageing population, age-standardisation or adjustment is often used to enhance the comparability of rates to account for differences in age structure. The age-adjusted (Australian population) incidence rate for South Australia in 2022 was 581.8 new cases per 100,000 for males and 426.5 for females (Table A2.61). Figure 7 shows the incidence trends in both numbers and rate of cancers in South Australia since 1977.

Between 2018 and 2022, cancer incidence rates in South Australia decreased by 1.3%.

Figure 7 - Trends in cancer incidence - numbers and rates, South Australia, 1977-2022




Male incidence rates decreased 1.3% per annum between 2018 and 2022, while female rates decreased by 1.4% (see Table A2.61, change in incidence and mortality calculated using a Poisson regression model).

Mortality

The age-adjusted mortality rate for South Australia in 2022 was 193.3 deaths per 100,000 for males and 132.5 for females. Figure 8 shows the mortality trends in both numbers and rate of cancers in South Australia since 1977.

Figure 8 - Trends in cancer mortality - numbers and rates, South Australia, 1977-2022



Male mortality rates decreased by 3.4% per annum between 2018 and 2022 while female rates decreased by 1.3% (see Table A2.61, change in incidence and mortality calculated using a Poisson regression model).

Projections

Numbers of cases, deaths and rates have been projected from 2022 to 2025 for all cancers and for each of the most common cancers (Table 7 and Table 8) based on the previous 10 years of data held in the SACR. The exception being prostate cancer incidence, which has been projected based on the previous 5 years of data, due to non-linear trends.

These projections account for the current age/sex patterns of cancer and changing populations over the projected years. The overall cancer projections show a slight increase in the incidence rates for males, and a plateau in the incidence rates for females, from 2022 through to 2025. Mortality rates for males are expected to plateau while female rates are expected to decrease slightly over the same time period (Table 7 and Table 8).

Table 7 - Male cancer incidence, mortality rates (2022) and projections (2023-2025), South Australia

Males Site/Year	Incidence (new cases)				Mortality (deaths)			
	2022	2023	2024	2025	2022	2023	2024	2025
Prostate*	190.8 (2178)	205.8 (2392)	205.8 (2442)	213.8 (2578)	23.3 (261)	24.2 (279)	23.6 (283)	23.3 (289)
Colorectal	54.1 (577)	51.7 (553)	48.6 (524)	46.5 (505)	19.2 (207)	18.8 (207)	18.0 (203)	16.7 (191)
Lung	51.4 (575)	51.9 (595)	52.3 (611)	51.6 (616)	35.3 (398)	36.1 (414)	35.2 (413)	34.5 (413)
Melanoma	38.8 (418)	44.2 (489)	42.7 (485)	42.0 (489)	3.4 (39)	2.6 (31)	2.2 (28)	2.3 (28)
NHL	23.4 (253)	24.3 (270)	23.4 (265)	23.2 (267)	6.5 (73)	6.7 (77)	6.8 (80)	6.4 (78)
All cancers	581.8 (6384)	605.9 (6789)	609.1 (6964)	612.6 (7138)	193.3 (2148)	195.0 (2217)	190.2 (2225)	186.0 (2234)

Notes: Rates are expressed per 100,000 and standardised to the Australian 2011 population. Number of new cases and deaths are presented in brackets. *Prostate incidence based on previous 5 years. NHL – Non-Hodgkin lymphoma

Table 8 - Female cancer incidence, mortality rates (2022) and projections (2023-2025), South Australia

Females Site/Year	Incidence (new cases)				Mortality (deaths)			
	2022	2023	2024	2025	2022	2023	2024	2025
Breast	138.3 (1548)	136.8 (1547)	136.8 (1572)	137.0 (1598)	17.0 (221)	16.5 (213)	16.1 (213)	14.9 (205)
Colorectal	43.5 (536)	44.3 (549)	43.4 (544)	42.9 (547)	14.3 (191)	13.6 (184)	13.2 (184)	13.2 (188)
Melanoma	28.6 (332)	31.3 (368)	31.3 (375)	31.4 (384)	1.5 (21)	1.4 (20)	1.6 (23)	1.7 (25)
Lung	35.9 (454)	40.2 (524)	39.3 (524)	38.6 (524)	24.8 (331)	24.1 (329)	23.6 (332)	23.0 (331)
NHL	16.0 (192)	15.8 (194)	15.1 (188)	14.9 (188)	3.6 (49)	3.8 (52)	3.7 (53)	3.6 (53)
All cancers	426.5 (5007)	441.6 (5254)	437.3 (5285)	435.0 (5333)	132.5 (1753)	128.5 (1732)	126.8 (1756)	125.3 (1775)

Notes: Rates are expressed per 100,000 and standardised to the Australian 2011 population. Number of new cases and deaths are presented in brackets. NHL – Non-Hodgkin lymphoma

Most Common Cancers

Figure 9 shows the trends in female breast cancer incidence and mortality in South Australia from 1977. Female breast cancer incidence rates in South Australia have decreased slightly by 0.6% per annum between 2018 and 2022, and mortality rates have decreased by 3.0% per annum over the same period (Table A2.28). Female breast cancer incidence rates are projected to plateau between 2022 and 2025, while mortality rates are projected to decrease (Table 8 and Figure 9).

Figure 9 – Female breast cancer incidence and mortality, South Australia, 1977-2022 with projections to 2025




Figure 10 shows the trends in prostate cancer incidence and mortality in South Australia from 1977. Prostate cancer incidence rates in South Australia have increased by 3.6% per annum between 2018 and 2022, and mortality rates have decreased by 4.0% per annum over the same period (Table A2.38). Prostate cancer incidence rates are projected to increase, while mortality rates are projected to plateau between 2022 and 2025 (Table 7 and Figure 10). It should be noted that prostate cancer incidence rates vary and can be influenced by levels of diagnostic testing.

Figure 10 - Prostate cancer incidence and mortality, South Australia, 1977-2022 with projections to 2025




Figure 11 shows the trends in lung cancer incidence and mortality in South Australia from 1977. Lung cancer incidence rates in males have decreased by 3.6% per annum between 2018 and 2022, and mortality rates have decreased by 4.6% per annum over the same period (Table A2.19). Lung cancer incidence rates in females have decreased by 0.9% per annum between 2018 and 2022, and mortality rates have decreased by 0.4% per annum over the same period (Table A2.19). Lung cancer incidence rates for males are projected to plateau, and mortality rates are also projected to plateau between 2022 and 2025 (Table 7 and Figure 11). Lung cancer incidence rates are projected to plateau for females, and mortality rates are projected to decrease over the same period (Table 8 and Figure 11).

Figure 11 - Lung cancer incidence and mortality, South Australia, 1977-2022 with projections to 2025




Figure 12 shows the trends in colorectal cancer incidence and mortality in South Australia from 1977. Colorectal cancer incidence rates in males have decreased by 3.7% per annum between 2018 and 2022, and mortality rates have decreased by 3.9% per annum over the same period (Table A2.12). Colorectal cancer incidence rates in females have also decreased by 3.7% per annum between 2018 and 2022, and mortality rates have decreased by 2.6% per annum over the same period (Table A2.12).

Colorectal cancer incidence and mortality rates for males and females are projected to decrease between 2022 and 2025 (Table 7, Table 8 and Figure 12).

Figure 12 - Colorectal cancer incidence and mortality, South Australia, 1977-2022 with projections to 2025





Figure 13 shows the trends in melanoma incidence and mortality in South Australia from 1977. Melanoma incidence rates in males have decreased by 4.4% per annum between 2018 and 2022, while mortality rates have decreased by 5.7% per annum over the same period (Table A2.23). Melanoma incidence rates in females have increased by 0.6% per annum between 2018 and 2022, while mortality rates have increased by 3.2% per annum over the same period (Table A2.23).

Melanoma incidence rates for both males and females are projected to increase between 2022 and 2025. Mortality rates are projected to decrease for males and plateau for females over the same period (Table 7, Table 8 and Figure 13).

Figure 13 - Melanoma incidence and mortality, South Australia, 1977-2022 with projections to 2025



Appendix 1 – Methods and Terminology

A number of terms are used to define concepts in cancer registry work. Some of the most common ones are discussed below, as well as the methodology used in creating this report.

Inclusion criteria

All cancer cases that were resident in South Australia at diagnosis and with a diagnosis date from 01/01/1977 through to the reporting year were included as incident cancers. The mortality data include the deaths in the reporting year for all those cancer cases that met the incidence inclusion criteria. As a result, a small number of mortality cases may have died in a jurisdiction outside South Australia.

Projections of cancer rates for selected sites

Key sites were selected as the base for projections. Projections of cancer rates for selected sites were done separately for males and females. Ten years of prior data, which best reflected recent trends in incidence for these sites, were used to model the projections for three subsequent years. The expected incidence and mortality for the projected years were computed using the “FORECAST” function in Excel for all the age groups separately. If any of the expected counts for the projected years was negative, it was set to zero before modelling the projections. The 2011 census population data from ABS were used to calculate the projected rates.

Age-specific rate

Age-specific incidence or mortality rates were calculated by dividing the number of new cases or deaths in each age group by the at risk population for that age group and multiplying by 100,000. These rates are usually presented in five-year age groups and by sex.

Cancer incidence

Cancer incidence is defined as the number of new cases of cancer notified for a specified period and for a specified population. It is usually presented as either the number of new cases or as a rate per 100,000 population.

Cancer mortality

Cancer mortality is defined as the number of deaths where cancer is specified as the underlying cause of death. The underlying cause of death is derived from the death certificate issued by a certified medical practitioner and is based on the World Health Organisation’s rules for attribution of cause of death. The main source of death information comes from linking the SACR records to the Registry of Births, Deaths and Marriages. Information about death and its cause may also be notified for cancer cases that die in hospital. Non-cancer deaths are also recorded on the Registry; however these are not coded specifically to their cause of death, only to a generic non-cancer death code.

Crude rate

A crude incidence or mortality rate is defined as the number of new cancer cases or deaths divided by the population at risk in a specified time period. Crude incidence and mortality rates in this report were calculated using the estimated resident South Australian population for 2022 (mid-year estimates) and are expressed as cases or deaths per 100,000 population per annum.

Age-standardised rate

A crude rate can be a misleading way to characterise a population that includes people of different ages. This problem is even more challenging when summary rates of two populations are being compared. An age-standardised rate is a summary rate that has been constructed to reflect what would be the case if the population of interest had the age distribution of some other, known population, e.g. a standard or reference population. Age-standardisation facilitates more logical comparison between populations.

Standard populations

There are two standard populations used in this report – the New World Population and the Australian Standard Population 2011. The New World Population is an estimate of the proportional age distribution of the whole world and the Australian Standard Population is the actual Australian population from the 2011 Census.

Risk

Cumulative risk is the risk an individual would have of developing or dying from a particular cancer, over a defined life span, if that person were not to die beforehand from another cause. Cumulative risk is usually calculated using the following formula:

$$\text{Cumulative risk} = (1 - e^{-\text{cumulative rate}/100})$$

The cumulative rate is the sum of the age-specific incidence or mortality rates over a certain specified age range (life expectancy or other specified range). It is calculated by using the formula:

$$\text{Cumulative rate} = \frac{5 \times (\text{sum of age-specific rates}) \times 100}{100,000}$$

This formula assumes that age groups are arranged in five-yearly blocks. Typically this rate ranges from less than 1 per cent for rare cancers to around nine per cent for common cancers. It is a good approximation to the cumulative risk and expressed as a percent.

Lifetime risk is another common way of expressing risk, where the risk is expressed as a 1 in x chance of being diagnosed with or dying of a cancer. It is calculated by the following formula:

$$\text{Lifetime risk} = 1 / \text{cumulative risk}$$

For example a cumulative rate of, say, 4.4 percent for lung cancer in males would mean that one out of every 23 males would be expected to be diagnosed with lung cancer by age 75 years if he were not to die before that age from another disease.

Persons-Years of Life Lost (PYLL)

Years of potential life lost is a measure of the number of years of life lost per annum due to premature death from a particular cause, given a specified life expectancy. While life expectancy has changed, as discussed above, this report adopted the international approach of reporting this measure to age 74. There are a number of methods used to estimate cancer impact. This report used the simple approximation of:

$$\text{PYLL} = 75 - \text{age at death} \times \text{number of deaths at each age}$$

The calculation in this report was performed on five-year age groups from 0-4 through to 70-74 years.

Appendix 2 – List of Site-Specific Tables

All incidence and mortality rates in this appendix are per 100,000 people, adjusted to the Australian 2011 population.

<u>Table</u>	<u>ICDO-3 codes</u>
A2.1 Lip	C00
A2.2 Tongue	C01 C02
A2.3 Salivary Gland	C07 C08
A2.4 Mouth	C03-C06
A2.5 Oropharynx	C09 C10
A2.6 Nasopharynx	C11
A2.7 Hypopharynx	C12 C13
A2.8 Unspecified sites – lip, oral cavity and pharynx	C14
A2.9 Oesophagus	C15
A2.10 Stomach	C16
A2.11 Small intestine	C17
A2.12 Colon and rectum	C18-C20
A2.13 Anus, anal canal and anorectum	C21
A2.14 Liver and intrahepatic bile ducts	C22
A2.15 Gallbladder and bile ducts	C23 C24
A2.16 Pancreas	C25
A2.17 Nose, nasal cavities, middle ear and accessory sinuses	C30 C31
A2.18 Larynx	C32
A2.19 Trachea, bronchus and lung	C33 C34
A2.20 Heart, mediastinum and pleura	C38
A2.21 Thymus	C37.9
A2.22 Bone, joints and articular cartilage	C40-C41
A2.23 Melanoma of skin	C44. + M872-879
A2.24 Skin of lip	C44.0 (M800-811)
A2.25 Skin of anus (including perineum and perianal skin)	C44.5 (M800-811 8542)
A2.26 Connective and other soft tissue	C44. + M800-958 (excl tables A2.23 A2.24 A2.25) C47 C49
A2.27 Retroperitoneum and peritoneum	C48
A2.28 Female breast	C50f
A2.29 Male breast	C50m
A2.30 Vulva	C51
A2.31 Vagina	C52.9
A2.32 Cervix uteri	C53
A2.33 Body of the uterus	C54 C55
A2.34 Ovary	C56.9
A2.35 Other and unspecified female genitalia	C57
A2.36 Placenta	C58.9
A2.37 Penis	C60
A2.38 Prostate	C61.9
A2.39 Testis	C62
A2.40 Other male genitalia	C63
A2.41 Kidney	C64
A2.42 Renal pelvis, other and unspecified urinary organs	C65 C66 C68
A2.43 Bladder	C67
A2.44 Eye	C69
A2.45 Brain	C71
A2.46 Cranial nerves, spinal cord, meninges etc.	C70 C72
<u>Table</u>	<u>ICDO-3 codes</u>
A2.47 Thyroid gland	C73
A2.48 Other endocrine glands	C74 C75
A2.49 Other unspecified sites	C26 C39 C42 C76 C77 C80
A2.50 Non-Hodgkin lymphoma	M9591 9597 967-972 9735 9737 9738
A2.51 Hodgkin lymphoma	M965-966
A2.52 Other lymphomas	M9590 9596

A2.53	Mast cell tumours	M974
A2.54	Malignancy of histiocytes and accessory lymphoid cells	M975
A2.55	Multiple myeloma/plasma cell tumours	M9731-9734
A2.56	Immunoproliferative neoplasms	M976
A2.57	All leukemias	M980-994
A2.58	Polycythaemia vera	M9950
A2.59	Myelodysplastic syndromes	M998 999
A2.60	Other chronic myeloproliferative and haematological disorders	M996 9971 9975
A2.61	All cancers	
A2.62	Mesothelioma	M905
A2.63	Kaposi sarcoma	M9140
A2.64	Acute lymphocytic leukemia	M9826 9835-9837
A2.65	Chronic lymphocytic leukemia	M9823
A2.66	Other and unspecified lymphoid leukemia	M9820 9826-9837
A2.67	Acute myeloid leukemia	M9840 9861 9865-9874 9891-9920 9930-9931
A2.68	Chronic myeloid leukemia	M9863 9875-9876
A2.69	Other and unspecified myeloid leukemias	M9860
A2.70	Other specified leukemias	M994
A2.71	Leukemias NOS	M9800-9805
A2.72	Lip, and skin of lip (non-melanoma)	C00 C44.0 (M80-811)
A2.73	Melanoma of lip	C44.0 + M872-879
A2.74	Melanoma of eyelid, including canthus	C44.1 + M872-879
A2.75	Melanoma of ear	C44.2 + M872-879
A2.76	Melanoma of other and unspecified parts of face	C44.3 + M872-879
A2.77	Melanoma of scalp and neck	C44.4 + M872-879
A2.78	Melanoma of trunk	C44.5 + M872-879
A2.79	Melanoma of upper limb, including shoulder	C44.6 + M872-879
A2.80	Melanoma of lower limb, including hip	C44.7 + M872-879
A2.81	Melanoma of other site	C44.8 + M872-879
A2.82	Melanoma, site unspecified	C44.9 + M872-879

Table A2.1 – Cancer of the Lip

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	2	1	3	3.3	1.6	2.4	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	6	1	7	10.3	1.7	6.0	0	0	0	0.0	0.0	0.0
55–59	4	1	5	7.2	1.7	4.4	0	0	0	0.0	0.0	0.0
60–64	3	1	4	5.4	1.7	3.5	0	0	0	0.0	0.0	0.0
65–69	6	0	6	12.2	0.0	5.8	0	0	0	0.0	0.0	0.0
70–74	5	4	9	11.4	8.2	9.7	0	0	0	0.0	0.0	0.0
75–79	1	2	3	2.9	5.3	4.2	0	0	0	0.0	0.0	0.0
80–84	3	1	4	14.3	3.9	8.6	0	0	0	0.0	0.0	0.0
85+	3	3	6	16.1	10.3	12.5	0	1	1	0.0	3.4	2.1
Total/Crude rate	33	14	47	3.7	1.5	2.6	0	1	1	0.0	0.1	0.1
AS Rate (Aust)				3.2	1.1	2.1				0.0	0.1	0.0
Confidence Interval (95%)				2.1 – 4.3	0.5 – 1.7	1.5 – 2.7				0.0 – 0.0	0.0 – 0.2	0.0 – 0.1
AS Rate (World)				2.2	0.7	1.4				0.0	0.0	0.0
Confidence Interval (95%)				1.5 – 2.9	0.3 – 1.1	1.0 – 1.8				0.0 – 0.0	0.0 – 0.1	0.0 – 0.0
Lifetime Risk				1 in 403	1 in 1339	1 in 629				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.5	0.3	0.4				0.0	0.1	0.0
Trend 2018–2022 (per annum)				-13.2%	-2.1%	-11.1%				-18.6%	-9.1%	-13.8%

Table A2.2 – Cancer of the Tongue

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	1	1	0.0	1.7	0.8	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
50–54	8	2	10	13.8	3.4	8.5	0	0	0	0.0	0.0	0.0
55–59	8	3	11	14.3	5.2	9.7	0	1	1	0.0	1.7	0.9
60–64	15	4	19	27.0	6.8	16.6	3	0	3	5.4	0.0	2.6
65–69	13	5	18	26.4	9.3	17.5	8	1	9	16.2	1.9	8.8
70–74	7	3	10	15.9	6.2	10.8	3	1	4	6.8	2.1	4.3
75–79	7	3	10	20.6	7.9	13.9	1	1	2	2.9	2.6	2.8
80–84	2	3	5	9.6	11.7	10.7	1	1	2	4.8	3.9	4.3
85+	1	2	3	5.4	6.8	6.3	0	1	1	0.0	3.4	2.1
Total/Crude rate	63	28	91	7.0	3.0	5.0	16	6	22	1.8	0.7	1.2
AS Rate (Aust)				6.0	2.4	4.1				1.4	0.5	0.9
Confidence Interval (95%)				4.5 – 7.5	1.5 – 3.4	3.3 – 5.0				0.7 – 2.1	0.1 – 0.8	0.5 – 1.3
AS Rate (World)				4.2	1.7	2.9				0.9	0.3	0.6
Confidence Interval (95%)				3.2 – 5.2	1.1 – 2.4	2.3 – 3.5				0.5 – 1.4	0.1 – 0.5	0.3 – 0.8
Lifetime Risk				1 in 199	1 in 556	1 in 297				1 in 704	1 in 3,540	1 in 1,208
PYLL										105	28	133
% of all cancers				1.0	0.6	0.8				0.7	0.3	0.6
Trend 2018–2022 (per annum)				-1.8%	0.3%	-1.1%				0.6%	-12.6%	-4.1%

Table A2.3 – Cancer of the Salivary gland

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
40–44	1	1	2	1.8	1.8	1.8	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
50–54	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
55–59	2	3	5	3.6	5.2	4.4	1	1	2	1.8	1.7	1.8
60–64	1	1	2	1.8	1.7	1.7	0	0	0	0.0	0.0	0.0
65–69	2	2	4	4.1	3.7	3.9	1	0	1	2.0	0.0	1.0
70–74	2	0	2	4.5	0.0	2.2	0	0	0	0.0	0.0	0.0
75–79	2	1	3	5.9	2.6	4.2	1	0	1	2.9	0.0	1.4
80–84	2	0	2	9.6	0.0	4.3	1	1	2	4.8	3.9	4.3
85+	2	2	4	10.7	6.8	8.3	2	0	2	10.7	0.0	4.2
Total/Crude rate	15	12	27	1.7	1.3	1.5	6	2	8	0.7	0.2	0.4
AS Rate (Aust)				1.4	1.1	1.2				0.6	0.2	0.3
Confidence Interval (95%)				0.7 – 2.1	0.5 – 1.8	0.8 – 1.7				0.1 – 1.0	0.0 – 0.4	0.1 – 0.6
AS Rate (World)				0.9	0.8	0.9				0.3	0.1	0.2
Confidence Interval (95%)				0.5 – 1.3	0.4 – 1.3	0.5 – 1.2				0.1 – 0.5	0.0 – 0.3	0.1 – 0.3
Lifetime Risk				1 in 1141	1 in 1263	1 in 1207				1 in 5,238	1 in 11,570	1 in 7,324
PYLL										25	18	43
% of all cancers				0.2	0.2	0.2				0.3	0.1	0.2
Trend 2018–2022 (per annum)				-8.7%	3.8%	-4.1%				-11.8%	21.2%	-4.8%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.4 – Cancer of the Mouth

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
35–39	1	1	2	1.6	1.6	1.6	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	2	4	6	3.4	6.8	5.1	1	0	1	1.7	0.0	0.9
55–59	5	2	7	8.9	3.5	6.2	1	1	2	1.8	1.7	1.8
60–64	5	3	8	9.0	5.1	7.0	0	0	0	0.0	0.0	0.0
65–69	4	2	6	8.1	3.7	5.8	1	1	2	2.0	1.9	1.9
70–74	5	2	7	11.4	4.1	7.6	1	0	1	2.3	0.0	1.1
75–79	5	6	11	14.7	15.8	15.3	2	0	2	5.9	0.0	2.8
80–84	6	2	8	28.7	7.8	17.2	1	1	2	4.8	3.9	4.3
85+	0	4	4	0.0	13.7	8.3	1	1	2	5.4	3.4	4.2
Total/Crude rate	34	26	60	3.8	2.8	3.3	8	4	12	0.9	0.4	0.7
AS Rate (Aust)				3.1	2.1	2.6				0.7	0.3	0.5
Confidence Interval (95%)				2.1 – 4.2	1.3 – 3.0	2.0 – 3.3				0.2 – 1.2	0.0 – 0.6	0.2 – 0.8
AS Rate (World)				2.1	1.4	1.8				0.4	0.2	0.3
Confidence Interval (95%)				1.5 – 2.8	0.9 – 2.0	1.3 – 2.2				0.2 – 0.7	0.0 – 0.4	0.1 – 0.5
Lifetime Risk				1 in 454	1 in 808	1 in 587				1 in 2,560	1 in 5,562	1 in 3,549
PYLL										50	25	75
% of all cancers				0.5	0.5	0.5				0.4	0.2	0.3
Trend 2018–2022 (per annum)				0.9%	1.5%	1.2%				3.3%	-9.4%	-3.2%

Table A2.5 – Cancer of the Oropharynx

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	1	1	2	1.9	1.8	1.8	1	0	1	1.9	0.0	0.9
50–54	5	2	7	8.6	3.4	6.0	2	0	2	3.4	0.0	1.7
55–59	6	1	7	10.7	1.7	6.2	0	0	0	0.0	0.0	0.0
60–64	8	1	9	14.4	1.7	7.9	5	0	5	9.0	0.0	4.4
65–69	6	0	6	12.2	0.0	5.8	3	0	3	6.1	0.0	2.9
70–74	12	1	13	27.3	2.1	14.0	3	2	5	6.8	4.1	5.4
75–79	4	1	5	11.8	2.6	7.0	1	0	1	2.9	0.0	1.4
80–84	1	1	2	4.8	3.9	4.3	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	1	0	1	5.4	0.0	2.1
Total/Crude rate	45	8	53	5.0	0.9	2.9	16	2	18	1.8	0.2	1.0
AS Rate (Aust)				4.2	0.8	2.4				1.5	0.1	0.8
Confidence Interval (95%)				2.9 – 5.4	0.2 – 1.3	1.7 – 3.1				0.8 – 2.3	0.0 – 0.3	0.4 – 1.2
AS Rate (World)				3.0	0.6	1.8				1.0	0.1	0.5
Confidence Interval (95%)				2.2 – 3.9	0.2 – 0.9	1.3 – 2.2				0.5 – 1.6	0.0 – 0.2	0.3 – 0.8
Lifetime Risk				1 in 255	1 in 1871	1 in 461				1 in 736	1 in 4,868	1 in 1,307
PYLL										165	5	170
% of all cancers				0.7	0.2	0.5				0.7	0.1	0.5
Trend 2018–2022 (per annum)				-6.5%	1.1%	-5.5%				3.1%	-4.8%	1.7%

Table A2.6 – Cancer of the Nasopharynx

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	1	1	2	1.8	1.7	1.8
60–64	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
65–69	1	0	1	2.0	0.0	1.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	1	0	1	2.9	0.0	1.4	0	1	1	0.0	2.6	1.4
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	1	1	0.0	3.4	2.1
Total/Crude rate	2	2	4	0.2	0.2	0.2	1	3	4	0.1	0.3	0.2
AS Rate (Aust)				0.2	0.2	0.2				0.1	0.2	0.2
Confidence Interval (95%)				0.0 – 0.4	0.0 – 0.5	0.0 – 0.4				0.0 – 0.3	0.0 – 0.5	0.0 – 0.4
AS Rate (World)				0.1	0.2	0.1				0.1	0.1	0.1
Confidence Interval (95%)				0.0 – 0.2	0.0 – 0.4	0.0 – 0.3				0.0 – 0.2	0.0 – 0.3	0.0 – 0.2
Lifetime Risk				1 in 9853	1 in 5672	1 in 7231				1 in 11,180	1 in 11,570	1 in 11,375
PYLL										18	18	35
% of all cancers				0.0	0.0	0.0				0.0	0.2	0.1
Trend 2018–2022 (per annum)				11.1%	-7.7%	3.5%				-10.3%	151.9%	7.2%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.7 – Cancer of the Hypopharynx

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	2	0	2	3.7	0.0	1.8	0	0	0	0.0	0.0	0.0
50–54	3	0	3	5.2	0.0	2.6	1	0	1	1.7	0.0	0.9
55–59	0	0	0	0.0	0.0	0.0	1	0	1	1.8	0.0	0.9
60–64	3	0	3	5.4	0.0	2.6	0	0	0	0.0	0.0	0.0
65–69	1	0	1	2.0	0.0	1.0	1	0	1	2.0	0.0	1.0
70–74	4	0	4	9.1	0.0	4.3	1	0	1	2.3	0.0	1.1
75–79	1	0	1	2.9	0.0	1.4	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	1	0	1	4.8	0.0	2.1
85+	0	0	0	0.0	0.0	0.0	1	0	1	5.4	0.0	2.1
Total/Crude rate	14	0	14	1.6	0.0	0.8	6	0	6	0.7	0.0	0.3
AS Rate (Aust)				1.4	0.0	0.7				0.6	0.0	0.3
Confidence Interval (95%)				0.6 – 2.1	0.0 – 0.0	0.3 – 1.0				0.1 – 1.0	0.0 – 0.0	0.0 – 0.5
AS Rate (World)				1.0	0.0	0.5				0.4	0.0	0.2
Confidence Interval (95%)				0.5 – 1.5	0.0 – 0.0	0.2 – 0.8				0.1 – 0.6	0.0 – 0.0	0.0 – 0.3
Lifetime Risk				1 in 788	N/A	1 in 1625				1 in 2,560	N/A	1 in 5,285
PYLL										50	0	50
% of all cancers				0.2	0.0	0.1				0.3	0.0	0.2
Trend 2018–2022 (per annum)				46.3%	-14.7%	28.2%				19.2%	16.6%	18.7%

Table A2.8 – Cancer of Unspecified sites - lip, oral cavity and pharynx

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	2	0	2	3.6	0.0	1.7	1	0	1	1.8	0.0	0.9
65–69	1	0	1	2.0	0.0	1.0	0	0	0	0.0	0.0	0.0
70–74	2	0	2	4.5	0.0	2.2	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	1	1	0.0	3.4	2.1	0	0	0	0.0	0.0	0.0
Total/Crude rate	5	1	6	0.6	0.1	0.3	1	0	1	0.1	0.0	0.1
AS Rate (Aust)				0.4	0.1	0.2				0.1	0.0	0.0
Confidence Interval (95%)				0.0 – 0.8	0.0 – 0.2	0.0 – 0.4				0.0 – 0.3	0.0 – 0.0	0.0 – 0.1
AS Rate (World)				0.3	0.0	0.2				0.1	0.0	0.0
Confidence Interval (95%)				0.0 – 0.6	0.0 – 0.1	0.0 – 0.3				0.0 – 0.2	0.0 – 0.0	0.0 – 0.1
Lifetime Risk				1 in 1967	N/A	1 in 4102				1 in 11,124	N/A	1 in 22,913
PYLL										13	0	13
% of all cancers				0.1	0.0	0.1				0.0	0.0	0.0
Trend 2018–2022 (per annum)				-10.7%	-6.4%	-8.7%				-17.1%	-15.1%	-15.8%

Table A2.9 – Cancer of the Oesophagus

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	1	0	1	1.6	0.0	0.8
30–34	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.6	0.8
40–44	2	0	2	3.7	0.0	1.8	0	0	0	0.0	0.0	0.0
45–49	3	0	3	5.6	0.0	2.8	1	0	1	1.9	0.0	0.9
50–54	3	1	4	5.2	1.7	3.4	5	1	6	8.6	1.7	5.1
55–59	12	1	13	21.5	1.7	11.4	7	0	7	12.5	0.0	6.2
60–64	13	5	18	23.4	8.5	15.7	9	3	12	16.2	5.1	10.5
65–69	12	5	17	24.4	9.3	16.5	15	2	17	30.5	3.7	16.5
70–74	25	2	27	56.8	4.1	29.1	10	3	13	22.7	6.2	14.0
75–79	20	6	26	58.9	15.8	36.1	15	4	19	44.2	10.5	26.4
80–84	10	7	17	47.8	27.3	36.5	9	5	14	43.0	19.5	30.1
85+	13	3	16	69.6	10.3	33.4	14	7	21	74.9	24.0	43.8
Total/Crude rate	113	31	144	12.6	3.4	7.9	86	26	112	9.6	2.8	6.2
AS Rate (Aust)				10.1	2.5	6.0				7.8	2.0	4.7
Confidence Interval (95%)				8.2 – 12.0	1.6 – 3.3	5.0 – 7.0				6.1 – 9.5	1.2 – 2.7	3.8 – 5.6
AS Rate (World)				6.4	1.5	3.8				4.8	1.1	2.9
Confidence Interval (95%)				5.3 – 7.6	1.0 – 2.0	3.2 – 4.5				3.8 – 5.8	0.7 – 1.6	2.3 – 3.4
Lifetime Risk				1 in 143	1 in 742	1 in 246				1 in 213	1 in 1,094	1 in 365
PYLL										560	120	680
% of all cancers				1.8	0.6	1.3				4.0	1.5	2.9
Trend 2018–2022 (per annum)				-2.5%	-3.4%	-2.9%				-2.0%	10.7%	0.5%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.10 – Cancer of the Stomach

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
25–29	1	0	1	1.6	0.0	0.8	1	0	1	1.6	0.0	0.8
30–34	0	3	3	0.0	4.9	2.5	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	2	5	7	3.7	8.9	6.3	0	1	1	0.0	1.8	0.9
45–49	2	1	3	3.7	1.8	2.8	1	1	2	1.9	1.8	1.8
50–54	4	3	7	6.9	5.1	6.0	0	1	1	0.0	1.7	0.9
55–59	12	5	17	21.5	8.6	14.9	0	1	1	0.0	1.7	0.9
60–64	11	10	21	19.8	17.0	18.3	10	4	14	18.0	6.8	12.2
65–69	18	4	22	36.5	7.5	21.4	6	4	10	12.2	7.5	9.7
70–74	29	7	36	65.9	14.4	38.8	18	4	22	40.9	8.2	23.7
75–79	28	8	36	82.4	21.1	50.0	16	7	23	47.1	18.4	32.0
80–84	17	8	25	81.2	31.3	53.7	11	11	22	52.6	43.0	47.3
85+	15	12	27	80.3	41.1	56.4	15	12	27	80.3	41.1	56.4
Total/Crude rate	139	67	206	15.5	7.3	11.3	78	46	124	8.7	5.0	6.8
AS Rate (Aust)				12.3	5.7	8.7				6.8	3.5	5.0
Confidence Interval (95%)				10.2 – 14.4	4.3 – 7.1	7.5 – 10.0				5.2 – 8.3	2.5 – 4.5	4.1 – 5.9
AS Rate (World)				7.7	3.9	5.7				3.8	2.0	2.8
Confidence Interval (95%)				6.5 – 8.9	2.9 – 4.9	4.9 – 6.4				3.0 – 4.6	1.4 – 2.5	2.3 – 3.3
Lifetime Risk				1 in 126	1 in 286	1 in 178				1 in 269	1 in 678	1 in 393
PYLL										290	190	480
% of all cancers				2.2	1.3	1.8				3.6	2.6	3.2
Trend 2018–2022 (per annum)				-2.5%	3.5%	-0.5%				-6.0%	1.4%	-3.8%

Table A2.11 – Cancer of the Small intestine

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
35–39	1	2	3	1.6	3.2	2.4	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
50–54	4	2	6	6.9	3.4	5.1	0	0	0	0.0	0.0	0.0
55–59	5	3	8	8.9	5.2	7.0	0	0	0	0.0	0.0	0.0
60–64	2	4	6	3.6	6.8	5.2	1	1	2	1.8	1.7	1.7
65–69	5	4	9	10.2	7.5	8.8	3	0	3	6.1	0.0	2.9
70–74	6	6	12	13.6	12.3	12.9	3	1	4	6.8	2.1	4.3
75–79	1	7	8	2.9	18.4	11.1	2	3	5	5.9	7.9	7.0
80–84	4	3	7	19.1	11.7	15.0	2	1	3	9.6	3.9	6.4
85+	4	4	8	21.4	13.7	16.7	4	4	8	21.4	13.7	16.7
Total/Crude rate	33	37	70	3.7	4.0	3.8	15	10	25	1.7	1.1	1.4
AS Rate (Aust)				3.1	3.1	3.1				1.3	0.7	1.0
Confidence Interval (95%)				2.1 – 4.2	2.0 – 4.1	2.3 – 3.8				0.6 – 2.0	0.3 – 1.1	0.6 – 1.3
AS Rate (World)				2.1	2.1	2.1				0.7	0.3	0.5
Confidence Interval (95%)				1.4 – 2.8	1.4 – 2.8	1.6 – 2.6				0.4 – 1.0	0.1 – 0.5	0.3 – 0.7
Lifetime Risk				1 in 431	1 in 477	1 in 453				1 in 1,361	1 in 5,332	1 in 2,228
PYLL										43	15	58
% of all cancers				0.5	0.7	0.6				0.7	0.6	0.6
Trend 2018–2022 (per annum)				2.0%	6.4%	3.8%				-3.0%	2.0%	-0.4%

Table A2.12 – Cancer of the Colon and rectum

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	2	2	4	3.8	4.0	3.9	0	0	0	0.0	0.0	0.0
20–24	3	1	4	5.2	1.9	3.6	0	1	1	0.0	1.9	0.9
25–29	2	2	4	3.2	3.4	3.3	0	0	0	0.0	0.0	0.0
30–34	9	8	17	14.8	13.1	13.9	3	0	3	4.9	0.0	2.5
35–39	11	13	24	18.0	20.9	19.5	3	1	4	4.9	1.6	3.3
40–44	11	19	30	20.1	33.8	27.1	2	5	7	3.7	8.9	6.3
45–49	20	14	34	37.0	25.6	31.3	1	3	4	1.9	5.5	3.7
50–54	42	30	72	72.4	50.7	61.5	4	7	11	6.9	11.8	9.4
55–59	38	25	63	68.0	43.2	55.4	13	3	16	23.3	5.2	14.1
60–64	64	46	110	115.1	78.0	96.0	16	17	33	28.8	28.8	28.8
65–69	77	52	129	156.3	97.1	125.5	22	16	38	44.7	29.9	37.0
70–74	97	62	159	220.3	127.4	171.5	21	13	34	47.7	26.7	36.7
75–79	63	70	133	185.5	184.4	184.9	22	20	42	64.8	52.7	58.4
80–84	67	84	151	320.1	328.1	324.5	36	26	62	172.0	101.6	133.3
85+	71	108	179	379.9	366.3	371.6	64	79	143	342.4	270.4	298.5
Total/Crude rate	577	536	1,113	64.1	58.1	61.1	207	191	398	23.0	20.7	21.9
AS Rate (Aust)				54.1	43.5	48.6				19.2	14.3	16.5
Confidence Interval (95%)				49.6 – 58.6	39.7 – 47.3	45.7 – 51.5				16.6 – 21.8	12.2 – 16.4	14.9 – 18.1
AS Rate (World)				35.7	28.3	31.9				10.6	7.9	9.1
Confidence Interval (95%)				32.8 – 38.6	25.8 – 30.8	30.0 – 33.8				9.2 – 11.9	6.7 – 9.2	8.2 – 10.0
Lifetime Risk				1 in 28	1 in 41	1 in 33				1 in 121	1 in 167	1 in 141
PYLL										1,068	910	1,978
% of all cancers				9.0	10.7	9.8				9.6	10.9	10.2
Trend 2018–2022 (per annum)				-3.7%	-3.7%	-3.7%				-3.9%	-2.6%	-3.3%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.13 – Cancer of the Anus, anal canal, anorectum

South Australia Year – 2022											
Incidence						Mortality					
New cases			Rates			Deaths			Rates		
Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
45–49	3	3	6	5.6	5.5	5.5	0	2	2	0.0	3.7
50–54	2	3	5	3.4	5.1	4.3	1	1	2	1.7	1.7
55–59	0	2	2	0.0	3.5	1.8	0	1	1	0.0	1.7
60–64	1	7	8	1.8	11.9	7.0	0	2	2	0.0	3.4
65–69	1	2	3	2.0	3.7	2.9	0	1	1	0.0	1.9
70–74	2	4	6	4.5	8.2	6.5	0	1	1	0.0	2.1
75–79	4	2	6	11.8	5.3	8.3	1	2	3	2.9	5.3
80–84	0	1	1	0.0	3.9	2.1	0	1	1	0.0	3.9
85+	1	5	6	5.4	17.1	12.5	1	1	2	5.4	3.4
Total/Crude rate	14	29	43	1.6	3.1	2.4	3	12	15	0.3	1.3
AS Rate (Aust)				1.3	2.5	2.0				0.3	1.1
Confidence Interval (95%)				0.6 – 2.1	1.6 – 3.5	1.4 – 2.6				0.0 – 0.6	0.4 – 1.7
AS Rate (World)				1.0	1.7	1.4				0.2	0.8
Confidence Interval (95%)				0.4 – 1.5	1.0 – 2.4	0.9 – 1.8				0.0 – 0.4	0.3 – 1.2
Lifetime Risk				1 in 1152	1 in 529	1 in 717				1 in 11,598	1 in 1,390
PYLL										23	130
% of all cancers				0.2	0.6	0.4				0.1	0.7
Trend 2018–2022 (per annum)				2.6%	-2.2%	-1.0%				-15.8%	2.4%

Table A2.14 – Cancer of the Liver and intrahepatic bile ducts

South Australia Year – 2022											
Incidence						Mortality					
New cases			Rates			Deaths			Rates		
Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	1	0	1	1.7	0.0
25–29	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.7
30–34	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.6
40–44	0	2	2	0.0	3.6	1.8	1	1	2	1.8	1.8
45–49	1	0	1	1.9	0.0	0.9	2	0	2	3.7	0.0
50–54	4	0	4	6.9	0.0	3.4	2	2	4	3.4	3.4
55–59	13	1	14	23.3	1.7	12.3	4	2	6	7.2	3.5
60–64	14	1	15	25.2	1.7	13.1	14	5	19	25.2	8.5
65–69	16	7	23	32.5	13.1	22.4	12	4	16	24.4	7.5
70–74	19	4	23	43.1	8.2	24.8	18	4	22	40.9	8.2
75–79	15	13	28	44.2	34.2	38.9	12	10	22	35.3	26.3
80–84	17	8	25	81.2	31.3	53.7	16	6	22	76.4	23.4
85+	14	10	24	74.9	34.2	50.1	16	9	25	85.6	30.8
Total/Crude rate	113	47	160	12.6	5.1	8.8	98	45	143	10.9	4.9
AS Rate (Aust)				10.2	3.5	6.6				8.9	3.5
Confidence Interval (95%)				8.3 – 12.1	2.5 – 4.5	5.6 – 7.7				7.1 – 10.7	2.5 – 4.6
AS Rate (World)				6.3	2.1	4.1				5.3	2.2
Confidence Interval (95%)				5.2 – 7.3	1.5 – 2.6	3.5 – 4.7				4.3 – 6.3	1.5 – 2.9
Lifetime Risk				1 in 151	1 in 669	1 in 252				1 in 185	1 in 555
PYLL										565	300
% of all cancers				1.8	0.9	1.4				4.6	2.6
Trend 2018–2022 (per annum)				-1.5%	-5.3%	-3.0%				-0.1%	6.9%

Table A2.15 – Cancer of the Gallbladder and bile ducts

South Australia Year – 2022											
Incidence						Mortality					
New cases			Rates			Deaths			Rates		
Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
35–39	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0
40–44	0	1	1	0.0	1.8	0.9	0	1	1	0.0	1.8
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
50–54	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0
55–59	2	0	2	3.6	0.0	1.8	1	1	2	1.8	1.7
60–64	3	3	6	5.4	5.1	5.2	2	7	9	3.6	11.9
65–69	9	5	14	18.3	9.3	13.6	4	4	8	8.1	7.5
70–74	6	11	17	13.6	22.6	18.3	4	2	6	9.1	4.1
75–79	3	9	12	8.8	23.7	16.7	5	10	15	14.7	26.3
80–84	10	7	17	47.8	27.3	36.5	5	9	14	23.9	35.2
85+	8	10	18	42.8	34.2	37.6	11	13	24	58.9	44.5
Total/Crude rate	42	47	89	4.7	5.1	4.9	32	47	79	3.6	5.1
AS Rate (Aust)				3.8	3.4	3.6				2.9	3.5
Confidence Interval (95%)				2.6 – 4.9	2.4 – 4.4	2.8 – 4.3				1.9 – 3.8	2.5 – 4.5
AS Rate (World)				2.1	2.0	2.1				1.4	1.9
Confidence Interval (95%)				1.5 – 2.7	1.4 – 2.6	1.6 – 2.5				1.0 – 1.9	1.4 – 2.5
Lifetime Risk				1 in 470	1 in 495	1 in 482				1 in 886	1 in 742
PYLL										83	173
% of all cancers				0.7	0.9	0.8				1.5	2.7
Trend 2018–2022 (per annum)				-4.5%	-6.3%	-5.6%				3.6%	-0.3%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.16 – Cancer of the Pancreas

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	1	1	2	1.6	1.7	1.7	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
35–39	2	0	2	3.3	0.0	1.6	0	0	0	0.0	0.0	0.0
40–44	1	1	2	1.8	1.8	1.8	0	2	2	0.0	3.6	1.8
45–49	2	3	5	3.7	5.5	4.6	2	2	4	3.7	3.7	3.7
50–54	7	7	14	12.1	11.8	12.0	5	3	8	8.6	5.1	6.8
55–59	14	7	21	25.0	12.1	18.5	6	9	15	10.7	15.6	13.2
60–64	18	12	30	32.4	20.4	26.2	18	14	32	32.4	23.8	27.9
65–69	23	20	43	46.7	37.3	41.8	22	20	42	44.7	37.3	40.9
70–74	42	23	65	95.4	47.3	70.1	30	15	45	68.1	30.8	48.5
75–79	27	35	62	79.5	92.2	86.2	28	35	63	82.4	92.2	87.6
80–84	19	28	47	90.8	109.4	101.0	26	18	44	124.2	70.3	94.6
85+	26	27	53	139.1	92.4	110.6	24	36	60	128.4	123.2	125.2
Total/Crude rate	182	166	348	20.2	18.0	19.1	161	154	315	17.9	16.7	17.3
AS Rate (Aust)				16.2	12.8	14.4				14.2	11.6	12.8
Confidence Interval (95%)				13.8 – 18.6	10.8 – 14.8	12.8 – 15.9				12.0 – 16.4	9.7 – 13.5	11.4 – 14.3
AS Rate (World)				10.1	7.9	8.9				8.3	6.9	7.6
Confidence Interval (95%)				8.6 – 11.5	6.7 – 9.1	8.0 – 9.8				7.1 – 9.6	5.8 – 8.0	6.7 – 8.4
Lifetime Risk				1 in 91	1 in 142	1 in 112				1 in 119	1 in 167	1 in 141
PYLL										738	708	1,445
% of all cancers				2.9	3.3	3.1				7.5	8.8	8.1
Trend 2018–2022 (per annum)				0.8%	-1.4%	-0.2%				2.7%	3.5%	3.2%

Table A2.17 – Cancer of the Nose, nasal cavities, middle ear and accessory sinuses

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	1	0	1	1.7	0.0	0.9	1	0	1	1.7	0.0	0.9
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	3	1	4	5.4	1.7	3.5	0	0	0	0.0	0.0	0.0
65–69	1	1	2	2.0	1.9	1.9	1	0	1	2.0	0.0	1.0
70–74	1	2	3	2.3	4.1	3.2	1	0	1	2.3	0.0	1.1
75–79	0	0	0	0.0	0.0	0.0	1	1	2	2.9	2.6	2.8
80–84	0	1	1	0.0	3.9	2.1	0	0	0	0.0	0.0	0.0
85+	2	0	2	10.7	0.0	4.2	2	1	3	10.7	3.4	6.3
Total/Crude rate	10	7	17	1.1	0.8	0.9	6	2	8	0.7	0.2	0.4
AS Rate (Aust)				1.0	0.6	0.8				0.5	0.1	0.3
Confidence Interval (95%)				0.4 – 1.6	0.1 – 1.1	0.4 – 1.2				0.1 – 1.0	0.0 – 0.3	0.1 – 0.5
AS Rate (World)				0.7	0.5	0.6				0.3	0.1	0.2
Confidence Interval (95%)				0.2 – 1.1	0.1 – 0.8	0.3 – 0.8				0.1 – 0.6	0.0 – 0.1	0.1 – 0.3
Lifetime Risk				1 in 1329	1 in 1805	1 in 1533				1 in 3,320	N/A	1 in 6,885
PYLL										33	0	33
% of all cancers				0.2	0.1	0.1				0.3	0.1	0.2
Trend 2018–2022 (per annum)				10.8%	-3.1%	3.0%				9.3%	-13.0%	-0.9%

Table A2.18 – Cancer of the Larynx

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	2	1	3	3.4	1.7	2.6	0	0	0	0.0	0.0	0.0
55–59	2	0	2	3.6	0.0	1.8	0	0	0	0.0	0.0	0.0
60–64	4	2	6	7.2	3.4	5.2	4	0	4	7.2	0.0	3.5
65–69	4	1	5	8.1	1.9	4.9	1	0	1	2.0	0.0	1.0
70–74	6	0	6	13.6	0.0	6.5	1	1	2	2.3	2.1	2.2
75–79	6	0	6	17.7	0.0	8.3	2	0	2	5.9	0.0	2.8
80–84	6	1	7	28.7	3.9	15.0	1	0	1	4.8	0.0	2.1
85+	3	1	4	16.1	3.4	8.3	5	1	6	26.8	3.4	12.5
Total/Crude rate	34	6	40	3.8	0.7	2.2	14	2	16	1.6	0.2	0.9
AS Rate (Aust)				3.1	0.5	1.7				1.3	0.1	0.6
Confidence Interval (95%)				2.0 – 4.1	0.1 – 0.9	1.2 – 2.2				0.6 – 2.0	0.0 – 0.3	0.3 – 1.0
AS Rate (World)				1.9	0.3	1.1				0.7	0.1	0.3
Confidence Interval (95%)				1.3 – 2.5	0.1 – 0.6	0.7 – 1.4				0.3 – 1.0	0.0 – 0.2	0.2 – 0.5
Lifetime Risk				1 in 529	1 in 2877	1 in 917				1 in 1,741	1 in 9,735	1 in 3,021
PYLL										60	3	63
% of all cancers				0.5	0.1	0.4				0.7	0.1	0.4
Trend 2018–2022 (per annum)				5.5%	-1.1%	4.3%				-1.7%	-20.7%	-4.7%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.19 – Cancer of the Trachea, bronchus and lung

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	2	3	1.6	3.2	2.4	2	0	2	3.3	0.0	1.6
40–44	2	4	6	3.7	7.1	5.4	0	0	0	0.0	0.0	0.0
45–49	16	10	26	29.6	18.3	23.9	5	3	8	9.3	5.5	7.4
50–54	18	17	35	31.0	28.8	29.9	8	6	14	13.8	10.1	12.0
55–59	27	25	52	48.3	43.2	45.7	16	20	36	28.6	34.6	31.7
60–64	58	59	117	104.3	100.1	102.1	41	30	71	73.7	50.9	62.0
65–69	100	76	176	203.0	141.9	171.2	59	45	104	119.8	84.0	101.2
70–74	90	60	150	204.4	123.3	161.8	64	46	110	145.3	94.5	118.7
75–79	100	96	196	294.4	252.9	272.5	70	65	135	206.1	171.2	187.7
80–84	92	59	151	439.6	230.5	324.5	64	50	114	305.8	195.3	245.0
85+	71	45	116	379.9	154.0	242.1	69	66	135	369.2	225.9	281.8
Total/Crude rate	575	454	1,029	63.9	49.3	56.5	398	331	729	44.2	35.9	40.0
AS Rate (Aust)				51.4	35.9	42.8				35.3	24.8	29.5
Confidence Interval (95%)				47.1 – 55.6	32.5 – 39.3	40.2 – 45.5				31.8 – 38.8	22.1 – 27.5	27.4 – 31.7
AS Rate (World)				31.1	23.0	26.7				20.4	14.6	17.3
Confidence Interval (95%)				28.7 – 33.6	20.9 – 25.1	25.1 – 28.3				18.5 – 22.3	13.1 – 16.2	16.1 – 18.5
Lifetime Risk				1 in 32	1 in 43	1 in 37				1 in 51	1 in 72	1 in 60
PYLL										1,788	1,395	3,183
% of all cancers				9.0	9.1	9.0				18.5	18.9	18.7
Trend 2018–2022 (per annum)				-3.6%	-0.9%	-2.4%				-4.6%	-0.4%	-2.8%

Table A2.20 – Cancer of the Heart, mediastinum and pleura

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	1	0	1	1.9	0.0	1.0	1	0	1	1.9	0.0	1.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	2	1	3	3.6	1.7	2.6	0	0	0	0.0	0.0	0.0
65–69	4	0	4	8.1	0.0	3.9	5	3	8	10.2	5.6	7.8
70–74	8	2	10	18.2	4.1	10.8	6	0	6	13.6	0.0	6.5
75–79	16	7	23	47.1	18.4	32.0	10	2	12	29.4	5.3	16.7
80–84	18	4	22	86.0	15.6	47.3	14	2	16	66.9	7.8	34.4
85+	9	2	11	48.2	6.8	23.0	17	4	21	91.0	13.7	43.8
Total/Crude rate	59	16	75	6.6	1.7	4.1	53	11	64	5.9	1.2	3.5
AS Rate (Aust)				5.1	1.1	2.9				4.7	0.8	2.5
Confidence Interval (95%)				3.8 – 6.4	0.6 – 1.7	2.3 – 3.6				3.4 – 6.0	0.3 – 1.2	1.9 – 3.1
AS Rate (World)				2.8	0.6	1.6				2.4	0.4	1.3
Confidence Interval (95%)				2.2 – 3.5	0.4 – 0.9	1.3 – 2.0				1.8 – 2.9	0.2 – 0.6	1.0 – 1.6
Lifetime Risk				1 in 599	1 in 3445	1 in 1049				1 in 780	1 in 3,570	1 in 1,315
PYLL										110	23	133
% of all cancers				0.9	0.3	0.7				2.5	0.6	1.6
Trend 2018–2022 (per annum)				-1.2%	-13.2%	-4.8%				-1.3%	-7.3%	-3.3%

Table A2.21 – Cancer of the Thymus

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
55–59	3	0	3	5.4	0.0	2.6	1	0	1	1.8	0.0	0.9
60–64	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
65–69	2	0	2	4.1	0.0	1.9	1	0	1	2.0	0.0	1.0
70–74	0	0	0	0.0	0.0	0.0	1	0	1	2.3	0.0	1.1
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	1	0	1	4.8	0.0	2.1	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	8	2	10	0.9	0.2	0.5	3	0	3	0.3	0.0	0.2
AS Rate (Aust)				0.8	0.2	0.5				0.3	0.0	0.1
Confidence Interval (95%)				0.3 – 1.4	0.0 – 0.5	0.2 – 0.8				0.0 – 0.6	0.0 – 0.0	0.0 – 0.3
AS Rate (World)				0.6	0.2	0.4				0.2	0.0	0.1
Confidence Interval (95%)				0.2 – 1.0	0.0 – 0.5	0.2 – 0.7				0.0 – 0.4	0.0 – 0.0	0.0 – 0.2
Lifetime Risk				1 in 1541	1 in 5625	1 in 2468				1 in 3,285	N/A	1 in 6,825
PYLL										28	0	28
% of all cancers				0.1	0.0	0.1				0.1	0.0	0.1
Trend 2018–2022 (per annum)				28.5%	-4.6%	7.8%				-19.3%	-21.4%	-20.3%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.22 – Cancer of the Bone, joints and articular cartilage

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	1	1	0.0	2.1	1.0	0	0	0	0.0	0.0	0.0
5–9	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
10–14	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	1	0	1	1.7	0.0	0.9	0	1	1	0.0	1.9	0.9
25–29	2	0	2	3.2	0.0	1.7	1	0	1	1.6	0.0	0.8
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	1	2	1.6	1.6	1.6	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	2	0	2	3.4	0.0	1.7	0	0	0	0.0	0.0	0.0
55–59	2	1	3	3.6	1.7	2.6	1	0	1	1.8	0.0	0.9
60–64	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	2	1	3	4.5	2.1	3.2	1	1	2	2.3	2.1	2.2
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	1	0	1	4.8	0.0	2.1
85+	0	1	1	0.0	3.4	2.1	0	0	0	0.0	0.0	0.0
Total/Crude rate	14	5	19	1.6	0.5	1.0	4	2	6	0.4	0.2	0.3
AS Rate (Aust)				1.5	0.5	1.0				0.4	0.2	0.3
Confidence Interval (95%)				0.7 – 2.3	0.0 – 0.9	0.5 – 1.5				0.0 – 0.8	0.0 – 0.5	0.1 – 0.5
AS Rate (World)				1.5	0.4	1.0				0.3	0.2	0.2
Confidence Interval (95%)				0.7 – 2.3	0.0 – 0.9	0.5 – 1.4				0.0 – 0.6	0.0 – 0.5	0.0 – 0.5
Lifetime Risk				1 in 786	1 in 2671	1 in 1217				1 in 3,521	1 in 5,110	1 in 4,205
PYLL										68	55	123
% of all cancers				0.2	0.1	0.2				0.2	0.1	0.2
Trend 2018–2022 (per annum)				24.3%	-1.3%	12.3%				47.4%	-10.8%	9.3%

Table A2.23 – Melanoma of skin

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	2	0	2	3.8	0.0	1.9	0	0	0	0.0	0.0	0.0
20–24	2	1	3	3.4	1.9	2.7	0	0	0	0.0	0.0	0.0
25–29	2	5	7	3.2	8.4	5.8	0	0	0	0.0	0.0	0.0
30–34	4	6	10	6.6	9.8	8.2	0	0	0	0.0	0.0	0.0
35–39	5	9	14	8.2	14.5	11.4	0	0	0	0.0	0.0	0.0
40–44	10	14	24	18.3	24.9	21.6	0	0	0	0.0	0.0	0.0
45–49	15	18	33	27.8	32.9	30.4	0	0	0	0.0	0.0	0.0
50–54	28	26	54	48.3	44.0	46.1	1	1	2	1.7	1.7	1.7
55–59	33	25	58	59.0	43.2	51.0	1	1	2	1.8	1.7	1.8
60–64	38	28	66	68.3	47.5	57.6	2	0	2	3.6	0.0	1.7
65–69	54	40	94	109.6	74.7	91.4	1	5	6	2.0	9.3	5.8
70–74	68	48	116	154.4	98.6	125.1	8	1	9	18.2	2.1	9.7
75–79	66	37	103	194.3	97.5	143.2	8	2	10	23.6	5.3	13.9
80–84	43	31	74	205.5	121.1	159.0	7	2	9	33.4	7.8	19.3
85+	48	44	92	256.8	150.6	192.0	11	9	20	58.9	30.8	41.7
Total/Crude rate	418	332	750	46.5	36.0	41.2	39	21	60	4.3	2.3	3.3
AS Rate (Aust)				38.8	28.6	33.2				3.4	1.5	2.4
Confidence Interval (95%)				35.0 – 42.6	25.4 – 31.8	30.8 – 35.7				2.3 – 4.5	0.9 – 2.2	1.8 – 3.0
AS Rate (World)				25.7	20.2	22.7				1.8	0.8	1.3
Confidence Interval (95%)				23.2 – 28.1	18.0 – 22.5	21.1 – 24.4				1.3 – 2.3	0.5 – 1.2	1.0 – 1.6
Lifetime Risk				1 in 40	1 in 50	1 in 45				1 in 733	1 in 1,351	1 in 964
PYLL										93	80	173
% of all cancers				6.5	6.6	6.6				1.8	1.2	1.5
Trend 2018–2022 (per annum)				-4.4%	0.6%	-2.3%				-5.7%	3.2%	-3.2%

Table A2.24 – Cancer of the Skin of lip

South Australia Year – 2022												
Incidence						Mortality						
New cases			Rates			Deaths			Rates			
Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
40–44	1	1	2	1.8	1.8	1.8	0	0	0	0.0	0.0	0.0
45–49	1	3	4	1.9	5.5	3.7	0	0	0	0.0	0.0	0.0
50–54	4	0	4	6.9	0.0	3.4	0	1	1	0.0	1.7	0.9
55–59	5	3	8	8.9	5.2	7.0	0	0	0	0.0	0.0	0.0
60–64	4	1	5	7.2	1.7	4.4	0	0	0	0.0	0.0	0.0
65–69	3	2	5	6.1	3.7	4.9	0	0	0	0.0	0.0	0.0
70–74	7	2	9	15.9	4.1	9.7	0	0	0	0.0	0.0	0.0
75–79	1	3	4	2.9	7.9	5.6	0	0	0	0.0	0.0	0.0
80–84	2	3	5	9.6	11.7	10.7	0	0	0	0.0	0.0	0.0
85+	4	5	9	21.4	17.1	18.8	0	0	0	0.0	0.0	0.0
Total/Crude rate	33	23	56	3.7	2.5	3.1	0	1	1	0.0	0.1	0.1
AS Rate (Aust)				3.2	1.9	2.5				0.0	0.1	0.1
Confidence Interval (95%)				2.1 – 4.3	1.1 – 2.8	1.9 – 3.2				0.0 – 0.0	0.0 – 0.3	0.0 – 0.2
AS Rate (World)				2.2	1.3	1.7				0.0	0.1	0.0
Confidence Interval (95%)				1.5 – 2.9	0.7 – 1.8	1.3 – 2.2				0.0 – 0.0	0.0 – 0.3	0.0 – 0.1
Lifetime Risk				1 in 398	1 in 910	1 in 561				N/A	1 in 11,826	1 in 23,423
PYLL										0	23	23
% of all cancers				0.5	0.5	0.5				0.0	0.1	0.0
Trend 2018–2022 (per annum)				-8.0%	2.7%	-4.5%				-9.4%	undefined	41.5%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.25 – Cancer of the Skin of anus (including perineum, perianal skin)

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
65–69	1	1	2	2.0	1.9	1.9	0	0	0	0.0	0.0	0.0
70–74	1	5	6	2.3	10.3	6.5	0	0	0	0.0	0.0	0.0
75–79	1	2	3	2.9	5.3	4.2	0	3	3	0.0	7.9	4.2
80–84	1	0	1	4.8	0.0	2.1	0	0	0	0.0	0.0	0.0
85+	1	2	3	5.4	6.8	6.3	0	0	0	0.0	0.0	0.0
Total/Crude rate	8	11	19	0.9	1.2	1.0	0	3	3	0.0	0.3	0.2
AS Rate (Aust)				0.8	0.8	0.8				0.0	0.2	0.1
Confidence Interval (95%)				0.2 – 1.3	0.3 – 1.2	0.4 – 1.1				0.0 – 0.0	0.0 – 0.4	0.0 – 0.2
AS Rate (World)				0.5	0.5	0.5				0.0	0.1	0.1
Confidence Interval (95%)				0.1 – 0.8	0.2 – 0.8	0.3 – 0.7				0.0 – 0.0	0.0 – 0.2	0.0 – 0.1
Lifetime Risk				1 in 2054	1 in 1453	1 in 1680				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.1	0.2	0.2				0.0	0.2	0.1
Trend 2018–2022 (per annum)				29.9%	31.4%	30.8%				16.7%	undefined	undefined

Table A2.26 – Cancer of the Connective and other soft tissue

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	1	2	3	2.0	4.2	3.1	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	1	2	3	1.8	3.8	2.8	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	3	3	0.0	5.1	2.5	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
35–39	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
40–44	1	2	3	1.8	3.6	2.7	0	0	0	0.0	0.0	0.0
45–49	6	3	9	11.1	5.5	8.3	0	0	0	0.0	0.0	0.0
50–54	5	0	5	8.6	0.0	4.3	1	0	1	1.7	0.0	0.9
55–59	5	1	6	8.9	1.7	5.3	1	0	1	1.8	0.0	0.9
60–64	3	7	10	5.4	11.9	8.7	0	0	0	0.0	0.0	0.0
65–69	8	5	13	16.2	9.3	12.6	2	1	3	4.1	1.9	2.9
70–74	13	8	21	29.5	16.4	22.7	6	1	7	13.6	2.1	7.6
75–79	6	4	10	17.7	10.5	13.9	4	0	4	11.8	0.0	5.6
80–84	13	9	22	62.1	35.2	47.3	1	5	6	4.8	19.5	12.9
85+	20	13	33	107.0	44.5	68.9	7	6	13	37.5	20.5	27.1
Total/Crude rate	83	60	143	9.2	6.5	7.9	22	13	35	2.4	1.4	1.9
AS Rate (Aust)				7.9	5.1	6.3				1.9	0.9	1.4
Confidence Interval (95%)				6.2 – 9.6	3.7 – 6.4	5.3 – 7.4				1.1 – 2.7	0.4 – 1.4	0.9 – 1.8
AS Rate (World)				4.9	3.7	4.2				1.0	0.4	0.7
Confidence Interval (95%)				3.8 – 6.0	2.6 – 4.8	3.4 – 5.0				0.6 – 1.4	0.2 – 0.6	0.5 – 0.9
Lifetime Risk				1 in 230	1 in 318	1 in 269				1 in 944	1 in 5,100	1 in 1,640
PYLL										70	10	80
% of all cancers				1.3	1.2	1.3				1.0	0.7	0.9
Trend 2018–2022 (per annum)				0.4%	0.4%	0.3%				0.1%	-11.4%	-4.8%

Table A2.27 – Cancer of Retroperitoneum and peritoneum

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	1	1	0.0	1.7	0.8	0	1	1	0.0	1.7	0.8
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	2	0	2	3.7	0.0	1.8	0	0	0	0.0	0.0	0.0
50–54	2	1	3	3.4	1.7	2.6	0	0	0	0.0	0.0	0.0
55–59	0	2	2	0.0	3.5	1.8	0	3	3	0.0	5.2	2.6
60–64	1	1	2	1.8	1.7	1.7	0	0	0	0.0	0.0	0.0
65–69	0	3	3	0.0	5.6	2.9	0	3	3	0.0	5.6	2.9
70–74	0	2	2	0.0	4.1	2.2	2	5	7	4.5	10.3	7.6
75–79	1	4	5	2.9	10.5	7.0	2	2	4	5.9	5.3	5.6
80–84	0	1	1	0.0	3.9	2.1	0	2	2	0.0	7.8	4.3
85+	1	2	3	5.4	6.8	6.3	1	3	4	5.4	10.3	8.3
Total/Crude rate	7	17	24	0.8	1.8	1.3	5	19	24	0.6	2.1	1.3
AS Rate (Aust)				0.8	1.4	1.1				0.4	1.5	1.0
Confidence Interval (95%)				0.2 – 1.3	0.7 – 2.0	0.6 – 1.5				0.0 – 0.7	0.8 – 2.2	0.6 – 1.4
AS Rate (World)				0.6	0.9	0.8				0.2	1.0	0.6
Confidence Interval (95%)				0.1 – 1.0	0.5 – 1.4	0.4 – 1.1				0.1 – 0.4	0.5 – 1.4	0.4 – 0.9
Lifetime Risk				1 in 2235	1 in 1097	1 in 1449				1 in 4,404	1 in 880	1 in 1,436
PYLL										5	135	140
% of all cancers				0.1	0.3	0.2				0.2	1.1	0.6
Trend 2018–2022 (per annum)				-3.8%	-11.1%	-9.5%				-18.0%	-5.2%	-9.6%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.28 – Cancer of the Female breast

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	3	3	0.0	5.1	2.5	0	0	0	0.0	0.0	0.0
30–34	0	11	11	0.0	18.0	9.0	0	0	0	0.0	0.0	0.0
35–39	0	43	43	0.0	69.3	34.9	0	0	0	0.0	0.0	0.0
40–44	0	58	58	0.0	103.1	52.3	0	3	3	0.0	5.3	2.7
45–49	0	110	110	0.0	201.3	101.2	0	4	4	0.0	7.3	3.7
50–54	0	173	173	0.0	292.6	147.7	0	10	10	0.0	16.9	8.5
55–59	0	137	137	0.0	236.8	120.4	0	14	14	0.0	24.2	12.3
60–64	0	220	220	0.0	373.2	192.0	0	20	20	0.0	33.9	17.5
65–69	0	201	201	0.0	375.4	195.5	0	25	25	0.0	46.7	24.3
70–74	0	236	236	0.0	484.9	254.6	0	26	26	0.0	53.4	28.0
75–79	0	138	138	0.0	363.5	191.9	0	30	30	0.0	79.0	41.7
80–84	0	115	115	0.0	449.2	247.2	0	32	32	0.0	125.0	68.8
85+	0	103	103	0.0	352.6	215.0	0	57	57	0.0	195.1	119.0
Total/Crude rate	0	1,548	1,548	0.0	168.1	85.0	0	221	221	0.0	24.0	12.1
AS Rate (Aust)				0.0	138.3	71.9				0.0	17.0	9.2
Confidence Interval (95%)				0.0 – 0.0	131.2 – 145.4	68.2 – 75.6				0.0 – 0.0	14.7 – 19.3	8.0 – 10.5
AS Rate (World)				0.0	99.7	51.4				0.0	10.1	5.4
Confidence Interval (95%)				0.0 – 0.0	94.6 – 104.7	48.8 – 54.0				0.0 – 0.0	8.8 – 11.5	4.7 – 6.1
Lifetime Risk				N/A	1 in 10	1 in 19				N/A	1 in 107	1 in 207
PYLL										0	1,180	1,180
% of all cancers				0.0	30.9	13.6				0.0	12.6	5.7
Trend 2018–2022 (per annum)				0.0%	-0.6%	-0.6%				0.0%	-3.0%	-3.0%

Table A2.29 – Cancer of the Male breast

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
55–59	2	0	2	3.6	0.0	1.8	0	0	0	0.0	0.0	0.0
60–64	2	0	2	3.6	0.0	1.7	0	0	0	0.0	0.0	0.0
65–69	2	0	2	4.1	0.0	1.9	0	0	0	0.0	0.0	0.0
70–74	2	0	2	4.5	0.0	2.2	0	0	0	0.0	0.0	0.0
75–79	4	0	4	11.8	0.0	5.6	1	0	1	2.9	0.0	1.4
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	1	0	1	5.4	0.0	2.1	0	0	0	0.0	0.0	0.0
Total/Crude rate	15	0	15	1.7	0.0	0.8	1	0	1	0.1	0.0	0.1
AS Rate (Aust)				1.4	0.0	0.7				0.1	0.0	0.0
Confidence Interval (95%)				0.7 – 2.1	0.0 – 0.0	0.3 – 1.0				0.0 – 0.2	0.0 – 0.0	0.0 – 0.1
AS Rate (World)				0.9	0.0	0.4				0.0	0.0	0.0
Confidence Interval (95%)				0.5 – 1.4	0.0 – 0.0	0.2 – 0.7				0.0 – 0.1	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				1 in 1034	N/A	1 in 2132				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.2	0.0	0.1				0.0	0.0	0.0
Trend 2018–2022 (per annum)				-3.7%	0.0%	-3.4%				-23.6%	0.0%	-22.8%

Table A2.30 – Cancer of the Vulva

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
35–39	0	2	2	0.0	3.2	1.6	0	0	0	0.0	0.0	0.0
40–44	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	2	2	0.0	3.4	1.7
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	6	6	0.0	11.2	5.8	0	1	1	0.0	1.9	1.0
70–74	0	4	4	0.0	8.2	4.3	0	1	1	0.0	2.1	1.1
75–79	0	6	6	0.0	15.8	8.3	0	1	1	0.0	2.6	1.4
80–84	0	11	11	0.0	43.0	23.6	0	0	0	0.0	0.0	0.0
85+	0	7	7	0.0	24.0	14.6	0	6	6	0.0	20.5	12.5
Total/Crude rate	0	38	38	0.0	4.1	2.1	0	11	11	0.0	1.2	0.6
AS Rate (Aust)				0.0	2.9	1.6				0.0	0.8	0.5
Confidence Interval (95%)				0.0 – 0.0	2.0 – 3.8	1.1 – 2.1				0.0 – 0.0	0.3 – 1.3	0.2 – 0.7
AS Rate (World)				0.0	1.8	0.9				0.0	0.4	0.2
Confidence Interval (95%)				0.0 – 0.0	1.2 – 2.3	0.7 – 1.2				0.0 – 0.0	0.2 – 0.7	0.1 – 0.4
Lifetime Risk				N/A	1 in 768	1 in 1482				N/A	1 in 2,739	1 in 5,321
PYLL										0	55	55
% of all cancers				0.0	0.8	0.3				0.0	0.6	0.3
Trend 2018–2022 (per annum)				0.0%	1.1%	1.0%				0.0%	-7.3%	-8.2%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.31 – Cancer of the Vagina

South Australia Year – 2022											
Incidence						Mortality					
New cases			Rates			Deaths			Rates		
Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.6	0	0	0	0.0	0.0	0.0
35–39	0	1	1	0.0	1.6	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	1	1	0.0	1.7	0	0	0	0.0	0.0	0.0
55–59	0	2	2	0.0	3.5	0	1	1	0.0	1.7	0.9
60–64	0	1	1	0.0	1.7	0	0	0	0.0	0.0	0.0
65–69	0	2	2	0.0	3.7	0	0	0	0.0	0.0	0.0
70–74	0	1	1	0.0	2.1	0	1	1	0.0	2.1	1.1
75–79	0	2	2	0.0	5.3	0	0	0	0.0	0.0	0.0
80–84	0	1	1	0.0	3.9	0	0	0	0.0	0.0	0.0
85+	0	1	1	0.0	3.4	0	1	1	0.0	3.4	2.1
Total/Crude rate	0	13	13	0.0	1.4	0.7	0	3	3	0.0	0.2
AS Rate (Aust)				0.0	1.1	0.6				0.0	0.2
Confidence Interval (95%)				0.0 – 0.0	0.5 – 1.8	0.3 – 0.9				0.0 – 0.0	0.0 – 0.5
AS Rate (World)				0.0	0.8	0.4				0.0	0.1
Confidence Interval (95%)				0.0 – 0.0	0.4 – 1.3	0.2 – 0.7				0.0 – 0.0	0.0 – 0.3
Lifetime Risk				N/A	1 in 1260	1 in 2457				N/A	1 in 5,287
PYLL										0	20
% of all cancers				0.0	0.3	0.1				0.0	0.2
Trend 2018–2022 (per annum)				0.0%	24.2%	24.1%				0.0%	-7.8%

Table A2.32 – Cancer of the Cervix uteri

South Australia Year – 2022											
Incidence						Mortality					
New cases			Rates			Deaths			Rates		
Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	1	1	0.0	1.9	0	0	0	0.0	0.0	0.0
25–29	0	1	1	0.0	1.7	0	0	0	0.0	0.0	0.0
30–34	0	5	5	0.0	8.2	0	3	3	0.0	4.9	2.5
35–39	0	8	8	0.0	12.9	0	1	1	0.0	1.6	0.8
40–44	0	12	12	0.0	21.3	0	2	2	0.0	3.6	1.8
45–49	0	8	8	0.0	14.6	0	4	4	0.0	7.3	3.7
50–54	0	6	6	0.0	10.1	0	5	5	0.0	8.5	4.3
55–59	0	4	4	0.0	6.9	0	0	0	0.0	0.0	0.0
60–64	0	4	4	0.0	6.8	0	1	1	0.0	1.7	0.9
65–69	0	3	3	0.0	5.6	0	2	2	0.0	3.7	1.9
70–74	0	2	2	0.0	4.1	0	0	0	0.0	0.0	0.0
75–79	0	2	2	0.0	5.3	0	1	1	0.0	2.6	1.4
80–84	0	3	3	0.0	11.7	0	0	0	0.0	0.0	0.0
85+	0	1	1	0.0	3.4	0	1	1	0.0	3.4	2.1
Total/Crude rate	0	60	60	0.0	6.5	3.3	0	20	20	0.0	2.2
AS Rate (Aust)				0.0	6.5	3.3				0.0	2.2
Confidence Interval (95%)				0.0 – 0.0	4.8 – 8.2	2.5 – 4.2				0.0 – 0.0	1.2 – 3.1
AS Rate (World)				0.0	5.7	2.9				0.0	1.9
Confidence Interval (95%)				0.0 – 0.0	4.3 – 7.1	2.2 – 3.6				0.0 – 0.0	1.1 – 2.6
Lifetime Risk				N/A	1 in 213	1 in 420				N/A	1 in 640
PYLL										0	480
% of all cancers				0.0	1.2	0.5				0.0	1.1
Trend 2018–2022 (per annum)				0.0%	-3.8%	-3.7%				0.0%	-0.2%

Table A2.33 – Cancer of the Body of the uterus

South Australia Year – 2022											
Incidence						Mortality					
New cases			Rates			Deaths			Rates		
Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.6	0	0	0	0.0	0.0	0.0
35–39	0	3	3	0.0	4.8	0	0	0	0.0	0.0	0.0
40–44	0	5	5	0.0	8.9	0	0	0	0.0	0.0	0.0
45–49	0	9	9	0.0	16.5	0	0	0	0.0	0.0	0.0
50–54	0	25	25	0.0	42.3	0	1	1	0.0	1.7	0.9
55–59	0	23	23	0.0	39.8	0	1	1	0.0	1.7	0.9
60–64	0	28	28	0.0	47.5	0	8	8	0.0	13.6	7.0
65–69	0	37	37	0.0	69.1	0	9	9	0.0	16.8	8.8
70–74	0	43	43	0.0	88.3	0	11	11	0.0	22.6	11.9
75–79	0	22	22	0.0	57.9	0	9	9	0.0	23.7	12.5
80–84	0	19	19	0.0	74.2	0	11	11	0.0	43.0	23.6
85+	0	12	12	0.0	41.1	0	5	5	0.0	17.1	10.4
Total/Crude rate	0	227	227	0.0	24.6	12.5	0	55	55	0.0	6.0
AS Rate (Aust)				0.0	19.5	10.2				0.0	4.2
Confidence Interval (95%)				0.0 – 0.0	16.9 – 22.1	8.8 – 11.5				0.0 – 0.0	3.1 – 5.3
AS Rate (World)				0.0	13.7	7.1				0.0	2.5
Confidence Interval (95%)				0.0 – 0.0	11.9 – 15.5	6.2 – 8.0				0.0 – 0.0	1.9 – 3.2
Lifetime Risk				N/A	1 in 63	1 in 122				N/A	1 in 355
PYLL										0	235
% of all cancers				0.0	4.5	2.0				0.0	3.1
Trend 2018–2022 (per annum)				0.0%	-4.0%	-4.0%				0.0%	-4.7%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.34 – Cancer of the Ovary

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	2	2	0.0	3.7	1.8	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.7	0.8
30–34	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
35–39	0	3	3	0.0	4.8	2.4	0	0	0	0.0	0.0	0.0
40–44	0	3	3	0.0	5.3	2.7	0	0	0	0.0	0.0	0.0
45–49	0	6	6	0.0	11.0	5.5	0	0	0	0.0	0.0	0.0
50–54	0	7	7	0.0	11.8	6.0	0	3	3	0.0	5.1	2.6
55–59	0	11	11	0.0	19.0	9.7	0	4	4	0.0	6.9	3.5
60–64	0	10	10	0.0	17.0	8.7	0	8	8	0.0	13.6	7.0
65–69	0	12	12	0.0	22.4	11.7	0	6	6	0.0	11.2	5.8
70–74	0	17	17	0.0	34.9	18.3	0	15	15	0.0	30.8	16.2
75–79	0	8	8	0.0	21.1	11.1	0	7	7	0.0	18.4	9.7
80–84	0	8	8	0.0	31.3	17.2	0	8	8	0.0	31.3	17.2
85+	0	9	9	0.0	30.8	18.8	0	10	10	0.0	34.2	20.9
Total/Crude rate	0	97	97	0.0	10.5	5.3	0	62	62	0.0	6.7	3.4
AS Rate (Aust)				0.0	8.5	4.4				0.0	4.8	2.6
Confidence Interval (95%)				0.0 – 0.0	6.8 – 10.3	3.5 – 5.3				0.0 – 0.0	3.6 – 6.0	1.9 – 3.2
AS Rate (World)				0.0	6.2	3.2				0.0	3.0	1.6
Confidence Interval (95%)				0.0 – 0.0	4.9 – 7.4	2.5 – 3.8				0.0 – 0.0	2.2 – 3.8	1.2 – 2.0
Lifetime Risk				N/A	1 in 152	1 in 296				N/A	1 in 289	1 in 558
PYLL										0	368	368
% of all cancers				0.0	1.9	0.9				0.0	3.5	1.6
Trend 2018–2022 (per annum)				0.0%	-0.2%	-0.5%				0.0%	-4.0%	-4.2%

Table A2.35 – Cancer of Other and unspecified female genitalia

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
40–44	0	2	2	0.0	3.6	1.8	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	2	2	0.0	3.4	1.7	0	2	2	0.0	3.4	1.7
55–59	0	4	4	0.0	6.9	3.5	0	0	0	0.0	0.0	0.0
60–64	0	4	4	0.0	6.8	3.5	0	2	2	0.0	3.4	1.7
65–69	0	6	6	0.0	11.2	5.8	0	2	2	0.0	3.7	1.9
70–74	0	4	4	0.0	8.2	4.3	0	1	1	0.0	2.1	1.1
75–79	0	7	7	0.0	18.4	9.7	0	3	3	0.0	7.9	4.2
80–84	0	3	3	0.0	11.7	6.4	0	7	7	0.0	27.3	15.0
85+	0	2	2	0.0	6.8	4.2	0	0	0	0.0	0.0	0.0
Total/Crude rate	0	35	35	0.0	3.8	1.9	0	17	17	0.0	1.8	0.9
AS Rate (Aust)				0.0	2.9	1.5				0.0	1.4	0.7
Confidence Interval (95%)				0.0 – 0.0	1.9 – 3.9	1.0 – 2.1				0.0 – 0.0	0.7 – 2.0	0.4 – 1.1
AS Rate (World)				0.0	2.0	1.1				0.0	0.8	0.4
Confidence Interval (95%)				0.0 – 0.0	1.4 – 2.7	0.7 – 1.4				0.0 – 0.0	0.5 – 1.2	0.2 – 0.6
Lifetime Risk				N/A	1 in 480	1 in 931				N/A	1 in 1,592	1 in 3,088
PYLL										0	88	88
% of all cancers				0.0	0.7	0.3				0.0	1.0	0.4
Trend 2018–2022 (per annum)				0.0%	14.8%	14.8%				0.0%	19.2%	19.3%

Table A2.36 – Cancer of the Placenta

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	0	1	1	0.0	0.1	0.1	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				0.0	0.1	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.3	0.0 – 0.2				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				0.0	0.1	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.3	0.0 – 0.2				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				N/A	1 in 12248	1 in 24427				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.0	0.0
Trend 2018–2022 (per annum)				0.0%	undefined	undefined				0.0%	0.0%	0.0%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.37 – Cancer of the Penis

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	1	0	1	1.6	0.0	0.8
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	2	0	2	3.7	0.0	1.8	0	0	0	0.0	0.0	0.0
50–54	2	0	2	3.4	0.0	1.7	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	1	0	1	1.8	0.0	0.9	1	0	1	1.8	0.0	0.9
65–69	2	0	2	4.1	0.0	1.9	1	0	1	2.0	0.0	1.0
70–74	1	0	1	2.3	0.0	1.1	0	0	0	0.0	0.0	0.0
75–79	1	0	1	2.9	0.0	1.4	1	0	1	2.9	0.0	1.4
80–84	0	0	0	0.0	0.0	0.0	1	0	1	4.8	0.0	2.1
85+	2	0	2	10.7	0.0	4.2	1	0	1	5.4	0.0	2.1
Total/Crude rate	12	0	12	1.3	0.0	0.7	6	0	6	0.7	0.0	0.3
AS Rate (Aust)				1.2	0.0	0.6				0.6	0.0	0.3
Confidence Interval (95%)				0.5 – 1.9	0.0 – 0.0	0.2 – 0.9				0.1 – 1.0	0.0 – 0.0	0.0 – 0.5
AS Rate (World)				0.8	0.0	0.4				0.4	0.0	0.2
Confidence Interval (95%)				0.4 – 1.3	0.0 – 0.0	0.2 – 0.6				0.1 – 0.6	0.0 – 0.0	0.0 – 0.3
Lifetime Risk				1 in 1172	N/A	1 in 2403				1 in 3,658	N/A	1 in 7,524
PYLL										58	0	58
% of all cancers				0.2	0.0	0.1				0.3	0.0	0.2
Trend 2018–2022 (per annum)				1.1%	0.0%	-0.4%				-11.5%	0.0%	-12.4%

Table A2.38 – Cancer of the Prostate

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
40–44	2	0	2	3.7	0.0	1.8	0	0	0	0.0	0.0	0.0
45–49	16	0	16	29.6	0.0	14.7	0	0	0	0.0	0.0	0.0
50–54	76	0	76	131.1	0.0	64.9	1	0	1	1.7	0.0	0.9
55–59	171	0	171	305.9	0.0	150.3	2	0	2	3.6	0.0	1.8
60–64	328	0	328	589.7	0.0	286.3	10	0	10	18.0	0.0	8.7
65–69	437	0	437	887.1	0.0	425.1	20	0	20	40.6	0.0	19.5
70–74	485	0	485	1,101.4	0.0	523.2	35	0	35	79.5	0.0	37.8
75–79	365	0	365	1,074.7	0.0	507.4	41	0	41	120.7	0.0	57.0
80–84	192	0	192	917.4	0.0	412.6	45	0	45	215.0	0.0	96.7
85+	105	0	105	561.8	0.0	219.2	107	0	107	572.5	0.0	223.4
Total/Crude rate	2,178	0	2,178	242.1	0.0	119.6	261	0	261	29.0	0.0	14.3
AS Rate (Aust)				190.8	0.0	90.3				23.3	0.0	10.1
Confidence Interval (95%)				182.7 – 198.9	0.0 – 0.0	86.4 – 94.1				20.4 – 26.1	0.0 – 0.0	8.8 – 11.3
AS Rate (World)				123.7	0.0	59.0				11.1	0.0	4.9
Confidence Interval (95%)				118.7 – 128.7	0.0 – 0.0	56.6 – 61.4				9.9 – 12.2	0.0 – 0.0	4.4 – 5.5
Lifetime Risk				1 in 7	N/A	1 in 14				1 in 140	N/A	1 in 292
PYLL										420	0	420
% of all cancers				34.1	0.0	19.1				12.2	0.0	6.7
Trend 2018–2022 (per annum)				3.6%	0.0%	3.5%				-4.0%	0.0%	-3.6%

Table A2.39 – Cancer of the Testis

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	4	0	4	6.9	0.0	3.6	0	0	0	0.0	0.0	0.0
25–29	12	0	12	19.5	0.0	9.9	0	0	0	0.0	0.0	0.0
30–34	17	0	17	27.9	0.0	13.9	0	0	0	0.0	0.0	0.0
35–39	21	0	21	34.4	0.0	17.1	0	0	0	0.0	0.0	0.0
40–44	7	0	7	12.8	0.0	6.3	0	0	0	0.0	0.0	0.0
45–49	10	0	10	18.5	0.0	9.2	1	0	1	1.9	0.0	0.9
50–54	5	0	5	8.6	0.0	4.3	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
65–69	1	0	1	2.0	0.0	1.0	0	0	0	0.0	0.0	0.0
70–74	1	0	1	2.3	0.0	1.1	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	79	0	79	8.8	0.0	4.3	1	0	1	0.1	0.0	0.1
AS Rate (Aust)				9.3	0.0	4.7				0.1	0.0	0.1
Confidence Interval (95%)				7.3 – 11.4	0.0 – 0.0	3.6 – 5.7				0.0 – 0.4	0.0 – 0.0	0.0 – 0.2
AS Rate (World)				9.3	0.0	4.6				0.1	0.0	0.1
Confidence Interval (95%)				7.4 – 11.2	0.0 – 0.0	3.7 – 5.6				0.0 – 0.3	0.0 – 0.0	0.0 – 0.2
Lifetime Risk				1 in 149	N/A	1 in 298				1 in 10,801	N/A	1 in 21,731
PYLL										28	0	28
% of all cancers				1.2	0.0	0.7				0.0	0.0	0.0
Trend 2018–2022 (per annum)				1.9%	0.0%	1.8%				-5.7%	0.0%	-4.7%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.40 – Cancer of Other male genital organs

South Australia Year – 2022											
Incidence						Mortality					
New cases			Rates			Deaths			Rates		
Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	1	0	1	2.0	0.0	1	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	2	0	2	9.6	0.0	4	1	0	4.8	0.0	2.1
85+	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	3	0	3	0.3	0.0	0.2	1	0	1	0.1	0.0
AS Rate (Aust)				0.3	0.0	0.1				0.1	0.0
Confidence Interval (95%)				0.0 – 0.6	0.0 – 0.0	0.0 – 0.3				0.0 – 0.3	0.0 – 0.0
AS Rate (World)				0.1	0.0	0.1				0.0	0.0
Confidence Interval (95%)				0.0 – 0.3	0.0 – 0.0	0.0 – 0.1				0.0 – 0.1	0.0 – 0.0
Lifetime Risk				1 in 9853	N/A	1 in 20563				N/A	N/A
PYLL										0	0
% of all cancers				0.0	0.0	0.0				0.0	0.0
Trend 2018–2022 (per annum)				26.1%	0.0%	20.4%				undefined	0.0%

Table A2.41 – Cancer of the Kidney

South Australia Year – 2022											
Incidence						Mortality					
New cases			Rates			Deaths			Rates		
Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	1	1	2	2.0	2.1	2.0	0	0	0	0.0	0.0
5–9	0	1	1	0.0	1.9	0.9	0	1	1	0.0	0.9
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0
25–29	4	1	5	6.5	1.7	4.1	0	0	0	0.0	0.0
30–34	3	3	6	4.9	4.9	4.9	0	0	0	0.0	0.0
35–39	2	1	3	3.3	1.6	2.4	1	0	1	1.6	0.8
40–44	6	3	9	11.0	5.3	8.1	1	0	1	1.8	0.9
45–49	13	4	17	24.1	7.3	15.6	2	0	2	3.7	1.8
50–54	15	5	20	25.9	8.5	17.1	2	0	2	3.4	1.7
55–59	18	16	34	32.2	27.7	29.9	5	2	7	8.9	6.2
60–64	38	14	52	68.3	23.8	45.4	8	0	8	14.4	7.0
65–69	38	11	49	77.1	20.5	47.7	7	4	11	14.2	10.7
70–74	40	13	53	90.8	26.7	57.2	5	5	10	11.4	10.8
75–79	24	13	37	70.7	34.2	51.4	16	1	17	47.1	23.6
80–84	17	9	26	81.2	35.2	55.9	9	7	16	43.0	34.4
85+	14	4	18	74.9	13.7	37.6	8	7	15	42.8	31.3
Total/Crude rate	233	99	332	25.9	10.7	18.2	64	27	91	7.1	5.0
AS Rate (Aust)				22.0	8.8	15.1				5.8	2.0
Confidence Interval (95%)				19.2 – 24.9	7.0 – 10.6	13.4 – 16.7				4.4 – 7.3	1.2 – 2.8
AS Rate (World)				15.4	6.5	10.8				3.6	1.2
Confidence Interval (95%)				13.4 – 17.4	5.2 – 7.8	9.6 – 12.0				2.8 – 4.5	0.7 – 1.7
Lifetime Risk				1 in 58	1 in 152	1 in 85				1 in 337	1 in 865
PYLL										423	145
% of all cancers				3.6	2.0	2.9				3.0	1.5
Trend 2018–2022 (per annum)				-3.0%	-3.2%	-3.1%				-1.4%	-2.7%

Table A2.42 – Cancer of the Renal pelvis, other and unspecified urinary organs

South Australia Year – 2022											
Incidence						Mortality					
New cases			Rates			Deaths			Rates		
Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0
45–49	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	1	1	2	1.8	1.7	1.8	0	1	1	0.0	1.7
60–64	6	1	7	10.8	1.7	6.1	0	0	0	0.0	0.0
65–69	1	1	2	2.0	1.9	1.9	1	2	3	2.0	3.7
70–74	5	2	7	11.4	4.1	7.6	1	0	1	2.3	0.0
75–79	4	4	8	11.8	10.5	11.1	0	1	1	0.0	2.6
80–84	3	7	10	14.3	27.3	21.5	4	3	7	19.1	11.7
85+	2	1	3	10.7	3.4	6.3	3	5	8	16.1	17.1
Total/Crude rate	23	17	40	2.6	1.8	2.2	9	12	21	1.0	1.3
AS Rate (Aust)				2.1	1.3	1.7				0.8	0.9
Confidence Interval (95%)				1.2 – 2.9	0.7 – 1.9	1.1 – 2.2				0.3 – 1.4	0.4 – 1.4
AS Rate (World)				1.3	0.7	1.0				0.4	0.4
Confidence Interval (95%)				0.8 – 1.8	0.4 – 1.0	0.7 – 1.3				0.2 – 0.6	0.2 – 0.7
Lifetime Risk				1 in 720	1 in 2128	1 in 1095				1 in 4,651	1 in 3,661
PYLL										10	33
% of all cancers				0.4	0.3	0.4				0.4	0.7
Trend 2018–2022 (per annum)				-6.9%	-5.8%	-6.5%				-14.2%	6.9%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.43 – Cancer of the Bladder

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	1	2	1.6	1.6	1.6	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.8	0.0	0.9	1	0	1	1.8	0.0	0.9
45–49	2	0	2	3.7	0.0	1.8	1	0	1	1.9	0.0	0.9
50–54	6	1	7	10.3	1.7	6.0	0	0	0	0.0	0.0	0.0
55–59	17	3	20	30.4	5.2	17.6	5	1	6	8.9	1.7	5.3
60–64	21	11	32	37.8	18.7	27.9	1	1	2	1.8	1.7	1.7
65–69	26	5	31	52.8	9.3	30.2	7	2	9	14.2	3.7	8.8
70–74	30	7	37	68.1	14.4	39.9	4	7	11	9.1	14.4	11.9
75–79	37	6	43	108.9	15.8	59.8	20	6	26	58.9	15.8	36.1
80–84	32	11	43	152.9	43.0	92.4	18	5	23	86.0	19.5	49.4
85+	45	26	71	240.8	89.0	148.2	34	15	49	181.9	51.3	102.3
Total/Crude rate	218	71	289	24.2	7.7	15.9	91	37	128	10.1	4.0	7.0
AS Rate (Aust)				19.7	5.3	11.9				8.3	2.5	5.0
Confidence Interval (95%)				17.0 – 22.3	4.0 – 6.5	10.5 – 13.3				6.5 – 10.0	1.7 – 3.4	4.2 – 5.9
AS Rate (World)				11.4	2.9	6.9				4.1	1.3	2.5
Confidence Interval (95%)				9.9 – 12.8	2.2 – 3.6	6.1 – 7.6				3.3 – 4.8	0.9 – 1.7	2.1 – 2.9
Lifetime Risk				1 in 97	1 in 394	1 in 159				1 in 531	1 in 929	1 in 679
PYLL										223	63	285
% of all cancers				3.4	1.4	2.5				4.2	2.1	3.3
Trend 2018–2022 (per annum)				-1.2%	0.8%	-0.6%				-2.8%	10.9%	0.0%

Table A2.44 – Cancer of the Eye

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	2	2	0.0	4.2	2.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
40–44	2	0	2	3.7	0.0	1.8	0	0	0	0.0	0.0	0.0
45–49	0	2	2	0.0	3.7	1.8	0	0	0	0.0	0.0	0.0
50–54	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
55–59	2	0	2	3.6	0.0	1.8	0	0	0	0.0	0.0	0.0
60–64	3	0	3	5.4	0.0	2.6	0	0	0	0.0	0.0	0.0
65–69	0	3	3	0.0	5.6	2.9	0	0	0	0.0	0.0	0.0
70–74	1	1	2	2.3	2.1	2.2	1	0	1	2.3	0.0	1.1
75–79	2	1	3	5.9	2.6	4.2	2	2	4	5.9	5.3	5.6
80–84	1	0	1	4.8	0.0	2.1	1	1	2	4.8	3.9	4.3
85+	4	0	4	21.4	0.0	8.3	2	1	3	10.7	3.4	6.3
Total/Crude rate	17	10	27	1.9	1.1	1.5	6	4	10	0.7	0.4	0.5
AS Rate (Aust)				1.7	1.0	1.3				0.5	0.3	0.4
Confidence Interval (95%)				0.9 – 2.5	0.4 – 1.7	0.8 – 1.8				0.1 – 0.9	0.0 – 0.5	0.1 – 0.6
AS Rate (World)				1.2	0.9	1.0				0.2	0.1	0.2
Confidence Interval (95%)				0.6 – 1.7	0.3 – 1.6	0.6 – 1.5				0.1 – 0.4	0.0 – 0.2	0.1 – 0.3
Lifetime Risk				1 in 1095	1 in 1163	1 in 1130				1 in 8,807	N/A	1 in 18,542
PYLL										3	0	3
% of all cancers				0.3	0.2	0.2				0.3	0.2	0.3
Trend 2018–2022 (per annum)				-0.9%	-12.6%	-7.0%				30.4%	5.3%	15.8%

Table A2.45 – Cancer of the Brain

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	1	1	0.0	2.1	1.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.9	0.9
10–14	2	3	5	3.6	5.6	4.6	0	0	0	0.0	0.0	0.0
15–19	1	1	2	1.9	2.0	1.9	0	0	0	0.0	0.0	0.0
20–24	3	0	3	5.2	0.0	2.7	0	0	0	0.0	0.0	0.0
25–29	4	3	7	6.5	5.1	5.8	0	1	1	0.0	1.7	0.8
30–34	1	1	2	1.6	1.6	1.6	1	2	3	1.6	3.3	2.5
35–39	4	4	8	6.6	6.4	6.5	0	1	1	0.0	1.6	0.8
40–44	1	0	1	1.8	0.0	0.9	2	1	3	3.7	1.8	2.7
45–49	2	1	3	3.7	1.8	2.8	4	1	5	7.4	1.8	4.6
50–54	8	3	11	13.8	5.1	9.4	5	0	5	8.6	0.0	4.3
55–59	16	5	21	28.6	8.6	18.5	12	4	16	21.5	6.9	14.1
60–64	12	13	25	21.6	22.1	21.8	8	7	15	14.4	11.9	13.1
65–69	10	6	16	20.3	11.2	15.6	9	7	16	18.3	13.1	15.6
70–74	15	6	21	34.1	12.3	22.7	4	9	13	9.1	18.5	14.0
75–79	11	15	26	32.4	39.5	36.1	12	8	20	35.3	21.1	27.8
80–84	5	6	11	23.9	23.4	23.6	5	3	8	23.9	11.7	17.2
85+	8	2	10	42.8	6.8	20.9	6	7	13	32.1	24.0	27.1
Total/Crude rate	103	70	173	11.4	7.6	9.5	68	52	120	7.6	5.6	6.6
AS Rate (Aust)				10.0	6.2	8.0				6.6	4.3	5.4
Confidence Interval (95%)				8.1 – 12.0	4.7 – 7.7	6.8 – 9.2				5.0 – 8.1	3.1 – 5.4	4.4 – 6.3
AS Rate (World)				7.5	4.9	6.2				4.5	3.0	3.7
Confidence Interval (95%)				6.0 – 9.0	3.6 – 6.1	5.2 – 7.1				3.4 – 5.5	2.1 – 3.9	3.0 – 4.4
Lifetime Risk				1 in 135	1 in 239	1 in 173				1 in 237	1 in 273	1 in 273
PYLL										718	530	1,248
% of all cancers				1.6	1.4	1.5				3.2	3.0	3.1
Trend 2018–2022 (per annum)				0.3%	3.9%	1.7%				-7.0%	-1.6%	-4.9%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.46 – Cancer of the Cranial nerves, spinal cord, meninges etc.

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	0	1	1	0.0	1.7	0.9	1	0	1	1.7	0.0	0.9
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	1	4	5	2.0	7.5	4.9	0	0	0	0.0	0.0	0.0
70–74	0	1	1	0.0	2.1	1.1	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	2	2	0.0	6.8	4.2	0	0	0	0.0	0.0	0.0
Total/Crude rate	4	8	12	0.4	0.9	0.7	1	0	1	0.1	0.0	0.1
AS Rate (Aust)				0.5	0.6	0.6				0.1	0.0	0.1
Confidence Interval (95%)				0.0 – 0.9	0.2 – 1.1	0.2 – 0.9				0.0 – 0.3	0.0 – 0.0	0.0 – 0.2
AS Rate (World)				0.4	0.4	0.4				0.1	0.0	0.0
Confidence Interval (95%)				0.0 – 0.9	0.1 – 0.7	0.2 – 0.7				0.0 – 0.3	0.0 – 0.0	0.0 – 0.1
Lifetime Risk				1 in 2690	1 in 1784	1 in 2103				1 in 11,598	N/A	1 in 23,423
PYLL										23	0	23
% of all cancers				0.1	0.2	0.1				0.0	0.0	0.0
Trend 2018–2022 (per annum)				0.3%	0.8%	1.3%				26.5%	-19.4%	-3.8%

Table A2.47 – Cancer of the Thyroid gland

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	1	1	2	1.8	1.9	1.8	0	0	0	0.0	0.0	0.0
15–19	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
20–24	2	5	7	3.4	9.3	6.3	0	0	0	0.0	0.0	0.0
25–29	0	7	7	0.0	11.8	5.8	0	0	0	0.0	0.0	0.0
30–34	4	5	9	6.6	8.2	7.4	0	0	0	0.0	0.0	0.0
35–39	0	6	6	0.0	9.7	4.9	0	0	0	0.0	0.0	0.0
40–44	6	2	8	11.0	3.6	7.2	0	0	0	0.0	0.0	0.0
45–49	3	12	15	5.6	22.0	13.8	0	0	0	0.0	0.0	0.0
50–54	6	9	15	10.3	15.2	12.8	2	0	2	3.4	0.0	1.7
55–59	4	12	16	7.2	20.7	14.1	1	0	1	1.8	0.0	0.9
60–64	6	10	16	10.8	17.0	14.0	2	0	2	3.6	0.0	1.7
65–69	5	16	21	10.2	29.9	20.4	1	1	2	2.0	1.9	1.9
70–74	2	5	7	4.5	10.3	7.6	2	1	3	4.5	2.1	3.2
75–79	4	5	9	11.8	13.2	12.5	1	1	2	2.9	2.6	2.8
80–84	6	6	12	28.7	23.4	25.8	2	3	5	9.6	11.7	10.7
85+	1	2	3	5.4	6.8	6.3	0	2	2	0.0	6.8	4.2
Total/Crude rate	50	104	154	5.6	11.3	8.5	11	8	19	1.2	0.9	1.0
AS Rate (Aust)				5.2	10.5	7.9				1.0	0.6	0.8
Confidence Interval (95%)				3.8 – 6.7	8.5 – 12.6	6.6 – 9.2				0.4 – 1.7	0.2 – 1.0	0.4 – 1.2
AS Rate (World)				4.2	8.9	6.5				0.7	0.3	0.5
Confidence Interval (95%)				3.0 – 5.3	7.1 – 10.6	5.5 – 7.6				0.3 – 1.1	0.1 – 0.5	0.3 – 0.7
Lifetime Risk				1 in 281	1 in 124	1 in 172				1 in 1,299	1 in 5,100	1 in 2,103
PYLL										100	10	110
% of all cancers				0.8	2.1	1.4				0.5	0.5	0.5
Trend 2018–2022 (per annum)				1.0%	-0.3%	0.1%				15.2%	11.2%	16.1%

Table A2.48 – Cancer of Other endocrine glands

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	2	2	0.0	4.2	2.0	0	1	1	0.0	2.1	1.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
30–34	1	1	2	1.6	1.6	1.6	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.6	0.8
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
55–59	0	1	1	0.0	1.7	0.9	1	0	1	1.8	0.0	0.9
60–64	3	0	3	5.4	0.0	2.6	1	0	1	1.8	0.0	0.9
65–69	1	0	1	2.0	0.0	1.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	1	0	1	5.4	0.0	2.1	0	1	1	0.0	3.4	2.1
Total/Crude rate	9	4	13	1.0	0.4	0.7	2	3	5	0.2	0.3	0.3
AS Rate (Aust)				1.0	0.5	0.7				0.2	0.3	0.3
Confidence Interval (95%)				0.3 – 1.6	0.0 – 1.0	0.3 – 1.1				0.0 – 0.5	0.0 – 0.7	0.0 – 0.5
AS Rate (World)				0.8	0.6	0.7				0.1	0.3	0.2
Confidence Interval (95%)				0.2 – 1.4	0.0 – 1.1	0.3 – 1.1				0.0 – 0.3	0.0 – 0.7	0.0 – 0.5
Lifetime Risk				1 in 1400	1 in 2648	1 in 1853				1 in 5,576	1 in 5,395	1 in 5,576
PYLL										30	110	140
% of all cancers				0.1	0.1	0.1				0.1	0.2	0.1
Trend 2018–2022 (per annum)				58.7%	22.5%	38.1%				-2.0%	undefined	52.8%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.49 – Cancer of Other and unspecified sites

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	1	1	2	2.0	2.1	2.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
35–39	2	1	3	3.3	1.6	2.4	1	1	2	1.6	1.6	1.6
40–44	2	3	5	3.7	5.3	4.5	0	2	2	0.0	3.6	1.8
45–49	4	1	5	7.4	1.8	4.6	0	0	0	0.0	0.0	0.0
50–54	7	8	15	12.1	13.5	12.8	1	1	2	1.7	1.7	1.7
55–59	8	11	19	14.3	19.0	16.7	4	6	10	7.2	10.4	8.8
60–64	13	8	21	23.4	13.6	18.3	10	3	13	18.0	5.1	11.3
65–69	7	12	19	14.2	22.4	18.5	4	2	6	8.1	3.7	5.8
70–74	28	13	41	63.6	26.7	44.2	9	7	16	20.4	14.4	17.3
75–79	19	22	41	55.9	57.9	57.0	10	15	25	29.4	39.5	34.8
80–84	23	21	44	109.9	82.0	94.6	20	19	39	95.6	74.2	83.8
85+	35	52	87	187.3	178.0	181.6	32	54	86	171.2	184.8	179.5
Total/Crude rate	150	153	303	16.7	16.6	16.6	91	110	201	10.1	11.9	11.0
AS Rate (Aust)				13.8	11.7	12.7				8.4	7.8	8.1
Confidence Interval (95%)				11.6 – 16.1	9.8 – 13.6	11.2 – 14.1				6.7 – 10.1	6.3 – 9.3	7.0 – 9.2
AS Rate (World)				8.2	6.8	7.5				4.2	3.9	4.1
Confidence Interval (95%)				6.9 – 9.5	5.7 – 7.9	6.6 – 8.3				3.4 – 5.0	3.2 – 4.6	3.5 – 4.6
Lifetime Risk				1 in 138	1 in 189	1 in 161				1 in 351	1 in 495	1 in 414
PYLL										308	300	608
% of all cancers				2.3	3.1	2.7				4.2	6.3	5.2
Trend 2018–2022 (per annum)				-3.9%	-0.6%	-2.4%				-5.8%	-0.6%	-3.5%

Table A2.50 – Non-Hodgkin lymphoma

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
10–14	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
15–19	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
20–24	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	1	0	1	1.6	0.0	0.8
30–34	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
35–39	2	2	4	3.3	3.2	3.3	0	0	0	0.0	0.0	0.0
40–44	7	4	11	12.8	7.1	9.9	1	1	2	1.8	1.8	1.8
45–49	11	5	16	20.4	9.1	14.7	0	0	0	0.0	0.0	0.0
50–54	10	16	26	17.2	27.1	22.2	1	1	2	1.7	1.7	1.7
55–59	23	18	41	41.1	31.1	36.0	2	2	4	3.6	3.5	3.5
60–64	33	23	56	59.3	39.0	48.9	2	5	7	3.6	8.5	6.1
65–69	30	32	62	60.9	59.8	60.3	5	5	10	10.2	9.3	9.7
70–74	51	29	80	115.8	59.6	86.3	7	8	15	15.9	16.4	16.2
75–79	34	27	61	100.1	71.1	84.8	19	5	24	55.9	13.2	33.4
80–84	17	16	33	81.2	62.5	70.9	13	5	18	62.1	19.5	38.7
85+	31	19	50	165.9	65.0	104.4	22	17	39	117.7	58.2	81.4
Total/Crude rate	253	192	445	28.1	20.8	24.4	73	49	122	8.1	5.3	6.7
AS Rate (Aust)				23.4	16.0	19.4				6.5	3.6	4.9
Confidence Interval (95%)				20.4 – 26.3	13.7 – 18.3	17.5 – 21.2				5.0 – 8.0	2.6 – 4.6	4.0 – 5.7
AS Rate (World)				15.5	10.8	13.1				3.4	2.0	2.6
Confidence Interval (95%)				13.6 – 17.5	9.3 – 12.4	11.8 – 14.3				2.7 – 4.1	1.5 – 2.6	2.2 – 3.1
Lifetime Risk				1 in 60	1 in 85	1 in 70				1 in 521	1 in 486	1 in 502
PYLL										218	210	428
% of all cancers				4.0	3.8	3.9				3.4	2.8	3.1
Trend 2018–2022 (per annum)				-4.4%	-1.6%	-3.2%				-6.7%	-5.4%	-6.4%

Table A2.51 – Hodgkin lymphoma

South Australia Year – 2022												
Incidence						Mortality						
New cases			Rates			Deaths			Rates			
Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
15–19	2	2	4	3.8	4.0	3.9	0	0	0	0.0	0.0	0.0
20–24	4	2	6	6.9	3.7	5.4	0	0	0	0.0	0.0	0.0
25–29	3	4	7	4.9	6.7	5.8	0	0	0	0.0	0.0	0.0
30–34	3	5	8	4.9	8.2	6.6	0	0	0	0.0	0.0	0.0
35–39	0	4	4	0.0	6.4	3.3	0	0	0	0.0	0.0	0.0
40–44	3	2	5	5.5	3.6	4.5	1	0	1	1.8	0.0	0.9
45–49	5	1	6	9.3	1.8	5.5	0	0	0	0.0	0.0	0.0
50–54	1	1	2	1.7	1.7	1.7	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	2	1	3	3.6	1.7	2.6	1	0	1	1.8	0.0	0.9
65–69	1	0	1	2.0	0.0	1.0	1	0	1	2.0	0.0	1.0
70–74	2	1	3	4.5	2.1	3.2	0	0	0	0.0	0.0	0.0
75–79	1	2	3	2.9	5.3	4.2	0	0	0	0.0	0.0	0.0
80–84	4	1	5	19.1	3.9	10.7	0	0	0	0.0	0.0	0.0
85+	2	0	2	10.7	0.0	4.2	1	0	1	5.4	0.0	2.1
Total/Crude rate	34	27	61	3.8	2.9	3.4	4	0	4	0.4	0.0	0.2
AS Rate (Aust)				3.8	3.0	3.4				0.4	0.0	0.2
Confidence Interval (95%)				2.5 – 5.1	1.9 – 4.2	2.5 – 4.2				0.0 – 0.8	0.0 – 0.0	0.0 – 0.4
AS Rate (World)				3.3	3.1	3.2				0.3	0.0	0.1
Confidence Interval (95%)				2.2 – 4.5	1.9 – 4.2	2.4 – 4.0				0.0 – 0.6	0.0 – 0.0	0.0 – 0.3
Lifetime Risk				1 in 410	1 in 480	1 in 443				1 in 3,535	N/A	1 in 7,280
PYLL										53	0	53
% of all cancers				0.5	0.5	0.5				0.2	0.0	0.1
Trend 2018–2022 (per annum)				1.0%	13.9%	5.6%				-12.2%	-11.9%	-12.1%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.52 – Other lymphomas

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	1	1	0.0	1.9	1.0	0	0	0	0.0	0.0	0.0
70–74	1	0	1	2.3	0.0	1.1	0	0	0	0.0	0.0	0.0
75–79	1	2	3	2.9	5.3	4.2	0	1	1	0.0	2.6	1.4
80–84	1	1	2	4.8	3.9	4.3	2	0	2	9.6	0.0	4.3
85+	2	0	2	10.7	0.0	4.2	1	1	2	5.4	3.4	4.2
Total/Crude rate	5	4	9	0.6	0.4	0.5	3	2	5	0.3	0.2	0.3
AS Rate (Aust)				0.4	0.3	0.3				0.3	0.1	0.2
Confidence Interval (95%)				0.1 – 0.8	0.0 – 0.6	0.1 – 0.6				0.0 – 0.6	0.0 – 0.3	0.0 – 0.4
AS Rate (World)				0.2	0.2	0.2				0.1	0.1	0.1
Confidence Interval (95%)				0.1 – 0.3	0.0 – 0.3	0.1 – 0.3				0.0 – 0.2	0.0 – 0.1	0.0 – 0.1
Lifetime Risk				1 in 8807	1 in 10710	1 in 9750				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.1	0.1	0.1				0.1	0.1	0.1
Trend 2018–2022 (per annum)				-17.1%	-8.0%	-14.4%				-15.3%	-13.2%	-14.4%

Table A2.53 – Mast cell tumours

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	1	1	0.0	1.9	1.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	1	0	1	2.9	0.0	1.4	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	1	2	3	0.1	0.2	0.1	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				0.1	0.2	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.2	0.0 – 0.5	0.0 – 0.3				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				0.0	0.2	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.1	0.0 – 0.4	0.0 – 0.2				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				N/A	1 in 5750	1 in 11202				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.0	0.0
Trend 2018–2022 (per annum)				38.9%	-14.3%	-3.3%				0.0%	0.0%	0.0%

Table A2.54 – Malignancy of histiocytes and accessory lymphoid cells

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	1	1	0.0	1.9	1.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	1	0	1	2.9	0.0	1.4	1	0	1	2.9	0.0	1.4
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	1	1	2	0.1	0.1	0.1	1	0	1	0.1	0.0	0.1
AS Rate (Aust)				0.1	0.1	0.1				0.1	0.0	0.0
Confidence Interval (95%)				0.0 – 0.2	0.0 – 0.2	0.0 – 0.2				0.0 – 0.2	0.0 – 0.0	0.0 – 0.1
AS Rate (World)				0.0	0.1	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.1	0.0 – 0.2	0.0 – 0.1				0.0 – 0.1	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				N/A	1 in 10710	1 in 20563				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.0	0.0
Trend 2018–2022 (per annum)				-25.2%	-8.7%	-19.8%				73.1%	0.0%	71.8%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.55 – Multiple myeloma/Plasma cell tumours

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	1	2	1.6	1.6	1.6	0	0	0	0.0	0.0	0.0
40–44	2	0	2	3.7	0.0	1.8	0	0	0	0.0	0.0	0.0
45–49	2	1	3	3.7	1.8	2.8	0	0	0	0.0	0.0	0.0
50–54	7	3	10	12.1	5.1	8.5	0	0	0	0.0	0.0	0.0
55–59	8	2	10	14.3	3.5	8.8	2	0	2	3.6	0.0	1.8
60–64	10	9	19	18.0	15.3	16.6	1	2	3	1.8	3.4	2.6
65–69	12	9	21	24.4	16.8	20.4	6	5	11	12.2	9.3	10.7
70–74	13	7	20	29.5	14.4	21.6	7	7	14	15.9	14.4	15.1
75–79	21	18	39	61.8	47.4	54.2	10	3	13	29.4	7.9	18.1
80–84	15	10	25	71.7	39.1	53.7	14	7	21	66.9	27.3	45.1
85+	7	14	21	37.5	47.9	43.8	9	13	22	48.2	44.5	45.9
Total/Crude rate	98	75	173	10.9	8.1	9.5	49	37	86	5.4	4.0	4.7
AS Rate (Aust)				8.9	5.8	7.3				4.3	2.6	3.4
Confidence Interval (95%)				7.1 – 10.7	4.4 – 7.1	6.2 – 8.4				3.1 – 5.5	1.8 – 3.4	2.7 – 4.1
AS Rate (World)				5.7	3.5	4.6				2.3	1.4	1.8
Confidence Interval (95%)				4.7 – 6.8	2.7 – 4.4	3.9 – 5.3				1.7 – 2.8	0.9 – 1.8	1.4 – 2.1
Lifetime Risk				1 in 187	1 in 332	1 in 241				1 in 598	1 in 738	1 in 663
PYLL										110	80	190
% of all cancers				1.5	1.5	1.5				2.3	2.1	2.2
Trend 2018–2022 (per annum)				-4.1%	-4.1%	-4.2%				2.1%	-4.2%	-0.5%

Table A2.56 – Immunoproliferative neoplasms

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	2	2	0.0	3.4	1.7	0	0	0	0.0	0.0	0.0
65–69	1	0	1	2.0	0.0	1.0	1	0	1	2.0	0.0	1.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	2	0	2	5.9	0.0	2.8	2	0	2	5.9	0.0	2.8
80–84	0	1	1	0.0	3.9	2.1	1	0	1	4.8	0.0	2.1
85+	0	1	1	0.0	3.4	2.1	0	0	0	0.0	0.0	0.0
Total/Crude rate	3	4	7	0.3	0.4	0.4	4	0	4	0.4	0.0	0.2
AS Rate (Aust)				0.2	0.3	0.3				0.3	0.0	0.2
Confidence Interval (95%)				0.0 – 0.5	0.0 – 0.7	0.1 – 0.5				0.0 – 0.7	0.0 – 0.0	0.0 – 0.3
AS Rate (World)				0.1	0.2	0.2				0.2	0.0	0.1
Confidence Interval (95%)				0.0 – 0.3	0.0 – 0.4	0.0 – 0.3				0.0 – 0.3	0.0 – 0.0	0.0 – 0.2
Lifetime Risk				1 in 9853	1 in 5895	1 in 7358				1 in 9,853	N/A	1 in 20,563
PYLL										8	0	8
% of all cancers				0.0	0.1	0.1				0.2	0.0	0.1
Trend 2018–2022 (per annum)				-15.2%	4.7%	-10.0%				35.5%	48.1%	38.8%

Table A2.57 – All leukaemias

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	4	4	8	8.0	8.4	8.2	0	1	1	0.0	2.1	1.0
5–9	7	4	11	13.0	7.8	10.4	0	0	0	0.0	0.0	0.0
10–14	4	0	4	7.2	0.0	3.7	0	0	0	0.0	0.0	0.0
15–19	1	2	3	1.9	4.0	2.9	0	0	0	0.0	0.0	0.0
20–24	0	2	2	0.0	3.7	1.8	0	0	0	0.0	0.0	0.0
25–29	1	1	2	1.6	1.7	1.7	1	0	1	1.6	0.0	0.8
30–34	2	1	3	3.3	1.6	2.5	1	1	2	1.6	1.6	1.6
35–39	4	0	4	6.6	0.0	3.3	1	0	1	1.6	0.0	0.8
40–44	3	0	3	5.5	0.0	2.7	0	0	0	0.0	0.0	0.0
45–49	0	3	3	0.0	5.5	2.8	1	1	2	1.9	1.8	1.8
50–54	4	4	8	6.9	6.8	6.8	0	1	1	0.0	1.7	0.9
55–59	6	3	9	10.7	5.2	7.9	3	2	5	5.4	3.5	4.4
60–64	12	6	18	21.6	10.2	15.7	5	4	9	9.0	6.8	7.9
65–69	17	13	30	34.5	24.3	29.2	7	5	12	14.2	9.3	11.7
70–74	20	11	31	45.4	22.6	33.4	9	5	14	20.4	10.3	15.1
75–79	14	11	25	41.2	29.0	34.8	12	4	16	35.3	10.5	22.2
80–84	16	9	25	76.4	35.2	53.7	13	5	18	62.1	19.5	38.7
85+	12	16	28	64.2	54.8	58.4	20	15	35	107.0	51.3	73.1
Total/Crude rate	127	90	217	14.1	9.8	11.9	73	44	117	8.1	4.8	6.4
AS Rate (Aust)				12.0	7.7	9.7				6.6	3.4	4.8
Confidence Interval (95%)				9.9 – 14.2	6.0 – 9.3	8.4 – 11.1				5.1 – 8.1	2.4 – 4.4	3.9 – 5.7
AS Rate (World)				9.2	5.9	7.5				3.7	2.1	2.8
Confidence Interval (95%)				7.4 – 11.0	4.4 – 7.5	6.3 – 8.7				2.9 – 4.5	1.4 – 2.8	2.3 – 3.3
Lifetime Risk				1 in 121	1 in 197	1 in 151				1 in 359	1 in 540	1 in 435
PYLL										345	300	645
% of all cancers				2.0	1.8	1.9				3.4	2.5	3.0
Trend 2018–2022 (per annum)				-6.0%	-4.3%	-5.3%				-1.9%	-2.6%	-2.4%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.58 – Polycythaemia vera

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	1	1	0.0	1.6	0.8	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	0	3	3	0.0	5.1	2.6	1	0	1	1.7	0.0	0.9
55–59	2	0	2	3.6	0.0	1.8	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	1	1	2	2.0	1.9	1.9	1	0	1	2.0	0.0	1.0
70–74	2	3	5	4.5	6.2	5.4	1	0	1	2.3	0.0	1.1
75–79	1	0	1	2.9	0.0	1.4	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	1	1	0.0	3.4	2.1	1	0	1	5.4	0.0	2.1
Total/Crude rate	7	9	16	0.8	1.0	0.9	4	0	4	0.4	0.0	0.2
AS Rate (Aust)				0.6	0.8	0.7				0.4	0.0	0.2
Confidence Interval (95%)				0.2 – 1.1	0.3 – 1.3	0.4 – 1.1				0.0 – 0.7	0.0 – 0.0	0.0 – 0.3
AS Rate (World)				0.5	0.6	0.5				0.2	0.0	0.1
Confidence Interval (95%)				0.1 – 0.8	0.2 – 1.0	0.3 – 0.8				0.0 – 0.5	0.0 – 0.0	0.0 – 0.2
Lifetime Risk				1 in 1667	1 in 1360	1 in 1494				1 in 3,320	N/A	1 in 6,885
PYLL										33	0	33
% of all cancers				0.1	0.2	0.1				0.2	0.0	0.1
Trend 2018–2022 (per annum)				-11.7%	-9.7%	-10.7%				-1.5%	-23.0%	-8.6%

Table A2.59 – Myelodysplastic syndromes

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	1	0	1	1.7	0.0	0.9	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
55–59	2	0	2	3.6	0.0	1.8	0	1	1	0.0	1.7	0.9
60–64	5	2	7	9.0	3.4	6.1	3	0	3	5.4	0.0	2.6
65–69	2	3	5	4.1	5.6	4.9	2	2	4	4.1	3.7	3.9
70–74	12	10	22	27.3	20.5	23.7	6	4	10	13.6	8.2	10.8
75–79	12	7	19	35.3	18.4	26.4	4	2	6	11.8	5.3	8.3
80–84	11	7	18	52.6	27.3	38.7	4	4	8	19.1	15.6	17.2
85+	15	4	19	80.3	13.7	39.7	15	6	21	80.3	20.5	43.8
Total/Crude rate	60	34	94	6.7	3.7	5.2	34	19	53	3.8	2.1	2.9
AS Rate (Aust)				5.3	2.5	3.7				3.0	1.3	2.1
Confidence Interval (95%)				3.9 – 6.6	1.6 – 3.3	2.9 – 4.4				2.0 – 4.1	0.7 – 1.9	1.5 – 2.6
AS Rate (World)				2.8	1.4	2.1				1.5	0.7	1.0
Confidence Interval (95%)				2.2 – 3.5	1.0 – 1.9	1.7 – 2.5				1.0 – 1.9	0.4 – 1.0	0.8 – 1.3
Lifetime Risk				1 in 439	1 in 641	1 in 524				1 in 867	1 in 1,462	1 in 1,101
PYLL										68	43	110
% of all cancers				0.9	0.7	0.8				1.6	1.1	1.4
Trend 2018–2022 (per annum)				-5.5%	-2.6%	-4.7%				0.6%	-2.0%	0.0%

Table A2.60 – Other chronic myeloproliferative and haematological disorders

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	2	1	3	3.2	1.7	2.5	0	0	0	0.0	0.0	0.0
30–34	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	2	2	0.0	3.6	1.8	0	0	0	0.0	0.0	0.0
45–49	1	2	3	1.9	3.7	2.8	0	0	0	0.0	0.0	0.0
50–54	1	3	4	1.7	5.1	3.4	0	0	0	0.0	0.0	0.0
55–59	1	1	2	1.8	1.7	1.8	1	0	1	1.8	0.0	0.9
60–64	2	4	6	3.6	6.8	5.2	0	0	0	0.0	0.0	0.0
65–69	3	4	7	6.1	7.5	6.8	0	0	0	0.0	0.0	0.0
70–74	5	4	9	11.4	8.2	9.7	0	0	0	0.0	0.0	0.0
75–79	2	1	3	5.9	2.6	4.2	1	1	2	2.9	2.6	2.8
80–84	4	4	8	19.1	15.6	17.2	7	3	10	33.4	11.7	21.5
85+	6	4	10	32.1	13.7	20.9	3	2	5	16.1	6.8	10.4
Total/Crude rate	28	30	58	3.1	3.3	3.2	12	6	18	1.3	0.7	1.0
AS Rate (Aust)				2.6	2.7	2.6				1.1	0.4	0.7
Confidence Interval (95%)				1.6 – 3.6	1.7 – 3.6	1.9 – 3.3				0.5 – 1.8	0.1 – 0.8	0.4 – 1.1
AS Rate (World)				1.7	1.9	1.8				0.5	0.2	0.3
Confidence Interval (95%)				1.0 – 2.3	1.1 – 2.6	1.3 – 2.2				0.3 – 0.7	0.1 – 0.3	0.2 – 0.5
Lifetime Risk				1 in 640	1 in 524	1 in 575				1 in 11,180	N/A	1 in 22,749
PYLL										18	0	18
% of all cancers				0.4	0.6	0.5				0.6	0.3	0.5
Trend 2018–2022 (per annum)				-9.3%	-2.8%	-7.0%				-2.7%	-16.1%	-9.4%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.61 – All cancers

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	7	14	21	14.0	29.3	21.5	0	2	2	0.0	4.2	2.0
5–9	9	5	14	16.7	9.7	13.3	0	2	2	0.0	3.9	1.9
10–14	10	7	17	18.0	13.2	15.6	0	0	0	0.0	0.0	0.0
15–19	11	10	21	20.6	19.8	20.2	1	0	1	1.9	0.0	1.0
20–24	23	17	40	39.6	31.6	35.8	1	2	3	1.7	3.7	2.7
25–29	35	34	69	56.7	57.3	57.0	5	4	9	8.1	6.7	7.4
30–34	50	61	111	82.1	99.6	90.9	5	6	11	8.2	9.8	9.0
35–39	66	115	181	108.2	185.3	147.1	9	7	16	14.8	11.3	13.0
40–44	78	149	227	142.8	264.8	204.7	9	19	28	16.5	33.8	25.3
45–49	152	225	377	281.5	411.7	347.0	22	21	43	40.7	38.4	39.6
50–54	305	373	678	526.0	630.8	578.9	46	49	95	79.3	82.9	81.1
55–59	483	365	848	864.1	631.0	745.5	93	84	177	166.4	145.2	155.6
60–64	776	571	1,347	1,395.2	968.7	1,175.8	179	144	323	321.8	244.3	281.9
65–69	971	627	1,598	1,971.1	1,170.9	1,554.3	241	190	431	489.2	354.8	419.2
70–74	1,175	679	1,854	2,668.4	1,395.1	1,999.9	293	209	502	665.4	429.4	541.5
75–79	940	635	1,575	2,767.6	1,672.5	2,189.6	356	269	625	1,048.2	708.5	868.9
80–84	683	531	1,214	3,263.4	2,074.2	2,609.1	357	264	621	1,705.8	1,031.3	1,334.7
85+	610	589	1,199	3,263.6	2,012.7	2,500.7	531	481	1,012	2,840.9	1,646.4	2,112.5
Total/Crude rate	6,384	5,007	11,391	709.7	543.6	625.6	2,148	1,753	3,901	238.8	190.3	214.3
AS Rate (Aust)				581.8	426.5	497.7				193.3	132.5	159.3
Confidence Interval (95%)				567.3 – 596.3	414.3 – 438.6	488.3 – 507.0				185.1 – 201.6	126.2 – 138.9	154.2 – 164.3
AS Rate (World)				382.1	297.0	336.4				107.4	77.7	91.1
Confidence Interval (95%)				372.8 – 391.4	288.4 – 305.6	330.1 – 342.7				103.2 – 111.7	74.0 – 81.5	88.3 – 93.9
Lifetime Risk				1 in 3	1 in 4	1 in 3				1 in 12	1 in 15	1 in 13
PYLL										9,235	8,608	17,843
% of all cancers				100.0	100.0	100.0				100.0	100.0	100.0
Trend 2018–2022 (per annum)				-1.3%	-1.4%	-1.3%				-3.4%	-1.3%	-2.5%

Table A2.62 – Mesothelioma

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	1	1	0.0	1.7	0.9	0	1	1	0.0	1.7	0.9
60–64	1	1	2	1.8	1.7	1.7	0	0	0	0.0	0.0	0.0
65–69	4	0	4	8.1	0.0	3.9	4	3	7	8.1	5.6	6.8
70–74	8	2	10	18.2	4.1	10.8	6	0	6	13.6	0.0	6.5
75–79	16	7	23	47.1	18.4	32.0	10	2	12	29.4	5.3	16.7
80–84	19	4	23	90.8	15.6	49.4	14	2	16	66.9	7.8	34.4
85+	10	3	13	53.5	10.3	27.1	16	4	20	85.6	13.7	41.7
Total/Crude rate	58	18	76	6.4	2.0	4.2	50	12	62	5.6	1.3	3.4
AS Rate (Aust)				5.0	1.3	2.9				4.4	0.9	2.4
Confidence Interval (95%)				3.7 – 6.3	0.7 – 1.9	2.3 – 3.6				3.2 – 5.6	0.4 – 1.4	1.8 – 3.0
AS Rate (World)				2.6	0.7	1.5				2.1	0.5	1.2
Confidence Interval (95%)				2.0 – 3.1	0.4 – 1.0	1.3 – 1.8				1.6 – 2.6	0.2 – 0.7	0.9 – 1.4
Lifetime Risk				1 in 713	1 in 2655	1 in 1156				1 in 920	1 in 2,729	1 in 1,413
PYLL										45	40	85
% of all cancers				0.9	0.4	0.7				2.3	0.7	1.6
Trend 2018–2022 (per annum)				-1.6%	-8.3%	-3.7%				-3.8%	-4.0%	-4.3%

Table A2.63 – Kaposi sarcoma

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	2	0	2	10.7	0.0	4.2	0	0	0	0.0	0.0	0.0
Total/Crude rate	2	0	2	0.2	0.0	0.1	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				0.2	0.0	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.5	0.0 – 0.0	0.0 – 0.2				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				0.1	0.0	0.0				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.1	0.0 – 0.0	0.0 – 0.1				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				N/A	N/A	N/A				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.0	0.0
Trend 2018–2022 (per annum)				2.7%	-12.5%	-2.4%				-33.3%	-25.0%	-30.0%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.64 – Acute lymphocytic leukaemia

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	3	1	4	6.0	2.1	4.1	0	1	1	0.0	2.1	1.0
5–9	4	2	6	7.4	3.9	5.7	0	0	0	0.0	0.0	0.0
10–14	3	0	3	5.4	0.0	2.8	0	0	0	0.0	0.0	0.0
15–19	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	1	0	1	1.6	0.0	0.8
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	2	2	0.0	3.7	1.8	0	1	1	0.0	1.8	0.9
50–54	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.7	0.9
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	1	1	2	1.8	1.7	1.7
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	1	1	0.0	2.1	1.1	0	1	1	0.0	2.1	1.1
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	10	7	17	1.1	0.8	0.9	2	5	7	0.2	0.5	0.4
AS Rate (Aust)				1.2	0.8	1.0				0.2	0.5	0.4
Confidence Interval (95%)				0.4 – 1.9	0.2 – 1.4	0.5 – 1.5				0.0 – 0.5	0.1 – 1.0	0.1 – 0.7
AS Rate (World)				1.6	1.0	1.3				0.2	0.5	0.3
Confidence Interval (95%)				0.5 – 2.7	0.2 – 1.8	0.6 – 2.0				0.0 – 0.5	0.0 – 1.0	0.1 – 0.6
Lifetime Risk				1 in 1065	1 in 1462	1 in 1218				1 in 5,850	1 in 2,135	1 in 3,102
PYLL										60	138	198
% of all cancers				0.2	0.1	0.1				0.1	0.3	0.2
Trend 2018–2022 (per annum)				-6.5%	-8.0%	-7.1%				-18.9%	-13.5%	-16.4%

Table A2.65 – Chronic lymphocytic leukaemia

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	1	1	0.0	1.7	0.9	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	2	0	2	3.6	0.0	1.8
60–64	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
65–69	5	2	7	10.2	3.7	6.8	0	1	1	0.0	1.9	1.0
70–74	7	2	9	15.9	4.1	9.7	2	0	2	4.5	0.0	2.2
75–79	2	4	6	5.9	10.5	8.3	2	1	3	5.9	2.6	4.2
80–84	3	5	8	14.3	19.5	17.2	2	2	4	9.6	7.8	8.6
85+	3	8	11	16.1	27.4	23.0	8	6	14	42.8	20.5	29.2
Total/Crude rate	22	22	44	2.4	2.4	2.4	16	10	26	1.8	1.1	1.4
AS Rate (Aust)				1.9	1.6	1.7				1.5	0.7	1.0
Confidence Interval (95%)				1.1 – 2.7	0.9 – 2.2	1.2 – 2.2				0.7 – 2.2	0.3 – 1.1	0.6 – 1.4
AS Rate (World)				1.1	0.8	1.0				0.7	0.3	0.5
Confidence Interval (95%)				0.7 – 1.5	0.5 – 1.1	0.7 – 1.2				0.4 – 1.0	0.1 – 0.4	0.3 – 0.6
Lifetime Risk				1 in 675	1 in 2098	1 in 1046				1 in 2,464	1 in 10,710	1 in 4,092
PYLL										40	8	48
% of all cancers				0.3	0.4	0.4				0.7	0.6	0.7
Trend 2018–2022 (per annum)				-12.1%	-8.0%	-10.7%				2.3%	-12.3%	-6.1%

Table A2.66 – Other and unspecified lymphoid leukaemia

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	3	1	4	6.0	2.1	4.1	0	1	1	0.0	2.1	1.0
5–9	4	2	6	7.4	3.9	5.7	0	0	0	0.0	0.0	0.0
10–14	3	0	3	5.4	0.0	2.8	0	0	0	0.0	0.0	0.0
15–19	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	1	0	1	1.6	0.0	0.8
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	2	2	0.0	3.7	1.8	0	1	1	0.0	1.8	0.9
50–54	0	0	0	0.0	0.0	0.0	0	1	1	0.0	1.7	0.9
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	1	1	2	1.8	1.7	1.7
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	1	1	2	2.3	2.1	2.2	2	2	4	4.5	4.1	4.3
75–79	0	1	1	0.0	2.6	1.4	0	0	0	0.0	0.0	0.0
80–84	1	0	1	4.8	0.0	2.1	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	1	0	1	5.4	0.0	2.1
Total/Crude rate	12	8	20	1.3	0.9	1.1	5	6	11	0.6	0.7	0.6
AS Rate (Aust)				1.3	0.9	1.1				0.5	0.6	0.5
Confidence Interval (95%)				0.6 – 2.1	0.3 – 1.5	0.6 – 1.6				0.0 – 0.9	0.1 – 1.1	0.2 – 0.8
AS Rate (World)				1.7	1.0	1.4				0.3	0.5	0.4
Confidence Interval (95%)				0.6 – 2.8	0.2 – 1.8	0.7 – 2.1				0.0 – 0.6	0.1 – 1.0	0.1 – 0.7
Lifetime Risk				1 in 950	1 in 1462	1 in 1143				1 in 2,513	1 in 1,751	1 in 2,066
PYLL										65	140	205
% of all cancers				0.2	0.2	0.2				0.2	0.3	0.3
Trend 2018–2022 (per annum)				-4.5%	-5.2%	-4.9%				-9.3%	-12.6%	-11.4%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.67 – Acute myeloid leukaemia

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	2	2	0.0	4.2	2.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	1	1	0.0	2.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	2	0	2	3.3	0.0	1.6	0	1	1	0.0	1.6	0.8
35–39	1	0	1	1.6	0.0	0.8	1	0	1	1.6	0.0	0.8
40–44	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	0	1	1	0.0	1.8	0.9	0	0	0	0.0	0.0	0.0
50–54	3	2	5	5.2	3.4	4.3	0	0	0	0.0	0.0	0.0
55–59	4	3	7	7.2	5.2	6.2	1	2	3	1.8	3.5	2.6
60–64	7	5	12	12.6	8.5	10.5	3	3	6	5.4	5.1	5.2
65–69	11	7	18	22.3	13.1	17.5	6	3	9	12.2	5.6	8.8
70–74	7	6	13	15.9	12.3	14.0	3	1	4	6.8	2.1	4.3
75–79	7	4	11	20.6	10.5	15.3	9	2	11	26.5	5.3	15.3
80–84	8	3	11	38.2	11.7	23.6	8	1	9	38.2	3.9	19.3
85+	7	2	9	37.5	6.8	18.8	7	2	9	37.5	6.8	18.8
Total/Crude rate	58	37	95	6.4	4.0	5.2	38	15	53	4.2	1.6	2.9
AS Rate (Aust)				5.4	3.2	4.2				3.4	1.2	2.2
Confidence Interval (95%)				4.0 – 6.8	2.2 – 4.3	3.3 – 5.0				2.3 – 4.4	0.6 – 1.9	1.6 – 2.8
AS Rate (World)				3.5	2.5	2.9				1.9	0.8	1.3
Confidence Interval (95%)				2.6 – 4.3	1.6 – 3.4	2.3 – 3.5				1.3 – 2.4	0.4 – 1.3	1.0 – 1.6
Lifetime Risk				1 in 287	1 in 383	1 in 331				1 in 720	1 in 1,122	1 in 886
PYLL										145	140	285
% of all cancers				0.9	0.7	0.8				1.8	0.9	1.4
Trend 2018–2022 (per annum)				-3.2%	-2.0%	-2.8%				-3.4%	1.2%	-1.7%

Table A2.68 – Chronic myeloid leukaemia

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
10–14	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	1	0	1	1.6	0.0	0.8
35–39	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	1	1	2	1.7	1.7	1.7	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	2	0	2	3.6	0.0	1.7	1	0	1	1.8	0.0	0.9
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	2	0	2	4.5	0.0	2.2	0	0	0	0.0	0.0	0.0
75–79	2	1	3	5.9	2.6	4.2	0	0	0	0.0	0.0	0.0
80–84	2	0	2	9.6	0.0	4.3	0	1	1	0.0	3.9	2.1
85+	0	1	1	0.0	3.4	2.1	0	2	2	0.0	6.8	4.2
Total/Crude rate	12	4	16	1.3	0.4	0.9	2	3	5	0.2	0.3	0.3
AS Rate (Aust)				1.2	0.4	0.7				0.2	0.2	0.2
Confidence Interval (95%)				0.5 – 1.8	0.0 – 0.7	0.4 – 1.1				0.0 – 0.5	0.0 – 0.4	0.0 – 0.4
AS Rate (World)				0.9	0.3	0.6				0.2	0.1	0.1
Confidence Interval (95%)				0.4 – 1.4	0.0 – 0.7	0.3 – 0.9				0.0 – 0.4	0.0 – 0.1	0.0 – 0.3
Lifetime Risk				1 in 1322	1 in 5497	1 in 2176				1 in 5,814	N/A	1 in 11,823
PYLL										55	0	55
% of all cancers				0.2	0.1	0.1				0.1	0.2	0.1
Trend 2018–2022 (per annum)				-8.0%	-12.8%	-10.0%				3.9%	78.1%	23.7%

Table A2.69 – Other and unspecified myeloid leukaemia

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	1	1	0.0	3.4	2.1
Total/Crude rate	0	0	0	0.0	0.0	0.0	0	1	1	0.0	0.1	0.1
AS Rate (Aust)				0.0	0.0	0.0				0.0	0.1	0.0
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0				0.0 – 0.0	0.0 – 0.2	0.0 – 0.1
AS Rate (World)				0.0	0.0	0.0				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0				0.0 – 0.0	0.0 – 0.1	0.0 – 0.0
Lifetime Risk				N/A	N/A	N/A				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.1	0.0
Trend 2018–2022 (per annum)				-7.4%	0.0%	-8.9%				-19.4%	undefined	-10.9%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.70 – Other specified leukaemias

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
60–64	2	1	3	3.6	1.7	2.6	0	0	0	0.0	0.0	0.0
65–69	0	3	3	0.0	5.6	2.9	1	0	1	2.0	0.0	1.0
70–74	3	2	5	6.8	4.1	5.4	2	2	4	4.5	4.1	4.3
75–79	3	1	4	8.8	2.6	5.6	1	1	2	2.9	2.6	2.8
80–84	2	1	3	9.6	3.9	6.4	3	1	4	14.3	3.9	8.6
85+	2	4	6	10.7	13.7	12.5	4	3	7	21.4	10.3	14.6
Total/Crude rate	14	12	26	1.6	1.3	1.4	11	7	18	1.2	0.8	1.0
AS Rate (Aust)				1.3	0.9	1.1				1.0	0.5	0.7
Confidence Interval (95%)				0.6 – 1.9	0.4 – 1.3	0.6 – 1.5				0.4 – 1.6	0.1 – 0.8	0.4 – 1.0
AS Rate (World)				0.8	0.5	0.6				0.5	0.2	0.3
Confidence Interval (95%)				0.4 – 1.2	0.2 – 0.8	0.4 – 0.9				0.2 – 0.7	0.1 – 0.4	0.2 – 0.5
Lifetime Risk				1 in 1426	1 in 1754	1 in 1574				1 in 3,044	1 in 4,868	1 in 3,783
PYLL										13	5	18
% of all cancers				0.2	0.2	0.2				0.5	0.4	0.5
Trend 2018–2022 (per annum)				-7.8%	-6.5%	-7.2%				3.9%	0.4%	1.8%

Table A2.71 – Leukaemias NOS

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	1	1	0.0	3.4	2.1	0	1	1	0.0	3.4	2.1
Total/Crude rate	1	1	2	0.1	0.1	0.1	0	1	1	0.0	0.1	0.1
AS Rate (Aust)				0.1	0.1	0.1				0.0	0.1	0.0
Confidence Interval (95%)				0.0 – 0.4	0.0 – 0.2	0.0 – 0.2				0.0 – 0.0	0.0 – 0.2	0.0 – 0.1
AS Rate (World)				0.1	0.0	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.4	0.0 – 0.1	0.0 – 0.2				0.0 – 0.0	0.0 – 0.1	0.0 – 0.0
Lifetime Risk				1 in 12337	N/A	1 in 24202				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.1	0.0
Trend 2018–2022 (per annum)				-1.8%	-0.8%	-2.2%				-13.9%	11.2%	-4.7%

Table A2.72 – Cancer of the Lip, and skin of lip (non-melanoma)

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	3	1	4	4.9	1.6	3.3	0	0	0	0.0	0.0	0.0
40–44	1	1	2	1.8	1.8	1.8	0	0	0	0.0	0.0	0.0
45–49	1	3	4	1.9	5.5	3.7	0	0	0	0.0	0.0	0.0
50–54	10	1	11	17.2	1.7	9.4	0	1	1	0.0	1.7	0.9
55–59	9	4	13	16.1	6.9	11.4	0	0	0	0.0	0.0	0.0
60–64	7	2	9	12.6	3.4	7.9	0	0	0	0.0	0.0	0.0
65–69	9	2	11	18.3	3.7	10.7	0	0	0	0.0	0.0	0.0
70–74	12	6	18	27.3	12.3	19.4	0	0	0	0.0	0.0	0.0
75–79	2	5	7	5.9	13.2	9.7	0	0	0	0.0	0.0	0.0
80–84	5	4	9	23.9	15.6	19.3	0	0	0	0.0	0.0	0.0
85+	7	8	15	37.5	27.4	31.3	0	1	1	0.0	3.4	2.1
Total/Crude rate	66	37	103	7.3	4.0	5.7	0	2	2	0.0	0.2	0.1
AS Rate (Aust)				6.4	3.0	4.6				0.0	0.2	0.1
Confidence Interval (95%)				4.8 – 7.9	2.0 – 4.0	3.7 – 5.5				0.0 – 0.0	0.0 – 0.4	0.0 – 0.2
AS Rate (World)				4.4	2.0	3.2				0.0	0.1	0.1
Confidence Interval (95%)				3.4 – 5.4	1.3 – 2.7	2.5 – 3.8				0.0 – 0.0	0.0 – 0.3	0.0 – 0.1
Lifetime Risk				1 in 200	1 in 542	1 in 297				N/A	1 in 11,826	1 in 23,423
PYLL										0	23	23
% of all cancers				1.0	0.7	0.9				0.0	0.1	0.1
Trend 2018–2022 (per annum)				-10.8%	0.8%	-7.9%				-15.3%	28.3%	-4.5%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.73 – Melanoma of lip

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	1	0	1	2.0	0.0	1.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	1	0	1	2.9	0.0	1.4	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	2	0	2	0.2	0.0	0.1	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				0.2	0.0	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.4	0.0 – 0.0	0.0 – 0.2				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				0.1	0.0	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.2	0.0 – 0.0	0.0 – 0.1				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				1 in 9853	N/A	1 in 20563				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.0	0.0
Trend 2018–2022 (per annum)				122.7%	undefined	198.0%				0.0%	-25.0%	-25.0%

Table A2.74 – Melanoma of eyelid, including canthus

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	2	0	2	4.1	0.0	1.9	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	1	0	1	2.9	0.0	1.4	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	1	0	1	4.8	0.0	2.1
85+	1	0	1	5.4	0.0	2.1	0	0	0	0.0	0.0	0.0
Total/Crude rate	4	0	4	0.4	0.0	0.2	1	0	1	0.1	0.0	0.1
AS Rate (Aust)				0.3	0.0	0.2				0.1	0.0	0.0
Confidence Interval (95%)				0.0 – 0.7	0.0 – 0.0	0.0 – 0.3				0.0 – 0.3	0.0 – 0.0	0.0 – 0.1
AS Rate (World)				0.2	0.0	0.1				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.4	0.0 – 0.0	0.0 – 0.2				0.0 – 0.1	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				1 in 4927	N/A	1 in 10282				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.1	0.0	0.0				0.0	0.0	0.0
Trend 2018–2022 (per annum)				-1.2%	-12.3%	-8.3%				undefined	0.0%	undefined

Table A2.75 – Melanoma of ear

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
40–44	1	0	1	1.8	0.0	0.9	0	0	0	0.0	0.0	0.0
45–49	1	0	1	1.9	0.0	0.9	0	0	0	0.0	0.0	0.0
50–54	2	1	3	3.4	1.7	2.6	0	0	0	0.0	0.0	0.0
55–59	1	0	1	1.8	0.0	0.9	1	0	1	1.8	0.0	0.9
60–64	0	1	1	0.0	1.7	0.9	1	0	1	1.8	0.0	0.9
65–69	2	0	2	4.1	0.0	1.9	0	0	0	0.0	0.0	0.0
70–74	1	0	1	2.3	0.0	1.1	1	0	1	2.3	0.0	1.1
75–79	6	0	6	17.7	0.0	8.3	0	0	0	0.0	0.0	0.0
80–84	4	3	7	19.1	11.7	15.0	2	0	2	9.6	0.0	4.3
85+	2	0	2	10.7	0.0	4.2	0	1	1	0.0	3.4	2.1
Total/Crude rate	21	5	26	2.3	0.5	1.4	5	1	6	0.6	0.1	0.3
AS Rate (Aust)				2.0	0.4	1.2				0.5	0.1	0.3
Confidence Interval (95%)				1.1 – 2.8	0.0 – 0.8	0.7 – 1.6				0.1 – 0.9	0.0 – 0.2	0.0 – 0.5
AS Rate (World)				1.3	0.3	0.8				0.3	0.0	0.1
Confidence Interval (95%)				0.8 – 1.8	0.0 – 0.5	0.5 – 1.0				0.1 – 0.5	0.0 – 0.1	0.0 – 0.3
Lifetime Risk				1 in 1184	1 in 5904	1 in 2006				1 in 3,415	N/A	1 in 7,066
PYLL										33	0	33
% of all cancers				0.3	0.1	0.2				0.2	0.1	0.2
Trend 2018–2022 (per annum)				11.1%	18.2%	12.9%				74.1%	undefined	141.3%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.76 – Melanoma of other and unspecified parts of face

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	3	3	0.0	5.1	2.5	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	2	2	0.0	3.7	1.8	0	0	0	0.0	0.0	0.0
50–54	3	2	5	5.2	3.4	4.3	0	0	0	0.0	0.0	0.0
55–59	3	0	3	5.4	0.0	2.6	0	0	0	0.0	0.0	0.0
60–64	4	4	8	7.2	6.8	7.0	0	0	0	0.0	0.0	0.0
65–69	7	4	11	14.2	7.5	10.7	0	0	0	0.0	0.0	0.0
70–74	8	6	14	18.2	12.3	15.1	1	0	1	2.3	0.0	1.1
75–79	7	3	10	20.6	7.9	13.9	1	0	1	2.9	0.0	1.4
80–84	4	4	8	19.1	15.6	17.2	1	0	1	4.8	0.0	2.1
85+	9	10	19	48.2	34.2	39.7	0	2	2	0.0	6.8	4.2
Total/Crude rate	46	38	84	5.1	4.1	4.6	3	2	5	0.3	0.2	0.3
AS Rate (Aust)				4.1	3.1	3.5				0.2	0.1	0.2
Confidence Interval (95%)				2.9 – 5.3	2.1 – 4.1	2.8 – 4.3				0.0 – 0.5	0.0 – 0.3	0.0 – 0.4
AS Rate (World)				2.5	2.0	2.2				0.1	0.0	0.1
Confidence Interval (95%)				1.8 – 3.2	1.3 – 2.7	1.7 – 2.7				0.0 – 0.3	0.0 – 0.1	0.0 – 0.2
Lifetime Risk				1 in 387	1 in 518	1 in 447				1 in 8,807	N/A	1 in 18,542
PYLL										3	0	3
% of all cancers				0.7	0.8	0.7				0.1	0.1	0.1
Trend 2018–2022 (per annum)				-4.9%	0.3%	-2.6%				-7.4%	1.3%	-5.1%

Table A2.77 – Melanoma of scalp and neck

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	1	1	0.0	1.9	0.9	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	2	0	2	3.7	0.0	1.8	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	5	1	6	8.6	1.7	5.1	0	0	0	0.0	0.0	0.0
55–59	6	1	7	10.7	1.7	6.2	0	0	0	0.0	0.0	0.0
60–64	2	4	6	3.6	6.8	5.2	0	0	0	0.0	0.0	0.0
65–69	8	4	12	16.2	7.5	11.7	0	1	1	0.0	1.9	1.0
70–74	10	3	13	22.7	6.2	14.0	2	0	2	4.5	0.0	2.2
75–79	5	3	8	14.7	7.9	11.1	3	0	3	8.8	0.0	4.2
80–84	2	2	4	9.6	7.8	8.6	1	1	2	4.8	3.9	4.3
85+	10	4	14	53.5	13.7	29.2	4	2	6	21.4	6.8	12.5
Total/Crude rate	50	23	73	5.6	2.5	4.0	10	4	14	1.1	0.4	0.8
AS Rate (Aust)				4.6	1.8	3.1				0.8	0.3	0.5
Confidence Interval (95%)				3.3 – 5.9	1.1 – 2.6	2.4 – 3.8				0.3 – 1.4	0.0 – 0.6	0.3 – 0.8
AS Rate (World)				2.9	1.2	2.0				0.4	0.1	0.3
Confidence Interval (95%)				2.2 – 3.7	0.7 – 1.7	1.6 – 2.5				0.2 – 0.6	0.0 – 0.3	0.1 – 0.4
Lifetime Risk				1 in 306	1 in 779	1 in 446				1 in 4,404	1 in 10,710	1 in 6,390
PYLL										5	8	13
% of all cancers				0.8	0.5	0.6				0.5	0.2	0.4
Trend 2018–2022 (per annum)				-6.4%	7.1%	-3.2%				6.8%	-1.1%	6.1%

Table A2.78 – Melanoma of trunk

South Australia Year – 2022												
Incidence							Mortality					
New cases			Rates				Deaths			Rates		
Males	Females	Persons	Males	Females	Persons		Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	1	1	2	1.6	1.7	1.7	0	0	0	0.0	0.0	0.0
30–34	1	2	3	1.6	3.3	2.5	0	0	0	0.0	0.0	0.0
35–39	1	1	2	1.6	1.6	1.6	0	0	0	0.0	0.0	0.0
40–44	4	5	9	7.3	8.9	8.1	0	0	0	0.0	0.0	0.0
45–49	7	7	14	13.0	12.8	12.9	0	0	0	0.0	0.0	0.0
50–54	8	7	15	13.8	11.8	12.8	1	1	2	1.7	1.7	1.7
55–59	11	6	17	19.7	10.4	14.9	0	0	0	0.0	0.0	0.0
60–64	19	5	24	34.2	8.5	20.9	0	0	0	0.0	0.0	0.0
65–69	16	10	26	32.5	18.7	25.3	0	3	3	0.0	5.6	2.9
70–74	21	9	30	47.7	18.5	32.4	2	0	2	4.5	0.0	2.2
75–79	21	6	27	61.8	15.8	37.5	1	0	1	2.9	0.0	1.4
80–84	15	4	19	71.7	15.6	40.8	0	0	0	0.0	0.0	0.0
85+	11	6	17	58.9	20.5	35.5	4	0	4	21.4	0.0	8.3
Total/Crude rate	136	69	205	15.1	7.5	11.3	8	4	12	0.9	0.4	0.7
AS Rate (Aust)				12.7	6.3	9.3				0.7	0.4	0.5
Confidence Interval (95%)				10.5 – 14.9	4.8 – 7.9	8.0 – 10.6				0.2 – 1.2	0.0 – 0.7	0.2 – 0.8
AS Rate (World)				8.5	4.8	6.5				0.4	0.3	0.3
Confidence Interval (95%)				7.1 – 9.9	3.6 – 5.9	5.6 – 7.4				0.1 – 0.6	0.0 – 0.5	0.1 – 0.5
Lifetime Risk				1 in 116	1 in 209	1 in 151				1 in 3,192	1 in 2,743	1 in 2,949
PYLL										28	45	73
% of all cancers				2.1	1.4	1.8				0.4	0.2	0.3
Trend 2018–2022 (per annum)				-4.8%	5.7%	-2.0%				-13.2%	33.2%	-8.8%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.79 – Melanoma of upper limb, including shoulder

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	1	1	0.0	1.7	0.8	0	0	0	0.0	0.0	0.0
30–34	1	2	3	1.6	3.3	2.5	0	0	0	0.0	0.0	0.0
35–39	0	5	5	0.0	8.1	4.1	0	0	0	0.0	0.0	0.0
40–44	2	4	6	3.7	7.1	5.4	0	0	0	0.0	0.0	0.0
45–49	2	4	6	3.7	7.3	5.5	0	0	0	0.0	0.0	0.0
50–54	8	7	15	13.8	11.8	12.8	0	0	0	0.0	0.0	0.0
55–59	9	10	19	16.1	17.3	16.7	0	0	0	0.0	0.0	0.0
60–64	7	3	10	12.6	5.1	8.7	0	0	0	0.0	0.0	0.0
65–69	13	14	27	26.4	26.1	26.3	0	0	0	0.0	0.0	0.0
70–74	21	15	36	47.7	30.8	38.8	1	1	2	2.3	2.1	2.2
75–79	17	14	31	50.1	36.9	43.1	1	2	3	2.9	5.3	4.2
80–84	11	12	23	52.6	46.9	49.4	2	1	3	9.6	3.9	6.4
85+	10	12	22	53.5	41.1	45.9	0	2	2	0.0	6.8	4.2
Total/Crude rate	102	103	205	11.3	11.2	11.3	4	6	10	0.4	0.7	0.5
AS Rate (Aust)				9.3	8.7	8.9				0.3	0.4	0.4
Confidence Interval (95%)				7.4 – 11.1	7.0 – 10.5	7.7 – 10.2				0.0 – 0.7	0.1 – 0.7	0.1 – 0.6
AS Rate (World)				6.1	6.2	6.1				0.2	0.2	0.2
Confidence Interval (95%)				4.9 – 7.2	5.0 – 7.4	5.3 – 6.9				0.1 – 0.3	0.1 – 0.3	0.1 – 0.3
Lifetime Risk				1 in 157	1 in 169	1 in 164				1 in 8,807	1 in 9,735	1 in 9,271
PYLL										3	3	5
% of all cancers				1.6	2.1	1.8				0.2	0.3	0.3
Trend 2018–2022 (per annum)				-3.0%	-2.1%	-2.6%				-12.5%	3.6%	-7.4%

Table A2.80 – Melanoma of lower limb, including hip

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	1	0	1	1.9	0.0	1.0	0	0	0	0.0	0.0	0.0
20–24	2	0	2	3.4	0.0	1.8	0	0	0	0.0	0.0	0.0
25–29	1	0	1	1.6	0.0	0.8	0	0	0	0.0	0.0	0.0
30–34	2	2	4	3.3	3.3	3.3	0	0	0	0.0	0.0	0.0
35–39	2	3	5	3.3	4.8	4.1	0	0	0	0.0	0.0	0.0
40–44	1	5	6	1.8	8.9	5.4	0	0	0	0.0	0.0	0.0
45–49	5	5	10	9.3	9.1	9.2	0	0	0	0.0	0.0	0.0
50–54	2	8	10	3.4	13.5	8.5	0	0	0	0.0	0.0	0.0
55–59	3	8	11	5.4	13.8	9.7	0	1	1	0.0	1.7	0.9
60–64	6	11	17	10.8	18.7	14.8	1	0	1	1.8	0.0	0.9
65–69	5	8	13	10.2	14.9	12.6	1	1	2	2.0	1.9	1.9
70–74	7	15	22	15.9	30.8	23.7	0	0	0	0.0	0.0	0.0
75–79	7	11	18	20.6	29.0	25.0	1	0	1	2.9	0.0	1.4
80–84	7	6	13	33.4	23.4	27.9	0	0	0	0.0	0.0	0.0
85+	5	12	17	26.8	41.1	35.5	3	2	5	16.1	6.8	10.4
Total/Crude rate	56	94	150	6.2	10.2	8.2	6	4	10	0.7	0.4	0.5
AS Rate (Aust)				5.5	8.2	6.9				0.6	0.3	0.4
Confidence Interval (95%)				4.0 – 6.9	6.5 – 9.9	5.8 – 8.0				0.1 – 1.0	0.0 – 0.6	0.2 – 0.7
AS Rate (World)				4.0	5.8	4.9				0.3	0.2	0.2
Confidence Interval (95%)				2.9 – 5.1	4.6 – 7.0	4.1 – 5.8				0.1 – 0.5	0.0 – 0.4	0.1 – 0.4
Lifetime Risk				1 in 285	1 in 170	1 in 211				1 in 5,225	1 in 5,562	1 in 5,410
PYLL										20	25	45
% of all cancers				0.9	1.9	1.3				0.3	0.2	0.3
Trend 2018–2022 (per annum)				-6.0%	-0.6%	-3.0%				-6.6%	-7.1%	-7.4%

Table A2.81 – Melanoma of other site

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
75–79	1	0	1	2.9	0.0	1.4	0	0	0	0.0	0.0	0.0
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	1	0	1	0.1	0.0	0.1	0	0	0	0.0	0.0	0.0
AS Rate (Aust)				0.1	0.0	0.0				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.2	0.0 – 0.0	0.0 – 0.1				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
AS Rate (World)				0.0	0.0	0.0				0.0	0.0	0.0
Confidence Interval (95%)				0.0 – 0.1	0.0 – 0.0	0.0 – 0.0				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0
Lifetime Risk				N/A	N/A	N/A				N/A	N/A	N/A
PYLL										0	0	0
% of all cancers				0.0	0.0	0.0				0.0	0.0	0.0
Trend 2018–2022 (per annum)				-11.0%	0.0%	-10.5%				0.0%	0.0%	0.0%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Table A2.82 – Melanoma, site unspecified

South Australia Year – 2022	Incidence						Mortality					
	New cases			Rates			Deaths			Rates		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0–4	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
5–9	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
10–14	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
15–19	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
20–24	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
25–29	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
30–34	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
35–39	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
40–44	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
45–49	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
50–54	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
55–59	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
60–64	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
65–69	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
70–74	0	0	0	0.0	0.0	0.0	1	0	1	2.3	0.0	1.1
75–79	0	0	0	0.0	0.0	0.0	1	0	1	2.9	0.0	1.4
80–84	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
85+	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0
Total/Crude rate	0	0	0	0.0	0.0	0.0	2	0	2	0.2	0.0	0.1
AS Rate (Aust)				0.0	0.0	0.0				0.1	0.0	0.1
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0				0.0 – 0.4	0.0 – 0.0	0.0 – 0.2
AS Rate (World)				0.0	0.0	0.0				0.1	0.0	0.0
Confidence Interval (95%)				0.0 – 0.0	0.0 – 0.0	0.0 – 0.0				0.0 – 0.2	0.0 – 0.0	0.0 – 0.1
Lifetime Risk				N/A	N/A	N/A				1 in 8,807	N/A	1 in 18,542
PYLL										3	0	3
% of all cancers				0.0	0.0	0.0				0.1	0.0	0.1
Trend 2018–2022 (per annum)				-16.8%	-14.3%	-15.1%				33.5%	55.0%	37.7%

Note: All rates are expressed per 100,000 population. Age-standardised rates (AS Rate) use the Australian 2011 and New World Standard populations (see Appendix 3)

Appendix 3 – Quality Measures

Table A3.1 display a series of commonly used data quality indices as defined by the Cancer Incidence in Five Continents Vol. X.

Table A3.1 Indices of data quality – cancers, 2022

MALES							
ICD-O-3	Site	Inc	Mort	M/I%	HV%	MV%	DCO%
C00	Lip	47	1	2	100	100	0.0
C01 C02	Tongue	91	22	24	100	100	0.0
C09 C10	Oropharynx	53	18	34	98	100	0.0
C16	Stomach	206	124	60	95	95	2.4
C18-C20	Colon and rectum	1113	398	36	93	93	3.8
C22	Liver and intrahepatic bile ducts	160	143	89	43	44	1.4
C23 C24	Gallbladder and bile ducts	89	79	89	72	81	1.3
C25	Pancreas	348	315	91	70	76	1.3
C33 C34	Trachea, bronchus and lung	1029	729	71	78	88	1.2
C38	Heart, mediastinum and pleura	75	64	85	81	91	1.6
C44._ + M872-879	Melanoma of skin	750	60	8	100	100	0.0
C50	Female breast	1548	221	14	100	100	2.3
C51	Vulva	38	11	29	97	97	0.0
C53	Cervix uteri	60	20	33	95	97	0.0
C54 C55	Body of the uterus	227	55	24	98	98	1.8
C56.9	Ovary	97	62	64	84	89	3.2
C61.9	Prostate	2178	261	12	98	98	1.5
C62	Testis	79	1	1	100	100	0.0
C64	Kidney	332	91	27	91	92	2.2
C67	Bladder	289	128	44	89	90	3.9
C71	Brain	173	120	69	80	80	2.5
C73	Thyroid gland	154	19	12	94	98	0.0
C26 C39 C42 C76 C77 C80	Other and unspecified primary	303	201	66	58	66	11.9
M9591 9597 967-972 9735 9737 9738	Non-Hodgkin lymphoma	445	122	27	96	98	0.8
M965-966	Hodgkin lymphoma	61	4	7	98	98	0.0
M9731-9734	Multiple myeloma/Plasma cell tumours	173	86	50	91	95	3.5
M980-994	All leukaemias	217	117	54	83	94	1.7
M998 999	Myelodysplastic syndromes	94	53	56	84	94	0.0
All cancers		11391	3901	34	91	93	2.4

Inc: incidence, Mort: mortality, M/I%: Mortality incidence ratio, HV%: histologic verification proportion: MV%: microscopic verification proportion, DCO%: Death certificate only notification proportion

Mortality-to-Incidence (M:I) Ratio

Compares the number of deaths due to a specific type of cancer over a specific period of time with the number of new cases of that type of cancer registered during the same period. M:I values greater than expected lead to a suspicion of incompleteness (incident cases missed). Cancers with a higher M:I ratio tend to have a poorer survival.

The overall M:I ratio for males was 34% and for females was 35%.

Death Certificate Only (DCO%)

Cases for which no other information than a death certificate has been used, despite a thorough trace-back procedure. An elevated DCO% is indicative of inadequate case finding procedures.

The overall DCO% for males was 2.0% and for females was 2.8%.

Microscopic Verification (MV%)

The percentage of cases diagnosed on the basis of microscopic verification. This includes all histologically verified cases, in addition to cases where cytology specimens were examined and also haematological malignancies - where the diagnosis was made on a full blood count (without a bone marrow biopsy).

The overall MV% for both males and females was 93%.

Histologic Verification (HV%)

The percentage of cases diagnosed on the basis of histologic verification.

The overall HV% for both males and females was 91%.

For more information

The South Australian Cancer Registry.
Epidemiology and Research Division, Preventive Health SA
preventivehealthsa.sacancerregistry@sa.gov.au
<https://www.preventivehealth.sa.gov.au/>